

## WEST Search History





DATE: Monday, March 22, 2004

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
	<i>DB=USPT; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L32	l31 not l10	100
<input type="checkbox"/>	L31	L30 with l1	100
<input type="checkbox"/>	L30	clostrid\$ or neurotoxin	6508
	<i>DB=EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L29	L28 and l15	65
<input type="checkbox"/>	L28	clostrid\$ not l25	2003
	<i>DB=PGPB; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L27	US-20030166238-A1.did.	1
	<i>DB=EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L26	L25 and l15	25
<input type="checkbox"/>	L25	neurotoxin	405
<input type="checkbox"/>	L24	l20 and l21 and l22 and l23	9
<input type="checkbox"/>	L23	endocyt\$6 or transport\$4	354269
<input type="checkbox"/>	L22	cleav\$ or protease or proteinase	41377
<input type="checkbox"/>	L21	bind\$4	389299
<input type="checkbox"/>	L20	L19 or l17	11724
<input type="checkbox"/>	L19	L18 with l15	161
<input type="checkbox"/>	L18	"single chain"	1387
<input type="checkbox"/>	L17	L16 with l15	11675
<input type="checkbox"/>	L16	gene or plasmid or protein	250407
<input type="checkbox"/>	L15	fus\$4 or chimera\$3	225808
	<i>DB=USPT; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L14	L13 same l12 same l8 not l10	2
<input type="checkbox"/>	L13	l5 same (l6 or l7)	15844
<input type="checkbox"/>	L12	l1 same l11	4544
<input type="checkbox"/>	L11	"single chain"	10437
<input type="checkbox"/>	L10	L9 and l3	25
<input type="checkbox"/>	L9	l5 same l6 same l7 same l8	35
<input type="checkbox"/>	L8	cleav\$ or protease or proteinase	97654
<input type="checkbox"/>	L7	endocyt\$6	3603
<input type="checkbox"/>	L6	transport\$	420621
<input type="checkbox"/>	L5	bind\$4	338897
<input type="checkbox"/>	L4	bnid\$4	15

<input type="checkbox"/>	L3	11 with L2	27127
<input type="checkbox"/>	L2	gene or plasmid or protein	174117
<input type="checkbox"/>	L1	fus\$4 or chimera\$3	238926

END OF SEARCH HISTORY

File 155:MEDLINE(R) 1966-2004Jan W2 (c) format only 2004 The Dialog Corp.

Set Items Description

Ref Items	RT	Index-term	
E1 0	1	FUSION PROTEINS, RECOMBINANT	
E2 0	1	FUSION PROTEINS, VIRAL	
E3 0	*FUSION PROTEIN		
E4 0	1	FUSION REGULATORY PROTEIN 1, HEAVY CHAIN	
E5 0	1	FUSION REGULATORY PROTEIN-1	
E6 1	FUSIONA		
E7 1	FUSIONABILITY		
E8 6	FUSIONABLE		
E9 1	FUSIONADAS		
E10 1	FUSIONADO		
E11 4	FUSIONADOS		
E12	349 FUSIONAL		
S1	39072	'RECOMBINANT FUSION PROTEINS'	
S2	28703	NEUROTOX?	
S3	126	S1 AND S2	
S4	32438	'TOXINS'	
S5	480	S1 AND S4	
S6	449	S5 NOT S3	
S7	328	S6 AND PY<2000	
S8	133	KEX OR YSC	
S9	0	S7 AND S8	
S10	11	S1 AND S8	
Ref Items	Type	RT	Index-term
R1	18851	1	*PROTEASES
R2	37428	X	81 ENDOPEPTIDASES
Ref Items	Type	RT	Index-term
R1	37428	81	*ENDOPEPTIDASES
R2	125	X	DC=D8.811.277.656.300.(ENDOPEPTIDASES)

R10	2467	N	11	ASPARTIC ENDOPEPTIDASES
R11	385	N	11	BATROXOBIN
R12	39	N	5	BRINOLASE
S11	37428	'ENDOPEPTIDASES'		
S12	9	S11 AND S7		
S13	1096	S1 AND S11		
S14	30746	MEMBRANE(5N) BIND?		
S15	62079	TRANSLOCAT?		
S16	3	S13 AND S14 AND S15		
S17	72	S15 AND S13 NOT S16		
S18	50	S17 NOT SECRET?		
S19	28490	BOTULIN? OR TETAN?		
S20	178	S1 AND S19		
S21	5	S20 AND S11		
Ref Items	Type	RT	Index-term	
E1 2	AU=FRANCIS	ISSAC R		
E2 1	AU=FRANCIS	ISSAMM		
E3	161	*AU=FRANCIS J		
E4 2	AU=FRANCIS	JA		
E5 9	AU=FRANCIS	JB		
E6 8	AU=FRANCIS	JC		
E7 6	AU=FRANCIS	JD		
E8 51	AU=FRANCIS	JE		
E9 1	AU=FRANCIS	JF		
E10 7	AU=FRANCIS	JG		
E11 1	AU=FRANCIS	JH		
E12 5	AU=FRANCIS	JJ		
E13 5	AU=FRANCIS	JK		
E14	89	AU=FRANCIS	JL	

R3 0	X	1	PEPTIDE PEPTIDOHYDROLASES
R4	18851	X	1 PROTEASES
R5	7695	X	1 PROTEINASES
R6	18978	B	107 PEPTIDE HYDROLASES
R7	777	N	3 ACROSIN
R8	433	N	10 ANCIROD
R9	468	N	12 ANISTREPLASE
R10	2467	N	11 ASPARTIC ENDOPEPTIDASES
R11	385	N	11 BATROXOBIN
R12	39	N	5 BRINOLASE
S11	37428	'	ENDOPEPTIDASES'
S12	9	S11	AND S7
S13	1096	S1	AND S11
S14	30746	MEMBRANE(9N)	BIND?
S15	62079	TRANSLOCAT?	
S16	3	S13	AND S14 AND S15
S17	72	S15	AND S13 NOT S16
S18	50	S17	NOT SECRET?
S19	28490	BOTULIN?	OR TETAN?
S20	178	S1	AND S19
S21	5	S20	AND S11
Ref Items Index-term			
E1 2	AU=FRANCIS	ISSAC R	
E2 1	AU=FRANCIS	ISSAM M	
E3	161	*AU=FRANCIS	J
E4 2	AU=FRANCIS	J A	
E5 9	AU=FRANCIS	J B	
E6 8	AU=FRANCIS	J C	
E7 6	AU=FRANCIS	J D	
E8 51	AU=FRANCIS	J E	
E9 1	AU=FRANCIS	J F	
E10 7	AU=FRANCIS	J G	
E11 1	AU=FRANCIS	J H	
E12 5	AU=FRANCIS	J J	
E13 5	AU=FRANCIS	J K	
E14	89	AU=FRANCIS	J L

E15	1	AU=FRANCIS J LYNN
E16	41	AU=FRANCIS J M
E17	4	AU=FRANCIS J N
E18	1	AU=FRANCIS J P
E19	10	AU=FRANCIS J R
E20	17	AU=FRANCIS J S
E21	4	AU=FRANCIS J T
E22	1	AU=FRANCIS J V
E23	34	AU=FRANCIS J W
E24	1	AU=FRANCIS J X
E25	1	AU=FRANCIS JACQUELINE
E26	3	AU=FRANCIS JAMES
E27	3	AU=FRANCIS JAMES N
E28	2	AU=FRANCIS JANE
E29	4	AU=FRANCIS JANE M
E30	1	AU=FRANCIS JASMINE H
E31	2	AU=FRANCIS JENNELLE
E32	2	AU=FRANCIS JENNIFER
E33	1	AU=FRANCIS JENNIFER D
E34	3	AU=FRANCIS JENNIFER L
E35	1	AU=FRANCIS JEREMY S
E36	2	AU=FRANCIS JOANNA C
E37	9	AU=FRANCIS JOHN L
E38	1	AU=FRANCIS JONATHAN M
E39	3	AU=FRANCIS JONATHAN W
E40	10	AU=FRANCIS JOSEPH
E41	1	AU=FRANCIS JOSEPH P
E42	2	AU=FRANCIS JOSEPH T
E43	1	AU=FRANCIS JOSHUA
E44	1	AU=FRANCIS JUDITH
E45	3	AU=FRANCIS JULIUS
E46	63	AU=FRANCIS K
E47	1	AU=FRANCIS K A
E48	10	AU=FRANCIS K C
S22	221	E3,E23-E26, E28, E31-E32, E40, E43-E45
S23	4	S19 AND S22

3/6/9	14613403	22394042	PMID: 12504596 Smad3-dependent induction of plasminogen activator inhibitor-1 in astrocytes mediates neuroprotective activity of transforming growth factor-beta1 against NMDA-induced necrosis. Dec 2002
3/6/10	14546728	22135753	PMID: 12140266 Plasma membrane targeting of SNAP-25 increases its local concentration and is necessary for SNARE complex formation and regulated exocytosis. Aug 15 2002
3/6/11	14423490	22394087	PMID: 12505422 Activation of GABA(A) receptors by gamma-butyrolactone: a novel pathophysiological mechanism. Nov 2002
3/6/12	14150739	22278759	PMID: 12391613 Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and carnitine. Nov 1 2002
3/6/13	14124312	22377806	PMID: 12430716 HIV-1 gp120 proteins and gp150 peptides are toxic to brain endothelial cells and neurons: possible pathway for HIV entry into the brain a HIV-associated dementia. Nov 2002
3/6/14	14109856	22287190	PMID: 12395596 Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Oct 25 2002
3/6/15	13924267	22143702	PMID: 12148278 [Expression and purification of recombinant huweritoxin-I in Pichia pastoris] Jan 2002
3/6/16	11912150	99355417	PMID: 10426463 Production of an immunoenzymatic tracer combining a scFv and the acetylcholinesterase of Bungarus fasciatus by genetic recombination Jul 16 1999

- 3/6/17 11874546 99315188 PMID: 10387025  
The functional role of positively charged amino acid side chains in alpha-bungarotoxin revealed by site-directed mutagenesis of a His-tagged recombinant alpha-bungarotoxin. Jun 15 1999
- 3/6/18 11837792 99278136 PMID: 10346912  
Enhancement of the endopeptidase activity of botulinum neurotoxin by its associated proteins and diethylethanolamine. May 25 1999
- 3/6/19 11773090 99211386 PMID: 10197529  
Neurexins are functional alpha-latrotoxin receptors. Mar 1999
- 3/6/20 11730254 99167063 PMID: 10069533  
Ischemia induces metallothionein III expression in neurons of rat brain. 1999
- 3/6/21 11723801 99160489 PMID: 10049679  
Recombinant and truncated tetanus neurotoxin light chain cloning, expression, purification, and proteolytic activity. Mar 1999
- 3/6/22 11885533 99121035 PMID: 9922280  
EmrE, a small *Escherichia coli* multidrug transporter, protects *Saccharomyces cerevisiae* from toxins by sequestration in the vacuole. Feb 1999
- 3/6/23 11624177 99057603 PMID: 9838137  
cDNA sequence analysis and expression of four long neurotoxin homologues from *Naja naja atra*. Nov 26 1998
- 3/6/24 11593846 99026267 PMID: 9806860  
Conjugative transfer of the *Escherichia coli*-*Clostridium perfringens* shuttle vector pJIR1457 to *Clostridium botulinum* type A strains. Nov 1998
- 3/6/25 1497567 98381840 PMID: 9717740  
Production of an expression system for a synaptobrevin fragment to monitor cleavage by botulinum neurotoxin B. Jul 1998
- 3/6/26 11496293 98330521 PMID: 9712688  
Ganglioside GT1b as a complementary receptor component for *Clostridium botulinum* neurotoxins. Aug 1998
- 3/6/27 11494208 98378355 PMID: 9714553  
Functional characterization of mongOOSE nicotinic acetylcholine receptor alpha-subunit: resistance to alpha-bungarotoxin and high sensitivity to acetylcholine. Jul 24 1998
- 3/6/28 11387700 98268836 PMID: 9607820  
Recombinant human eosinophil-derived neurotoxin (RHNase 2) functions as an effective antiviral agent against respiratory syncytial virus. Jun 1998
- 3/6/29 11203933 98036179 PMID: 9426210  
Transient expression of botulinum neurotoxin C1 light chain differentially inhibits calcium and glucose induced insulin secretion in clonal beta-cells. Dec 8 1997
- 3/6/30 11139735 98015419 PMID: 9353935  
Recombinant SNAP-25 is an effective substrate for *Clostridium botulinum* type A toxin endopeptidase activity in vitro. Oct 1997
- 3/6/31 11110445 971404680 PMID: 9261392  
Glycoprotein Ems of pestiviruses induces apoptosis in lymphocytes of several species. Sep 1997
- 3/6/32 11083093 971444337 PMID: 9236966  
A new potassium channel toxin from the sea anemone *Heteractis magnifica*: isolation, cDNA cloning, and functional expression. Sep 23 1997
- 3/6/33 11063272 97141717 PMID: 9268675  
High-level production and isotope labeling of snake neurotoxins, disulfide-rich proteins. Aug 1997
- 3/6/34 11050445 971404680 PMID: 9261392  
Glycoprotein Ems of pestiviruses induces apoptosis in lymphocytes of several species. Sep 1997
- 3/6/35 11026724 97330307 PMID: 9237097  
Cloning and cytotoxicity of a human pancreatic RNase immunodulcin. Jun 1997
- 3/6/36 10970079 97322809 PMID: 9179289  
In vitro folding and functional analysis of an anti-insect selective scorpion depressant neurotoxin produced in *Escherichia coli*. Jun 1997
- 3/6/37 10913157 97265242 PMID: 9111179  
Human immunodeficiency virus type 1 Tat protein induces death by apoptosis in primary human neuron cultures. Apr 1997
- 3/6/38 10891577 97243441 PMID: 9118897  
DNA fragmentation and prolonged expression of c-fos, c-jun, and hsp70 in kainic acid-induced neuronal cell death in transgenic mice overexpressing human Cu,Zn-superoxide dismutase. Mar 1997
- 3/6/39 10851392 97202741 PMID: 9050235  
Molecular characteristics of mammalian and insect amino acid transporters: implications for amino acid homeostasis. Jan 1997
- 3/6/40 10824716 97175716 PMID: 9023371  
Binding of the synaptic vesicle v-SNARE, synaptobrevin, to the plasma membrane t-SNARE, SNAP-25, can explain docked vesicles at neurotoxin-treated synapses. Feb 4 1997
- 3/6/41 10790005 97140301 PMID: 8996782  
Insulin-stimulated translocation of GLUT4 glucose transporters requires SNARE-complex proteins. Dec 24 1996
- 3/6/42 10667816 97016880 PMID: 8863493  
Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. Nov 1996
- 3/6/43 10605337 96422925 PMID: 8825526  
Effects of chlorotrifluoroethylene oligomer fatty acids on recombinant GABA receptors expressed in *Xenopus oocytes*. Jan 1996
- 3/6/44 10436837 96243500 PMID: 8711755  
Facile production of native-like kappa-bungarotoxin in yeast: an enhanced system for the production of a neuronal nicotinic acetylcholine receptor probe. Feb 1996
- 3/6/45 10421671 96228050 PMID: 8647268  
Botulinum neurotoxin light chains inhibit both Ca(2+)-induced and GTP analogue-induced catecholamine release from permeabilised adrenergic cells. May 20 1996
- 3/6/46 10357280 96160045 PMID: 8562308  
Clinical trials of targeted toxins. Oct 1995
- 3/6/47 10356144 96158928 PMID: 8562075  
A strongly interacting pair of residues on the contact surface of charybotoxin and a Shaker K<sup>+</sup> channel. Jan 1996
- 3/6/48 10348836 96151333 PMID: 8559190  
Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen. Oct 1995
- 3/6/49 10304915 96106945 PMID: 8535163  
Expression in *Escherichia coli* and purification of human eosinophil-derived neurotoxin with ribonuclease activity. Oct 1995
- 3/6/50 10272824 96074594 PMID: 7488184  
cDNA sequence analysis and expression of alpha-bungarotoxin from Taiwan banded krait (*Bungarus multicinctus*). Nov 22 1995
- 3/6/51 10271008 96072756 PMID: 7578132  
Expression and purification of the light chain of botulinum neurotoxin A: a single mutation abolishes its cleavage of SNAP-25 and neurotoxic after reconstitution with the heavy chain. Nov 21 1995
- 3/6/52 10261998 96063633 PMID: 7488136  
17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Nov 13 1995
- 3/6/53 10224506 96025759 PMID: 7592578  
High affinity binding of alpha-latrotoxin to recombinant neurexin I alpha. Oct 13 1995
- 3/6/54 10216937 96018129 PMID: 7570631  
Cloning and expression of mamba toxins. Apr 1995
- 3/6/55 10165787 22168883 PMID: 12180969  
Characterization of scorpion alpha-like toxin group using two new toxins from the scorpion *Leiurus quinquestriatus hebraeus*. Aug 2002
- 3/6/56 10156787 22152946 PMID: 12027804  
Cytotoxic potency of cardiotoxin from *Naja sputatrix*: development of a new cytolytic assay. Aug 15 2002
- 3/6/57 10149075 22140381 PMID: 12145319  
Amisyn, a novel syntaxin-binding protein that may regulate SNARE complex assembly. Aug 2 2002
- 3/6/58 10148812 22140034 PMID: 12145198  
Calmodulin and lipid binding to synaptobrevin regulates calcium-dependent exocytosis. Aug 1 2002
- 3/6/59 10088963 22043136 PMID: 120247391  
Refolding of the *Escherichia coli* expressed extracellular domain of alpha 7 nicotinic acetylcholine receptor. Jun 2002
- 3/6/60 09954415 21871794 PMID: 11880503  
Caspase-3-dependent, proteolytic cleavage of protein kinase Cdelta is essential for oxidative stress-mediated dopaminergic cell death a

- exposure to methylcyclopentadienyl manganese tetracarboxylate. Mar 1 2002
- 3/6/61 09638303 21850743 PMID: 11861082  
A unique approach for high level expression and production of a recombinant cobra neurotoxin in *Escherichia coli*. Apr 11 2002
- 3/6/62 09809576 21618056 PMID: 11767952  
A recombinant scFv/streptavidin-binding peptide fusion protein for the quantitative determination of the scorpion venom neurotoxin Aa1h. Nov 2001
- 3/6/63 09603835 21611849 PMID: 11746436  
Biologically active sequence (KQD) mediates the neurite outgrowth function of the gamma-1 chain of laminin-1. Dec 15 2001
- 3/6/64 09798253 21606007 PMID: 11736750  
Use of fusion protein constructs to generate potent immunotherapy and protection against scorpion toxins. Dec 12 2001
- 3/6/65 09770747 21575763 PMID: 11719263  
Cytochrome c oxidase subunit Vb interacts with human androgen receptor: a potential mechanism for neurotoxicity in spinobulbar muscular atrophy. Oct-Nov 1 2001
- 3/6/66 09865280 21477243 PMID: 11592857  
The neuronal calcium sensor protein VILP-1 is associated with amyloid plaques and extracellular tangles in Alzheimer's disease and promotes cell death and tau phosphorylation in vitro: a link between calcium sensors and Alzheimer's disease? Oct 2001
- 3/6/67 09642153 21429356 PMID: 11543686  
Properties and interaction of heterologously expressed glutamate decarboxylase isoenzymes GAD(65kDa) and GAD(67kDa) from human brain with ginkgoxin and its 5-phosphate. Sep 13 2001
- 3/6/68 09626045 21421248 PMID: 11520908  
Neurotrophins prevent HIV-1-induced neuronal apoptosis via a nuclear factor-kappaB (NF-kappaB)-dependent mechanism. Aug 2001
- 3/6/69 09688916 21372669 PMID: 11478868  
Expression of an active recombinant lysine 49 phospholipase A2 myotoxin as a fusion protein in bacteria. Oct 2001
- 3/6/70 09680364 21363578 PMID: 11470830  
A stoichiometric complex of neuexins and cystotyocyan in brain. Jul 23 2001
- 3/6/71 09672149 21354518 PMID: 11461976  
Role of alpha2-macroglobulin in regulating amyloid beta-protein neurotoxicity: protective or detrimental factor? Jul 2001
- 3/6/72 09490505 21267040 PMID: 11356871  
A common exocytic mechanism mediates axonal and dendritic outgrowth. Jun 1 2001
- 3/6/73 09439297 21210796 PMID: 11299302  
Human immunodeficiency virus type 1 Tat protein decreases cyclic AMP synthesis in rat microglia cultures. Apr 2001
- 3/6/74 09410039 21176902 PMID: 11281322  
Snp35p, yeast prion-like protein as an adapter for production of the Gag-p55 antigen of HIV-1 and the L-chain of botulinum neurotoxin in *Saccharomyces cerevisiae*. Jan-Feb 2001
- 3/6/75 09352619 21114032 PMID: 11160457  
Amyloid (beta)A2 activates a G-protein-coupled chemotactant receptor, FPR-like-1. Jan 15 2001
- 3/6/76 09349876 21111022 PMID: 11178934  
Inhibition of neuronal nitric oxide synthase by N-phenacyl imidazoles. Feb 2001
- 3/6/77 09348692 21109370 PMID: 11161470  
Akt1/PKBalpha protects PC12 cells against the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium and reduces the levels of oxygen-free radicals. Jan 2001
- 3/6/78 09237059 20549560 PMID: 10973942  
Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. Nov 17 2000
- 3/6/79 09202799 20513018 PMID: 11059270  
Expression and characterization of two kinds of recombinant snake neurotoxins. May 2000
- 3/6/80 09177907 20483654 PMID: 11027615  
The amino acid region 115-119 of ammodysin plays an important role in neurotoxicity. Oct 5 2000
- 3/6/81 09112657 20411243 PMID: 10964418  
Membrane localization and biological activity of SNAP-25 cysteine mutants in insulin-secreting cells. Sep 2000
- 3/6/82 09092184 20389730 PMID: 10930684  
Cloning, expression and evaluation of a recombinant sub-unit vaccine against *Clostridium botulinum* type F toxin. Sep 15 2000
- 3/6/83 09035114 20329465 PMID: 10873064  
Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Jun 2000
- 3/6/84 09030880 20324939 PMID: 10865133  
Measurement of exocytosis by amperometry in adrenergic chromaffin cells: effects of clostridial neurotoxins and activation of protein kinase C fusion pore kinetics. May 2000
- 3/6/85 09002356 20294906 PMID: 10833399  
Cloning, expression, and one-step purification of the minimal essential domain of the light chain of botulinum neurotoxin type A. Jun 2000
- 3/6/86 08856185 20141225 PMID: 10675534  
Identification and characterization of functional subunits of *Clostridium botulinum* type A progenitor toxin involved in binding to intestinal microvilli and erythrocytes. Feb 11 2000
- 3/6/87 08853128 20137988 PMID: 10672018  
Functional characterization and mechanism of action of recombinant human tyrosine 3-hydroxylase. Feb 2000
- 3/6/88 08835257 20119217 PMID: 10652444  
Microglial tissue plasminogen activator (tPA) triggers neuronal apoptosis in vitro. Feb 15 2000
- 3/6/89 08812762 20095669 PMID: 10630205  
Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease. Nov 1999
- 3/6/90 08792663 20074908 PMID: 10606730  
An in vivo assay for the identification of target proteases which cleave membrane-associated substrates. Dec 17 1999
- 3/6/91 08767091 20069063 PMID: 10600453  
Expression and purification of the Bmk1M1 neurotoxin from the scorpion *Buthus maritellii* Karsch. Dec 1999
- 3/6/92 08769428 20050851 PMID: 10581396  
Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. Nov 10 1999
- 3/6/93 08766143 20047427 PMID: 10582602  
Botulinum neurotoxin E-insensitive mutants of SNAP-25 fail to bind VAMP but support exocytosis. Dec 1999
- 3/6/94 08763553 20044741 PMID: 10574958  
Variability among the sites by which curareimetic toxins bind to torpedo acetylcholine receptor, as revealed by identification of the function residues of alpha-dobrotoxin. Dec 3 1999
- 3/6/95 08688676 95377281 PMID: 7649153  
Recombinant and chemical derivatives of apamin. Implication of post-transcriptional C-terminal amidation of apamin in biological activity. Aug 1995
- 3/6/96 08660219 95348616 PMID: 7623135  
Neurotrophin-4/5 enhances survival of cultured spiral ganglion neurons and protects them from cisplatin neurotoxicity. Jul 1995
- 3/6/97 08622454 95310981 PMID: 7790908  
Kainic acid-induced neuronal death is associated with DNA damage and a unique immediate-early gene response in c-fos-lacZ transgenic rats. Jun 1995
- 3/6/98 08546027 95234326 PMID: 7718248  
A mutated acetylcholine receptor subunit causes neuronal degeneration in *C. elegans*. Apr 1995
- 3/6/99 08525400 95213678 PMID: 7599335  
Protection against HIV-1 gp120-induced brain damage by neuronal expression of human amyloid precursor protein. Apr 1 1995
- 3/6/100 08374166 95062139 PMID: 7526378  
Engineering of protein epitopes: a single deletion in a snake toxin generates full binding capacity to a previously unrecognized antibody. Jul 1
- 3/6/101 08371481 95059454 PMID: 7969473  
Structural determinants of the blockade of N-type calcium channels by a peptide neurotoxin. Nov 17 1994
- 3/6/102 08326592 95014532 PMID: 7929408  
Expression and characterization of recombinant human eosinophil-derived neurotoxin and eosinophil-derived neurotoxin-anti-transferin receptor sFv. Oct 28 1994

3/6/103 08303720 94373331 PMID: 7522104  
Competitive antagonism by phenylglycine derivatives at type I metabotropic glutamate receptors. Jun 1994

3/6/104 08267296 94333357 PMID: 80555934  
Production of active, insect-specific scorpion neurotoxin in yeast. Jul 15 1994

3/6/105 08236041 94301996 PMID: 7518082  
Engineering a uniquely reactive thiol into a cysteine-rich peptide. Apr 1994

3/6/106 08198098 94264020 PMID: 7911329  
A single mutation in the recombinant light chain of tetanus toxin abolishes its proteolytic activity and removes the toxicity seen after reconstitution with native heavy chain. Jun 7 1994

3/6/107 08169290 94235190 PMID: 8179645  
Structure, function and expression of voltage-dependent sodium channels. Fall-Winter 1993

3/6/108 08143419 94209288 PMID: 8157645  
Functional expression and site-directed mutagenesis of a synthetic gene for alpha-bungarotoxin. Apr 15 1994

3/6/109 08093322 94159078 PMID: 8114918  
Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Jan 13 1994

3/6/110 08001602 94067319 PMID: 8247129  
Synaptic vesicle fusion complex contains unc-18 homologue bound to syntaxin. Nov 25 1993

3/6/111 07985762 94051479 PMID: 8233724  
Potentiation of N-methyl-D-aspartate-mediated brain injury by a human immunodeficiency virus-1-derived peptide in perinatal rodents. Aug 1993

3/6/112 07924263 93385095 PMID: 8373764  
Effects of mutations of Torpedo acetylcholine receptor alpha 1 subunit residues 184-200 on alpha-bungarotoxin binding in a recombinant fusion protein. Sep 21 1993

3/6/113 07724190 93179465 PMID: 8095049  
Characterization of a distinct binding site for the prokaryotic chaperone, GroEL, on a human granulocyte ribonuclease. Feb 25 1993

3/6/114 07611265 93065342 PMID: 1438289  
Deposition of betaA4 immunoreactivity and neuronal pathology in transgenic mice expressing the carboxyl-terminal fragment of the Alzheimer amyloid precursor in the brain. Nov 15 1992

3/6/115 07573392 93028327 PMID: 1409549  
Insertion of a disulfide-containing neurotoxin into E. coli alkaline phosphatase: the hybrid retains both biological activities. Apr 1992

3/6/116 07478586 92342135 PMID: 1635553  
Molecular neurotoxicology of trimethyltin: identification of stannin, a novel protein expressed in trimethyltin-sensitive cells. Jul 1992

3/6/117 07386593 92249751 PMID: 1577256  
Cloning of a Clostridium botulinum type B toxin gene fragment encoding the N-terminus of the heavy chain. Feb 1 1992

3/6/118 07281817 92144540 PMID: 1736994  
Substitution of Torpedo acetylcholine receptor alpha 1-subunit residues with snake alpha 1- and rat nerve alpha 3-subunit residues in recombinant fusion proteins: effect on alpha-bungarotoxin binding. Feb 11 1992

3/6/119 07268584 92131247 PMID: 1837849  
Intraocular implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids. 1991

3/6/120 07165311 92027518 PMID: 1658845  
Calcium channel antagonists and human immunodeficiency virus coat protein-mediated neuronal injury. Jul 1991

3/6/121 0713767 91372981 PMID: 1910014  
Characterization of the C3 gene of Clostridium botulinum types C and D and its expression in Escherichia coli. Oct 1991

3/6/122 06763084 91002534 PMID: 2207082  
Comparison of the toxin binding sites of the nicotinic acetylcholine receptor from Drosophila to human. Jul 10 1990

3/6/123 06739929 90365970 PMID: 1365462  
Expression and secretion of a functional scorpion insecticidal toxin in cultured mouse cells. Apr 1990

3/6/124 06580484 90306371 PMID: 2365072  
A recombinant snake neurotoxin generated by chemical cleavage of a hybrid protein recovers full biological properties. Jun 18 1990

3/6/125 06458371 90083145 PMID: 2687847

Direct expression in E. coli of a functionally active protein A—snake toxin fusion protein. Nov 1989

3/6/126 06343017 89359352 PMID: 2670934  
Cloning and expression of a synthetic gene for Cerebrallus laevis neurotoxin B-IV. Sep 15 1989

3/7/26 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.  
11496293 96380521 PMID: 9712688  
Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins.

Kozaki S, Kamata Y, Watarai S, Nishiki T, Mochida S

Department of Veterinary Science, College of Agriculture, Osaka Prefecture University, Sakai, Osaka, 599-8531, USA.  
Microbial pathogenesis [ENGLAND] Aug 1998, 25 (2) p19-9, ISSN 0882-4010 Journal Code: 8606191

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed  
Clostridium botulinum type B neurotoxin (BoNT/B) recognizes a complex of synaptobrevin II and ganglioside GT1b or GD1a at the high-affinity toxin binding site. Recombinant deletion mutants of synaptobrevin II allowed us to demonstrate that the N-terminal domain including the transmembrane region retains BoNT/B binding activity while the C-terminal domain is not involved in constituting the BoNT/B receptor. BoNT/B binding to reconstituted lipid vesicles containing synaptobrevin II and ganglioside showed that GT1b and GD1a confer the difference in the maximum binding capacity but not in the dissociation constant. The direct binding of GT1b to the deletion mutants revealed that the transmembrane region is required to bind GT1b, suggesting that synaptobrevin II binds to the ceramide portion of gangliosides within the plasma membrane. A monoclonal antibody against GT1b effectively inhibited not only BoNT/B binding to the reconstituted lipid vesicles and brain synaptosomes but also type A BoNT (BoNT/A) binding to brain synaptosomes. In addition, the monoclonal antibody antagonized the action of both BoNT/A and BoNT/B on synaptic transmission of rat superior cervical ganglion neurons. These results suggest that GT1b functions as a component of the receptor complex. Copyright 1998 Academic Press Record Date Created: 19980929 Record Date Complete 19980929

3/7/61 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

09938303 21850743 PMID: 11861082

A unique approach for high level expression and production of a recombinant cobra neurotoxin in Escherichia coli.

Wang Yongbao, Jing Liu, Xu Kangsen

School of Life Science, University of Science and Technology of China, Hefei, Anhui province, People's Republic of China, ywqiang@hncppp.org.cn

Journal of biotechnology (Netherlands) Apr 11 2002, 94 (3) p235-44, ISSN 0168-1656 Journal Code: 841927

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

In this report, we describe a simple approach to produce a large quantity of a recombinant cobra neurotoxin containing four p of disulfide bonds. A cDNA encoding the toxin was fused, in frame, to the carboxyl termini of thioredoxin via a linker sequence encoding two amino acids, Asp and Pro. Due to the presence of thioredoxin, a soluble form of the fusion protein was expressed in a compartment, sensitive to osmotic pressure, in Escherichia coli. The fusion protein was released into the solution with low ionic strength under an osmotic shock treatment, and purified in a single step using an ion exchange chromatography column. The purified protein was treated in diluted hydrochloric acid to induce hydrolysis of the protein at the Asp-Pro linker site. Then, the recombinant neurotoxin was purified by gel filtration of the acid-treated sample. When the biological activity of the purified toxin was assayed, it was as potent as the natural toxin. Using this protocol, approximately 12 mg of pure recombinant neurotoxin can be produced from one liter of bacterial culture. More importantly, this protocol can be easily used for the production of the toxin at a larger scale with low cost. The approach outlined in this report will be suitable for the production of other recombinant proteins especially those of the 'three-finger' family. Record Date Created: 20020225 Record Date Complete 20020517

3/7/117 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

07336559 92249751 PMID: 1577256

Cloning of a Clostridium botulinum type B toxin gene fragment encoding the N-terminus of the heavy chain.

Jung H H, Rhee S D, Yang K H

Department of Life Science, Korea Advanced Institute of Science and Technology, Taejeon, Korea.

FEMS microbiology letters [NETHERLANDS] Feb 1 1992, 70 (1) p69-72, ISSN 0378-1097 Journal Code: 7705721

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Two lambda g11 clones of the toxin gene of Clostridium botulinum type B were identified by the monoclonal antibody specific to the heavy chain of type B toxin. Neither of the expressed fusion proteins from the lysates of *Yersenia* E. coli Y1089 showed a botulinum toxic activity. One of the clones hybridized to the oligonucleotide probe which was synthesized according to the amino acid sequence of N-terminus of heavy chain. The sequence analysis revealed that highly homologous regions in N-terminus of heavy chain exist among botulinum neurotoxins (type A, B) and tetanus toxin on the amino acid sequence level. Record Date Created: 19920611 Record Date Completed: 19920611

3/7/124 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

06680484 90306371 PMID: 2365072

A recombinant snake neurotoxin generated by chemical cleavage of a hybrid protein recovers full biological properties.

Protein--genetics--GE, Mice: Molecular Sequence Data; Nerve Tissue Protein--genetics--GE; Pro-Opticomegalocornin--genetics--GE; Protein Conformation; Protein Structure; Tetrayl; Recombinant Fusion Proteins--genetics--GE; Recombinant Fusion Proteins--metabolism--ME; Tumor Cells, Cultured; CAS Registry No.: 0 (Antigens, Surface); 0 (Botulinum Toxins); 0 (Membrane Proteins); 0 (Nerve Tissue Proteins); 0 (Recombinant Fusion Proteins); 0 (SNAP receptor); 0 (botulinum toxin type E); 0 (synaptosomal-associated protein 25); 0 (syntaxin 1); 0 (vesicle-associated membrane protein); 52-90-4 (Cysteine); 66786-54-1 (Pro-Opticomegalocornin); 7440-70-2 (Calcium)

Record Date Created: 20020725 Record Date Completed: 20030311

3/5/17 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.  
11874546 99316188 PMID: 10387025

The functional role of positively charged amino acid side chains in alpha-bungarotoxin revealed by site-directed mutagenesis of His-tagged recombinant alpha-bungarotoxin.

Rosenthal J A; Levandoski M M; Chang B; Potts J F; Shi Q L; Hawrot E  
Department of Molecular Pharmacology, Physiology, and Biotechnology, Division of Biology and Medicine, Brown University, Providence, Rhode Island 02912, USA.

Biochemistry (UNITED STATES) Jun 15 1999, 38 (24) p7847-55, ISSN 0006-2960 Journal Code: 0370623  
Contract/Grant No.: GM076071; GM; NIGMS; GM326929; GM; NIGMS; NS34348; NS; NINDS Document type: Journal Article  
Languages: ENGLISH Main Citation Owner: NLM Record type: Completed Subfile: INDEX MEDICUS

A polyhistidine tag was added to the N-terminus of alpha-bungarotoxin (Bgtx) recombinantly expressed in *E. coli*. The His-tagged Bgtx was identical to native, venom-derived Bgtx in its apparent affinity for the nicotinic acetylcholine receptor (nAChR) Torpedo electric organ membranes. Furthermore, in a physiological assay involving mouse muscle nAChR expressed in *Xenopus oocytes*, the His-tagged Bgtx was as effective as authentic Bgtx at blocking acetylcholine-evoked currents. Ala-substitution mutagenesis of His-tagged Bgtx was used to evaluate the functional contribution of Arg36, a residue that is invariant among all alpha-neurotoxins. Replacement with Ala resulted in a 30-fold decrease in the apparent affinity for the Torpedo nAChR and a corresponding 150-fold increase in the IC50 for block of heterologously expressed mouse muscle nAChR, demonstrating the critical importance of this positive charge for the binding and functional activity of a long alpha-neurotoxin. The observed decrease in affinity corresponds to a DeltaDeltaG of 2.7 kcal/mol and indicates that Arg36 makes a major contribution to complex formation. This finding is consistent with the proposal that Arg36 mimics the positive charge found on acetylcholine and directs the toxin to interact with receptor sites normally involved in acetylcholine recognition. In comparison, Ala-substitution of the highly conserved Lys26 resulted in only a 9-fold decrease in apparent affinity. Truncation of the His-tag Bgtx following residue 67 produces a toxin lacking the seven C-terminal residues including the two positively charged residues Lys70 and Arg72. Truncation leads to a 7-fold decrease in apparent binding affinity.

Tags: Animal; Support; U.S. Gov't; P.H.S. Descriptors: Amino Acids--physiology--PH; Bungarotoxins--physiology--PH; Histidine--genetics--G \*Mutagenesis; Site-Directed; \*Recombinant Fusion Proteins--metabolism--ME; Amino Acid Substitution--genetics--GE; Amino Acids--genetic GE; Amino Acids--metabolism--ME; Bacteriophage T4--genetics--GE; Binding; Competitive--genetics--GE; Bungarotoxins--genetics--GE; Bungarotoxins--metabolism--ME; Escherichia coli--genetics--GE; Genetic Vectors--metabolism--ME; Genetic Vectors--pharmacology--PD; Histidine--metabolism--ME; Hydrogen Ion Concentration; Mice; Muscle Skeletal--drug effects--DE; Muscle, Skeletal--metabolism--ME; Nicotinic Antagonists--pharmacology--PD; Receptors; Nicotinic--biosynthesis--BI; Recombinant Fusion Proteins--isolation and purification--Recombinant Fusion Proteins--pharmacology--PD; Sequence Deletion; Torpedo; Viral Proteins--genetics--GE; CAS Registry No.: 0 (Amino Acids); 0 (Bungarotoxins); 0 (Genetic Vectors); 0 (Nicotinic Antagonists); 0 (Receptors; Nicotinic); 0 (Recombinant Fusion Proteins); 0 (Viral Proteins); 147258-48-8 (bacteriophage T4 gene 9 protein); 71-00-1 (Histidine)

Record Date Created: 19990715 Record Date Completed: 19990715

3/5/21 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.  
11723801 99160489 PMID: 10049679

Recombinant and truncated tetanus neurotoxin light chain: cloning, expression, purification, and proteolytic activity; Tonello F; Pellizzari R; Pasqualato S; Grandi G; Peggion E; Montecucco C  
Dipartimento di Scienze Biomediche, Università di Padova, Padova I-35121, Italy.  
Protein expression and purification (UNITED STATES) Mar 1999, 15 (2) p221-7, ISSN 1046-5928 Journal Code: 910149  
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed  
Subfile: INDEX MEDICUS

Tetanus neurotoxin (TeNT) consists of two disulfide-linked polypeptide chains, heavy (H) and light (L). The L chain is a zinc endopeptidase protein highly specific for vesicle-associated membrane protein (VAMP), which is an essential component of the exocytosis apparatus. Here we describe the cloning of the L chain of TeNT from *Clostridium tetani* strain Y-IV-3 (WS-15) and its expression in *Escherichia coli* as a glutathione S-transferase fusion protein. The full-length recombinant L chain, corresponding to residues 1-157, was obtained as a mixture of proteins of slightly different mass with identical N-terminal ends. To obtain a product useful for structural analysis and crystallization, a COOH-terminally truncated L chain (residues 1-142) was cloned, expressed, and purified with high yield. This truncated L chain is more active than the full-length and wild-type proteins in the hydrolysis of VAMP. Preliminary experiments of crystallization of the truncated recombinant L chain gave encouraging results. Copyright 1999 Academic Press.

Tags: Human; Support; Non-U.S. Gov't; Descriptors: \*Metalloendopeptidases--genetics--GE; \*Tetanus Toxin--genetics--GE; Cloning, Molecular; Crystallization; Escherichia coli; Gene Expression; Membrane Protein--metabolism--ME; Metalloendopeptidases--biosynthesis--B Metalloendopeptidases--isolation and purification--IP; Metalloendopeptidases--metabolism--ME; Peptide Fragments--biosynthesis--BI; Peptide Fragments--genetics--GE; Peptide Fragments--isolation and purification--IP; Peptide Fragments--metabolism--ME; Recombinant Fusion Proteins--biosynthesis--I; Recombinant Fusion Proteins--genetics--GE; Recombinant Fusion Proteins--isolation and purification--IP;

Boyet P; Pillet L; Ducancel F; Boulain J C; Tremeau O; Menez A  
Département de Biologie, Laboratoire d'ingénierie des Protéines C.E.N., Gif-sur-Yvette, France.  
FEBS letters (NETHERLANDS) Jun 18 1990, 266 (1-2) p87-90, ISSN 0014-5793 Journal Code: 0155157

Eratium in FEBS Lett 1990 Oct 1;271(1-2):258 Document type: Journal Article Languages: ENGLISH

Main Citation Owner: NLM Record type: Completed

We previously reported the production of a fused snake neurotoxin composed of protein A and erabutoxin a in *E. coli*. The hybrid had much lower toxicity and affinity for the acetylcholine nicotinic receptor than natural erabutoxin. By treating the hybrid with cyanogen bromide we generated a toxin which was purified in a single step by RP-HPLC. This compound, produced in a good yield, recovered all properties of native erabutoxin a, implying that the lower toxic activities of the hybrid were due to the bulky protein A and not to an incorrect folding of the toxin. This work serves as a basis for future studies of toxin-receptor interactions using engineered toxin mutants. Record Date Created: 19900814 Record Date Completed: 19900814

3/5/2 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.  
15377227 22613949 PMID: 12727273

Expression, purification, and efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation domain variants.

Jensen M J; Smith T J; Ahmed S A; Smith L A  
Division of Toxicology and Aerobiology, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702-5011, USA.  
Toxicon - official Journal of the International Society on Toxicology ( England) May 2003, 41 (6) p691-701, ISSN 0041-0101

Journal Code: 1307333 Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM  
Record type: Completed Subfile: INDEX MEDICUS

Clostridial neurotoxins are potent inhibitors of synaptic function, with the zinc-dependent proteolytic light chain (LC) portion of the toxin cleaving one of three neural SNARE proteins. In nature, the LC is expressed as a part of a much larger toxin and hemagglutinin complex, protecting it from environmental degradation and preserving its catalytic activity. We developed forms of the LC of type A botulinum neurotoxin (BoNT-A) with parts of the larger toxin gene, for use as reagents in high-throughput assays to screen for potential LC antagonists, to further elucidate the toxin's mechanism of action, and to study immunological responses to the toxin. Three BoNT-A constructs were engineered and expressed: the LC, LC with translocation region (LC+H(n)), and the LC with the belt portion of the translocation region (LC+BB). Purification was optimized to a two-step process, with relatively high yields of all three constructs obtained. Activity assays showed all three constructs to be active, with the LC being the most active. Immunogenic protection against native BoNT-A toxin challenge was observed for all three constructs, with the best protection observed with the LC+H(n) and LC+BB proteins.

Tags: Animal Descriptors: \*Botulinum Toxin Type A--isolation and purification--IP; \*Botulinum Toxin Type A--metabolism--ME; \*Catalytic Domain; \*Gene Expression; \*Genetic Engineering; Botulinum Toxin Type A--genetics--GE; Botulinum Toxin Type A--immunology--IM; Enzyme-Linked Immunosorbent Assay; Mice; Protein Transport; Recombinant Fusion Proteins--chromatography--CH; Recombinant Fusion Proteins--immunology--IM; Recombinant Fusion Proteins--isolation and purification--IP; Recombinant Fusion Proteins--metabolism--ME; Temperature; CAS Registry No.: 0 (Botulinum Toxin Type A); 0 (Recombinant Fusion Proteins)

Record Date Created: 20030502 Record Date Completed: 20030917

3/5/10 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.  
14546728 22135753 PMID: 12140265

Plasma membrane targeting of SNAP-25 increases its local concentration and is necessary for SNARE complex formation and regulated exocytosis.  
Kotlova Darshan K; McCarthy Ellen E; Baldini Giulia  
Department of Anatomy and Cell Biology, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA.

Journal of cell science (England) Aug 15 2002, 115 (Pt 16) p3341-51, ISSN 0021-9533 Journal Code: 0052457  
Contract/Grant No.: R01-DK53293; DK; NIDDK Document type: Journal Article Languages: ENGLISH  
Main Citation Owner: NLM Record type: Completed Subfile: INDEX MEDICUS

SNAP-25 is an integral protein of the plasma membrane involved in neurotransmission and hormone secretion. The cysteine-rich domain of SNAP-25 is essential for membrane binding and plasma-membrane targeting. However, this domain is not required for SNARE complex formation and fusion of membranes *in vitro*. In this paper, we describe an 'infect-cell'-based system designed to compare the effect of similar amounts of membrane-bound and soluble SNAP-25 proteins on regulated exocytosis. In transfected neuroblastoma cells, Botulinum neurotoxin E (BoNTE), a protease that cleaves SNAP-25, blocks regulated release of hormone. However, hormone release is rescued by expressing a wild-type SNAP-25 protein resistant to the toxin. BoNTE-resistant SNAP-25 proteins lacking the cysteine-rich domain or with all the cysteines substituted by alanines do not form SNARE complexes or rescue regulated exocytosis when expressed at the same level as membrane-bound SNAP-25, which is approximately four-fold higher than the endogenous protein. We conclude that the cysteine-rich domain of SNAP-25 is essential for Ca(2+)-dependent hormone release because, by targeting SNAP-25 to the plasma membrane, it increases its local concentration, leading to the formation of enough SNARE complexes to support exocytosis.

Tags: Animal; Support; U.S. Gov't; P.H.S. Descriptors: \*Cell Membrane--metabolism--ME; \*Exocytosis--physiology--PH; \*Membrane Protein--metabolism--ME; Nerve Tissue Protein--metabolism--ME; \*Protein Transport--physiology--PH; Amino Acid Sequence; Antigens, Surface--metabolism--ME; Botulinum Toxin--metabolism--ME; Calcium--metabolism--ME; Cysteine--metabolism--ME; Genes, Reporter; Membrane



- Recombinant Fusion Proteins--metabolism--ME. Spectrometry. Fluorescence. Substrate Specificity. Tetanus Toxin--biosynthesis--B1. Tetanus Toxin--isolation and purification--IP. Tetanus Toxin--metabolism--ME. CAS Registry No.: 0 (Membrane Proteins); 0 (Peptide Fragments); 0 (Recombinant Fusion Proteins); 0 (Tetanus Toxin); 0 (Vesicle-associated membrane protein). Enzyme No.: EC 3.4.24 (Metalloendopeptidases); EC 3.4.24.- (Zinc-endopeptidase, tetanus neurotoxin)  
Record Date Created: 19990511 Record Date Completed: 19990511
- 7/6/1 14867997 22451921 PMID: 12637391  
[Association expression of genes encoding gsl of Schistosoma japonicum and enterotoxigenic Escherichia coli]. 1999
- 7/6/2 12007058 99452975 PMID: 10521470  
Involvement of small GTPases in Mycoplasma fermentans membrane lipoproteins-mediated activation of macrophages. Oct 22 1999
- 7/6/3 11999258 99444908 PMID: 10517320  
The transcriptional activator CorR is involved in biosynthesis of the phytotoxin coronatine and binds to the omaABT promoter region in a temperature-dependent manner. Sep 1999
- 7/6/4 11976922 99421861 PMID: 10491008  
IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmune in nonobese diabetic mice. Oct 1 1999
- 7/6/5 11974124 99419014 PMID: 10488072  
Neosynthesis and activation of Rho by Escherichia coli cytotoxic necrotizing factor (CNF1) reverse cytopathic effects of ADP-ribosylated Rho. Sep 24 1999
- 7/6/6 11954727 99399090 PMID: 10470104  
Wortmannin, a phosphoinositide 3-kinase inhibitor, selectively enhances cytotoxicity of receptor-directed toxin chimeras in vitro and in vivo. May-Jun 1999
- 7/6/7 11942739 99386678 PMID: 10455034  
Analysis of agonist function at fusion proteins between the IP prostanoid receptor and cognate, unnatural and chimeric G-proteins. Sep 1 1999
- 7/6/8 11919255 99362764 PMID: 10430949  
The Xanthomonas Hrp type III system secretes proteins from plant and mammalian bacterial pathogens. Aug 3 1999
- 7/6/9 11914297 99357644 PMID: 10427035  
Activation process of ciproflaxin-specific insecticidal protein produced by Bacillus thuringiensis subsp. israelensis. Aug 1999
- 7/6/10 11905255 99348366 PMID: 10419539  
Yersinia enterocolitica type III secretion. On the role of YscE in targeting YscE into HeLa cells. Jul 30 1999
- 7/6/11 11905231 99348332 PMID: 10419515  
Ion channel activity of the BHK only Bcl-2 family member, BID. Jul 30 1999
- 7/6/12 11897702 99340543 PMID: 10417128  
The 5' region of crf1 harbours a translational regulatory mechanism for CNF1 synthesis and encodes the cell-binding domain of the toxin. Jul 1999
- 7/6/13 11887991 99330177 PMID: 10403383  
Exploiting retrograde transport of Shiga-like toxin 1 for the delivery of exogenous antigens into the MHC class I presentation pathway. Jun 18 1999
- 7/6/14 11882109 99323920 PMID: 10393809  
Rst167p, the budding yeast homolog of amphiphysin, colocalizes with actin patches. Aug 1999
- 7/6/15 11865823 99307182 PMID: 10377103  
Cytotoxic T-lymphocyte epitopes fused to anthrax toxin induce protective antiviral immunity. Jul 1999
- 7/6/16 11862205 99303467 PMID: 10376974  
An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (K4-ScFv)-ETA is a potent immunotoxin against a Hodgkin-derived cell line. Jun 1999
- 7/6/17 11853098 99294094 PMID: 10367674  
Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma. Jan-Feb 1999
- 7/6/18 11847433 99288230 PMID: 10356877  
High-level expression and purification of the recombinant diphtheria toxin DTGM for PHASE I clinical trials. Jun 1999
- 7/6/19 11815887 99255537 PMID: 10322014  
Direct interaction of the EpsC and EpsM proteins of the general secretion apparatus in Vibrio cholerae. May 1999
- 7/6/20 11814001 99253640 PMID: 10321723  
Cloning and cytotoxicity of fusion proteins of EGF and angiogenin. 1999
- 7/6/21 11799440 99238511 PMID: 10220447
- Intranuclear delivery of an antiviral peptide mediated by the B subunit of Escherichia coli heat-labile enterotoxin. Apr 27 1999
- 7/6/22 11795381 99234368 PMID: 10216313  
Crystallization and preliminary X-ray diffraction studies of the 51 kDa protein of the mosquito-larvicidal binary toxin from Bacillus sphaericus. Ma 1999
- 7/6/23 11775824 99214180 PMID: 10196187  
A novel cytotoxin from Clostridium difficile serogroup F is a functional hybrid between two other large clostridial cytotoxins. Apr 16 1999
- 7/6/24 11771897 99210155 PMID: 10195780  
Novel modifications to the C-terminus of LT-B that facilitate site-directed chemical coupling of antigens and the development of LT-B as a carrier for mucosal vaccines. Mar 17 1999
- 7/6/25 11759374 99196993 PMID: 10095114  
A new series of PET-derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins. Mar 18 1999
- 7/6/26 11755179 99192697 PMID: 10089527  
Crystallization and preliminary X-ray diffraction studies of alpha-toxin from two different strains (NCTC8237 and CER89143) of Clostridium perfringens. Nov 1 1998
- 7/6/27 11753200 99190638 PMID: 10092217  
Intracellular targeting of the endoplasmic reticulum/nuclear envelope by retrograde transport: may determine cell hypersensitivity to verotoxin glycoprotein ceramide fatty acid isozyme traffic. Dec 1998
- 7/6/28 11752309 99189747 PMID: 10089877  
Solution structure of BID, an intracellular amplifier of apoptotic signaling. Mar 5 1999
- 7/6/29 11747698 99185011 PMID: 10085027  
Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells. Apr 1999
- 7/6/30 11747681 99184994 PMID: 10085010  
An Archaeobacterium (Achimomyces) pyrogenes mutant deficient in production of the pore-forming cytolysin pyrolysin has reduced virulence. Apr 1999
- 7/6/31 11720993 99157583 PMID: 10048023  
Expression and properties of an aerolysin-Clostridium septicum alpha toxin hybrid protein. Feb 1999
- 7/6/32 11720819 99157408 PMID: 10047878  
Differential activity of cholera toxin and E. coli enterotoxin: construction and purification of mutant and hybrid derivatives. Nov 1998
- 7/6/33 11680321 99115680 PMID: 9914169  
The KDEL retrieval system is exploited by Pseudomonas exotoxin A, but not by Shiga-like toxin-1, during retrograde transport from the Golgi complex to the endoplasmic reticulum. Feb 1999
- 7/6/34 11680158 99115517 PMID: 9916051  
Deamidation of Cdc42 and Rac by Escherichia coli cytotoxic necrotizing factor 1: activation of c-Jun N-terminal kinase in HeLa cells. Feb 19
- 7/6/35 11672041 99107223 PMID: 9882205  
Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Jan 1 1999
- 7/6/36 11657978 99092760 PMID: 9876933  
Stepwise transplantation of an active site loop between heat-labile enterotoxins LT-II and LT-I and characterization of the obtained hybrid toxins. Nov 1998
- 7/6/37 11635815 99069581 PMID: 9852324  
Gating of skeletal and cardiac muscle sodium channels in mammalian cells. Jan 15 1999
- 7/6/38 11626571 99060051 PMID: 9843379  
Characterization of membrane translocation by anthrax protective antigen. Nov 10 1998
- 7/6/39 11606274 99039034 PMID: 9821593  
Positive selection vectors to generate fused genes for the expression of his-tagged proteins. Nov 1998
- 7/6/40 11596318 99028905 PMID: 9812362  
Functional interactions between ctpB and parD, two homologous conditional killer systems found in the Escherichia coli chromosome and in plasmid R1. Nov 1 1998
- 7/6/41 11593608 98455677 PMID: 9782357  
Prokaryotic expression of porcine epidemic diarrhoea virus ORF3. 1998
- 7/6/42 11546114 98437626 PMID: 9757112



- Crystallization of ccdB. Sep 1 1998
- 7/6/43 11531599 98422764 PMID: 9750370  
Bacterial phospholipases. 1998
- 7/6/44 11512796 98401141 PMID: 9731188  
Differences in cytotoxicity of native and engineered RfPs can be used to assess their ability to reach the cytoplasm. Aug 28 1998
- 7/6/45 11503002 98387897 PMID: 9719644  
Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv. Sep 4 1998
- 7/6/46 11502057 98386734 PMID: 9720265  
Recombinant antibody fragments. Aug 1998
- 7/6/47 11496172 98380400 PMID: 9712803  
Actino bacillus actinomycetemcomitans leukotoxin induces apoptosis in HL-60 cells. Sep 1998
- 7/6/48 11469699 98353391 PMID: 9687463  
Phage display of a biologically active Bacillus thuringiensis toxin. Aug 1998
- 7/6/49 11436654 98318336 PMID: 9655604  
Nicotinic agonists competitively antagonize serotonin at mouse 5-HT3 receptors expressed in *Xenopus* oocytes. May 15 1998
- 7/6/50 11430324 98312844 PMID: 9650824  
Affluent signals to the CNS appear not to condition the modulation of interleukin-1 receptors in the hippocampus. Sep-Dec 1997
- 7/6/51 11412641 98294443 PMID: 9630987  
An *Escherichia coli* hemolysin transport system-based vector for the export of polypeptides: export of Shiga-like toxin IIb subunit by *Salmonella typhimurium*  $\Delta$ roA. Jun 1996
- 7/6/52 11386068 98248937 PMID: 9567366  
Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology [ Immunotoxines recombinantes et toxines chimeres pour une therapie ciblée en oncologie. Dec 1997
- 7/6/53 11350445 98230732 PMID: 9563949  
Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. May 1 1998
- 7/6/54 11343319 98223384 PMID: 9563895  
Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo. Apr 1998
- 7/6/55 11337192 98217169 PMID: 9558086  
Increasing immunogenicity of antigens fused to Ig-binding proteins by cell surface targeting. Apr 15 1998
- 7/6/56 11325272 98204871 PMID: 9553863  
A modular DNA carrier protein based on the structure of diphtheria toxin mediates target cell-specific gene delivery. Apr 10 1998
- 7/6/57 11310748 98190040 PMID: 9521785  
The biochemistry of hemolysin toxin activation: characterization of HlyC, an internal protein acyltransferase. Mar 31 1998
- 7/6/58 11308636 98167903 PMID: 9529054  
The N-terminal part of the enzyme component (C2) of the binary *Clostridium botulinum* C2 toxin interacts with the binding component 2II and functions as a carrier system for a Rho ADP-ribosylating C3-like fusion toxin. Apr 1998
- 7/6/59 11308445 98167712 PMID: 9528863  
Belataxulin-Pseudomonas toxin fusion proteins bind but are not cytotoxic to cells expressing HER4: correlation of EGFR for cytotoxic activity. Mar 5 1998
- 7/6/60 11301954 98181049 PMID: 9514636  
Involvement of glutamic acid residue at position 7 in the formation of the intramolecular disulfide bond of *Escherichia coli* heat-stable enterotoxin I<sub>p</sub> in vivo. Mar 1998
- 7/6/61 11298186 98177234 PMID: 9508786  
Internalization of a Bacillus anthracis protective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies. Feb 1998
- 7/6/62 11275933 98154422 PMID: 9493371  
Production of a non-toxic site-directed mutant of *Clostridium perfringens* epsilon-toxin which induces protective immunity in mice. Feb 1998
- 7/6/63 11274724 98153210 PMID: 9485477  
Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1. Mar 3 1998
- 7/6/64 11274632 98153118 PMID: 9485385
- Streptolysin C: a proposed model of allosteric interaction between a pore-forming protein and its target lipid bilayer. Feb 24 1998
- 7/6/65 11269315 98147722 PMID: 9488398  
Chimeric clostridial cytotoxins: identification of the N-terminal region involved in protein substrate recognition. Mar 1998
- 7/6/66 11248187 98125736 PMID: 9466260  
Regulated transcription of *Clostridium difficile* toxin genes. Jan 1998
- 7/6/67 11233753 98111100 PMID: 9450639  
Site directed mutagenesis of histidine residues in anthrax toxin lethal factor binding domain reduces toxicity. Dec 1997
- 7/6/68 11219501 98096687 PMID: 9435018  
Construction and characterization of versatile cloning vectors for efficient delivery of native foreign proteins to the periplasm of *Escherichia coli*. 1997
- 7/6/69 11190157 98067174 PMID: 9403010  
Gening plant toxins to fuse. Oct 1997
- 7/6/70 11182550 98059866 PMID: 9395513  
Furin-mediated cleavage of Pseudomonas exotoxin-derived chimeric toxins Dec 12 1997
- 7/6/71 11168636 98044819 PMID: 9383562  
Bifunctional lacZ alpha-codB genes for selective cloning of PCR products. Nov 1997
- 7/6/72 11130131 98004523 PMID: 9342362  
Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. Oct 2 1997
- 7/6/73 11129676 98003946 PMID: 9343949  
Cytotoxicity of anthrax lethal factor microinjected into macrophage cells through Sendai virus envelopes. Feb-Apr 1997
- 7/6/74 11094612 97388302 PMID: 9247136  
Phage display of Bacillus thuringiensis CryIA(a) insecticidal toxin. Jul 7 1997
- 7/6/75 11093669 97387249 PMID: 9243285  
A recombinant GM-CSF-PE40 ligand toxin is functionally active but not cytotoxic to cells. Jun 1997
- 7/6/76 11073103 97427938 PMID: 9284126
- 7/6/77 11072462 97427296 PMID: 9282328  
Epitope conservation and immunohistochemical localization of the guanylin/stable toxin peptide receptor, guanylyl cyclase C. Sep 15 1997
- 7/6/78 11071892 97426721 PMID: 9287265  
Immune modulation and sepsis. Jun 1997
- 7/6/79 11034612 97388302 PMID: 9247136  
Phage display of Bacillus thuringiensis CryIA(a) insecticidal toxin. Jul 7 1997
- 7/6/80 11033669 97387249 PMID: 9243285  
A recombinant GM-CSF-PE40 ligand toxin is functionally active but not cytotoxic to cells. Jun 1997
- 7/6/81 11010370 97363719 PMID: 9220012  
Molecular localization of the *Escherichia coli* cytotoxic necrotizing factor CNF1 cell-binding and catalytic domains. Jun 1997
- 7/6/82 10994209 97347435 PMID: 9202074  
Rho proteins play a critical role in cell migration during the early phase of mucosal restitution. Jul 1 1997
- 7/6/83 10963780 97336906 PMID: 9193653  
Using secondary structure predictions and site-directed mutagenesis to identify and probe the role of potential active site motifs in the RT6 monof(ADP-ribosyl)transferases. 1997
- 7/6/84 10962992 97336105 PMID: 9192900  
Gin 63 of Rho is deamidated by *Escherichia coli* cytotoxic necrotizing factor-1. Jun 12 1997
- 7/6/85 10974561 97327728 PMID: 9210405  
Construction, expression and characterization of chimeric toxins containing the ribonucleolytic toxin restriction: intracellular mechanism of act Jun 15 1997
- 7/6/86 10961209 97313862 PMID: 9170263

- Cleavage of the synaptobrevin-vesicle-associated membrane protein (VAMP) of the mouse brain by the recombinant light chain of Clostridium botulinum type B toxin. May '15 1997
- 7/6/87 10937344 97289728 PMID: 9144199  
Channel formation by antipapotic protein Bc-2. May '13 1997
- 7/6/88 10920130 97272276 PMID: 9114042  
Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity. Apr 29 1997
- 7/6/89 10911411 97263493 PMID: 9109408  
Characterization and receptor specific toxicity of two diphtheria toxin-related interleukin-3 fusion proteins DAB389-nIL-3 and DAB399-(Gly4Ser)2-nIL-3. Apr 7 1997
- 7/6/90 10899020 97250967 PMID: 9096650  
Intra-tumoral application of a heparin-exotoxin-a fusion protein causes rapid tumor regression without adverse systemic or local effects. Mar 17 1997
- 7/6/91 10887084 97238939 PMID: 9083117  
A mechanism for toxin insertion into membranes is suggested by the crystal structure of the channel-forming domain of colicin E1. Mar '15 1997
- 7/6/92 10866676 97218154 PMID: 9065815  
In vitro effects of a recombinant toxin, MSCF-PE40, targeting c-kit receptors ectopically expressed in small cell lung cancers. Feb 26 1997
- 7/6/93 10653874 97205237 PMID: 9052741  
HNF1 alpha activates the rat UDP-glucosyltransferase UGT2B1 gene promoter. Feb 1997
- 7/6/94 10851131 97202479 PMID: 9049998  
Nucleotide sequence of a gene encoding the novel *Yersinia enterocolitica* heat-stable enterotoxin that includes a pro-region-like sequence in its mature toxin molecule. Feb 1997
- 7/6/95 10836413 97187652 PMID: 9035105  
A new class of antigen-specific killer cells. Jan 1997
- 7/6/96 10819657 97109543 PMID: 8951823  
*Pseudomonas* exotoxin exhibits increased sensitivity to furin when sequences at the cleavage site are mutated to resemble the arginine-rich loop of diphtheria toxin. Nov 1996
- 7/6/97 10812920 97102795 PMID: 8947035  
Homologues of the human multidrug resistance genes MRP and MDR contribute to heavy metal resistance in the soil nematode *Caenorhabditis elegans*. Nov 15 1996
- 7/6/98 10803648 97053160 PMID: 8938722  
Interaction of  $\text{Ca}^{2+}$ -activated  $\text{K}^{+}$  channels with refolded charybotoxins mutated at a central interaction residue. 1996
- 7/6/99 10803569 97053081 PMID: 8938643  
Molecular and biochemical characterization of a heat-labile cytotoxic enterotoxin from *Aeromonas hydrophila*. Nov 1996
- 7/6/100 10801193 97090693 PMID: 8936601  
Use of *Vibrio* spp. for expression of *Escherichia coli* enterotoxin B subunit fusion proteins: purification and characterization of a chimera containing a C-terminal fragment of DNA polymerase from herpes simplex virus type 1. Nov 1996
- 7/6/101 10795314 97084797 PMID: 8931131  
Characterization of a ricin fusion toxin targeted to the interleukin-2 receptor. Oct 1996
- 7/6/102 10787943 97138224 PMID: 8985250  
Potent antitumor activity of a new class of tumour-specific killer cells. Jan 2 1997
- 7/6/103 10776687 97126817 PMID: 8971711  
Comparative analysis of the virulence control systems of *Bordetella pertussis* and *Bordetella bronchiseptica*. Dec 1996
- 7/6/104 10776116 97126244 PMID: 8971168  
Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated *Pseudomonas* exotoxin for therapy of malignant astrocytoma. Dec '15 1996
- 7/6/105 10759657 97109543 PMID: 8951823  
*Pseudomonas* exotoxin exhibits increased sensitivity to furin when sequences at the cleavage site are mutated to resemble the arginine-rich loop of diphtheria toxin. Nov 1996
- 7/6/106 10752920 97102795 PMID: 8947035
- Homologues of the human multidrug resistance genes MRP and MDR contribute to heavy metal resistance in the soil nematode *Caenorhabditis elegans*. Nov 15 1996
- 7/6/107 10743648 97093160 PMID: 8938722  
Interaction of  $\text{Ca}^{2+}$ -activated  $\text{K}^{+}$  channels with refolded charybotoxins mutated at a central interaction residue. 1996
- 7/6/108 10743569 97093081 PMID: 8938643  
Molecular and biochemical characterization of a heat-labile cytotoxic enterotoxin from *Aeromonas hydrophila*. Nov 1996
- 7/6/109 10741193 97090693 PMID: 8936601  
Use of *Vibrio* spp. for expression of *Escherichia coli* enterotoxin B subunit fusion proteins: purification and characterization of a chimera containing a C-terminal fragment of DNA polymerase from herpes simplex virus type 1. Nov 1996
- 7/6/110 10735314 97084797 PMID: 8931131  
Characterization of a ricin fusion toxin targeted to the interleukin-2 receptor. Oct 1996
- 7/6/111 10729076 97078529 PMID: 8919453  
Identification and characterization of an extracellular protease activity produced by the marine *Vibrio* sp. 60. Feb 1 1996
- 7/6/112 10703540 97052810 PMID: 8897439  
Recombinant immunotoxins: protein engineering for cancer therapy. Oct 1996
- 7/6/113 10667118 97016182 PMID: 8862819  
Positive selection of recombinant DNA by *CodB*. Aug 1996
- 7/6/114 10597761 96415308 PMID: 8818275  
Construction of new insecticidal *Bacillus thuringiensis* recombinant strains by using the sporulation non-dependent expression system of *cpIIA* and a site specific recombination vector. Jul 18 1996
- 7/6/115 10591049 96405954 PMID: 8810079  
Use of translational fusions to the maltose-binding protein to produce and purify proteins in *Pseudomonas syringae* and assess their activity in vivo. Sep 1996
- 7/6/116 10579239 96391982 PMID: 8794167  
Protein engineering and design for drug delivery. Aug 1996
- 7/6/117 10575341 96387501 PMID: 8795010  
Heparin-binding capacity of the HIV-1 NEF-protein allows one-step purification and biochemical characterization. Jun 1996
- 7/6/118 10540323 96351741 PMID: 8741987  
Studies on the activity of barnase toxins in vitro and in vivo. Jan-Feb 1996
- 7/6/119 10522249 96333343 PMID: 8757837  
*Escherichia coli* hemolysin mutants with altered target cell specificity. Aug 1996
- 7/6/120 10516897 96327868 PMID: 8735086  
Serodiagnosis of listeriosis based upon detection of antibodies against recombinant truncated forms of listeriolysin O. Jun 1996
- 7/6/121 10513000 96323624 PMID: 8739196  
A recombinant *Escherichia coli* heat-stable enterotoxin b (STb) fusion protein eliciting neutralizing antibodies. Apr 1996
- 7/6/122 10512619 96323240 PMID: 8710889  
Fused polycationic peptide mediates delivery of diphtheria toxin A chain to the cytosol in the presence of antitoxin protective antigen. Aug 6 1996
- 7/6/123 10500026 96310688 PMID: 8740563  
The performance of e23(Fv)/PEs recombinant toxins targeting the erbB-2 protein. Apr 1996
- 7/6/124 10489724 96300228 PMID: 8706664  
A recombinant insect-specific alpha-toxin of *Buthus occulans* lunulatus scorpion confers protection against homologous mammalian toxins. Jun 1996
- 7/6/125 10485192 96294783 PMID: 8698498  
Amino acid residues in the pro region of *Escherichia coli* heat-stable enterotoxin I that affect efficiency of translocation across the inner membrane. Jul 1996
- 7/6/126 10480824 96290247 PMID: 8728098  
A continuous epitope from transmissible gastroenteritis virus S protein fused to *E. coli* heat-labile toxin B subunit expressed by attenuated *Salmonella* induces serum and secretory immunity. Mar 1996
- 7/6/127 10480514 96289937 PMID: 8660841

An improved circularly permuted interleukin 4 toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of gamma c chain in RCC cells does not improve sensitivity. Jul 10 1995

7/6/128 10468062 96275213 PMID: 8787077

Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of BR96 sFv-PE40 and heregulin-PE40. 1996

7/6/129 10429777 96236208 PMID: 8787415

New gene from nine *Bacillus sphaericus* strains encoding highly conserved 35.8-kilodalton mosquitoicidal toxins. Jun 1995

7/6/130 10428654 96234995 PMID: 8639641

Role of C&S, a human homologue to the yeast chromosome segregation gene CSE1, in toxin and tumor necrosis factor mediated apoptosis. May 28 1996

7/6/131 10427576 96234003 PMID: 8654560

Translational fusion of heat labile enterotoxin chain B and beta-subunit of human chorionic gonadotropin: periplasmic expression in *Escherichia coli* and its immunogenicity. May 27 1996

7/6/132 10404014 96209978 PMID: 8631856

Target: cell-specific DNA transfer mediated by a chimeric multidomain protein. Novel non-viral gene delivery system. May 3 1996

7/6/133 10403662 96209279 PMID: 8633853

Domain III substitution in *Bacillus thuringiensis* delta-endotoxin CryIA(b) results in superior toxicity for *Spodoptera exigua* and altered membrane protein recognition. May 1996

7/6/134 10399063 96204514 PMID: 8628234

Analysis of cryIIa expression in *sigE* and *sigK* mutants of *Bacillus thuringiensis*. Apr 10 1996

7/6/135 10395435 96200861 PMID: 8621095

A *Bacillus sphaericus* gene encoding a novel type of mosquitoicidal toxin of 31.8 kDa. Apr 17 1996

7/6/136 10394691 96200113 PMID: 8631720

Plasmid RK2 toxin protein *ParE*: purification and interaction with the *ParD* antitoxin protein. Mar 1996

7/6/137 10382592 96187879 PMID: 8609372

Cytotoxicity of KDEL-terminated ricin toxins correlates with distribution of the KDEL receptor in the Golgi. Feb 1996

7/6/138 10373241 96178238 PMID: 8617218

A specific targeting domain in mature exotoxin A is required for its extracellular secretion from *Pseudomonas aeruginosa*. Jan 15 1996

7/6/139 10364229 96167453 PMID: 8608178

IL2-rich fusion toxin is selectively cytotoxic in vitro to IL2 receptor-bearing tumor cells. Nov-Dec 1995

7/6/140 10360272 96163481 PMID: 8575455

Lipid interaction of the 37-kDa and 58-kDa fragments of the *Helicobacter pylori* cytotoxin. Dec 15 1995

7/6/141 10357255 96160040 PMID: 8562903

Targeting diphtheria toxin to growth factor receptors. Oct 1995

7/6/142 10345443 96147920 PMID: 8575044

[Construction and expression of the gene CD4V1V2-PE40, coding for a molecular targeted protein against AIDS] Aug 1995

7/6/143 10332216 96134516 PMID: 8527136

Improved expression of toxic proteins in *E. coli*. Aug 1995

7/6/144 10328564 96130835 PMID: 8594322

Identification by *in vitro* complementation of regions required for cell-invasive activity of *Bordetella pertussis* adenylate cyclase toxin. Sep 1995

7/6/145 10326603 96128870 PMID: 8596120

Disruption of herpes simplex virus ribonucleotide reductase quaternary structure by peptide inhibitors as a novel approach to antiviral therapy. Oct 1995

7/6/146 10294589 96096516 PMID: 8522171

Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterococcal *Escherichia coli*. Nov 20 1995

7/6/147 10285718 96087571 PMID: 8522489

Experimental therapies in the treatment of cutaneous T-cell lymphoma. Oct 1995

7/6/148 10249633 96051174 PMID: 8527486

A proposed mechanism of ADP-ribosylation catalyzed by the pertussis toxin S1 subunit. 1995

7/6/149 10240727 96042092 PMID: 7592381

A modified two-component regulatory system is involved in temperature-dependent biosynthesis of the *Pseudomonas syringae* phytotoxin coronatine. Nov 1995

7/6/150 102303919 96032221 PMID: 7549113

Identification of the essential regions for LukS- and H gamma II-specific functions of staphylococcal leukocidin and gamma-hemolysin. Aug 19

7/5/4 DIALOG(R)/File 155: MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

11/976922 99421861 PMID: 10491008

IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice

Zheng X X; Steele A W; Hancock W W; Kawamoto K; Li X C; Nickerson P W; Li Y; Tian Y; Strom T B

Department of Medicine, Division of Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA 02215, USA.

Journal of Immunology (Baltimore, Md. : 1950) (UNITED STATES) Oct 1 1999 , 163 (7) p4041-8, ISSN 0022-1767

Record type: Completed Subfile: AIM; INDEX MEDICUS; AIDS/HIV

Journal Code: 2985171R Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM

High affinity IL-2R5 is present on recently activated but not on resting or memory T cells. Selective targeting of T cells bearing high affinity IL-2R is an attractive therapy for many T cell-dependent cytopathic disease processes. A variety of rodent mAbs directed against the alpha-chain of the IL-2R, as well as IL-2 fusion toxins, have been used in animals and humans to achieve selective immunosuppression. Here we report on the development of a novel IL-2R targeting agent, a cytolytic chimeric IL-2/Fc fusion protein. This immunoglobulin binds specifically and with high affinity to IL-2R and is structurally capable of recruiting host Ab-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities. The Ig component ensures an extended circulating t1/2 of 25 h following systemic administration. To subsequently explore the mechanisms of the antidiabetogenic effects of IL-2/Fc, we have mutated the FcR binding and complement C1q binding (Fc-/-) domains of the Fc fragment to render the Fc unable to direct Ab-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities. In a model of passive transfer of diabetes in nonobese diabetic mice, lytic IL-2/Fc, but not nonlytic IL-2/Fc-/-, exhibit striking antidiabetogenic effects. Together with the negligible potential of IL-2/Fc for immunogenicity, this finding forecasts that cytolytic IL-2/Fc may offer a new therapeutic approach for selective targeting of auto and alloimmune T cells.

Tags: Animal, Female, Male; Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Descriptors: Cytotoxicity; Immunologic-genetics-GE; Diabetes Mellitus; Insulin-Dependent--immunology-IM; Diabetes Mellitus; Insulin-Dependent--prevention and control-FC; Gene Therapy; Immunoglobulins; Fe-genetics-GE; Interleukin-2-genetics-GE; \*Recombinant Fusion Proteins immunology-IM; Adoptive Transfer; Antibodies, Monoclonal--administration and dosage-AD; Antigens, CD4--immunology-IM; Binding, Western; CD4 Lymphocyte Count; Diabetes Mellitus; Insulin-Dependent-genetics-GE; Diabetes Mellitus; Insulin-Dependent--pathology-P Gene Targeting; Hsf1-Like1; Immunoglobulin s, Fc--therapeutic use--TU; Injections, Intraperitoneal; Interleukin-2--therapeutic use--TU; Lymphocyte Depletion; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Recombinant Fusion Proteins--blood-BL; Recombinant Fusion Proteins--chemistry-CM; Recombinant Fusion Proteins--therapeutic use--TU CAS Registry No.: 0 (Antibodies, Monoclonal); 0 (Antigens CD4); 0 (Immunoglobulins Fc); 0 (Interleukin-2); 0 (Receptors, Interleukin-2); 0 (Recombinant Fusion Proteins)

Record Date Created: 1999/02/1 Record Date Completed: 1999/02/1

7/5/13 DIALOG(R)/File 155: MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

11887991 99330177 PMID: 10403383

Exploiting retrograde transport of Shiga-like toxin 1 for the delivery of exogenous antigens into the MHC class I presentation pathway.

Noakes K L; Teisseries H T; Lord J M; Dunbar P R; Cerundolo V; Roberts L M

Department of Biological Sciences, University of Warwick, Coventry, UK.

FEBS letters (NETHERLANDS) Jun 18 1999 , 453 (1-2) p85-9, ISSN 0014-5793 Journal Code: 0155157

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Subfile: INDEX MEDICUS

Shiga-like toxin 1 (SLT1) from *Escherichia coli* O157:H7 enters mammalian cells by endocytosis from the cell surface to the endoplasmic reticulum before translocating into the cytosol. Here, SLT1 was engineered at its N- or C-terminus to carry a peptide derived from influenza virus Matrix protein for delivery to major histocompatibility complex (MHC) class I molecules. We show that SLT1 N-Ma was capable of sensitizing cells for lysis by appropriate cytotoxic T-lymphocytes whilst no killing of SLT1-resistance cells was observed. Our results demonstrate that peptide was liberated intracellularly and that retrograde transport of a disarmed cytotoxic protein can intersect the MHC class I presentation pathway.

Tags: Support, Non-U.S. Gov't Descriptors: Antigen Presentation; \*Antigens, Viral--metabolism-ME; Bacterial Toxins--immunology-IM; \*Histocompatibility Antigens Class I; \*Viral Matrix Proteins--immunology-IM; Antigens, Viral--genetics-GE Antigens, Viral--immunology-IM; Bacterial Toxins--genetics-GE; Bacterial Toxins--metabolism-ME; Biological Transport Cytotoxicity; Immunologic; Endoplasmic Reticulum--metabolism-ME; Recombinant Fusion Proteins--immunology-IM; Recombinant Fusion Proteins--metabolism-ME; Shiga-Like Toxin 1; T-Lymphocytes; Cytotoxic-Immunology-IM; Viral Matrix Proteins--genetics-GE; Viral Matrix Proteins--metabolism-ME CAS Registry No.: 0 (Antigens, Viral); 0 (Bacterial Toxins (Histocompatibility Antigens Class I)); 0 (Recombinant Fusion Proteins); 0 (Shiga-Like Toxin 1); 0 (Viral Matrix Proteins); 0 (influenza virus membrane protein)

Record Date Created: 1999/08/02 Record Date Completed: 1999/08/02

7/5/17 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

11853088 99294094 PMID: 10367674

Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma.

Pun R K

Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda Maryland 20892, USA.

Toxicologic pathology (UNITED STATES) Jan-Feb 1999, 27 (1) p53-7, ISSN 0192-6233 Journal Code: 7905907 Document type: Journal Article Review, Review, Tutorial Languages: ENGLISH Main Citation Owner: NLM

Record type: Completed Subfile: INDEX MEDICUS

About 12,000 Americans are diagnosed with malignant astrocytoma each year. Despite surgery, radiotherapy, and chemotherapy, the prognosis of these patients remains poor. Targeted toxins based on the identification of novel antigens or receptors provide a promising new approach to treating cancer. We have identified one such cell surface protein in the form of interleukin (IL)-4 receptors (IL-4R) on human malignant astrocytoma. Normal brain tissues from frontal cortex and temporal lobe cortex do not express IL-4R. To target IL-4R, we generated a chimeric fusion protein composed of IL-4 and Pseudomonas exotoxin (IL-4-PE). This toxin is highly cytotoxic to IL-4R-bearing human brain cancer cells. Preclinical toxicologic experiments were performed in mice, rats, and guinea pigs to determine a maximum tolerated dose. Intrathecal administration in cynomolgus monkeys produced high cerebrospinal fluid levels without any central nervous system or other abnormalities. When IL-4-PE was injected into the right frontal cortex of rats, localized necrosis was observed at 1,000 but not < or = 100 microg/ml doses. Intravenous administration of this biologic to monkeys produced reversible grade 3 or grade 4 elevations of hepatic enzymes in a dose-dependent manner. These results indicate that localized administration can produce nontoxic levels of IL-4-PE that may have significant activity against astrocytoma. In vivo experiments with nude mice have demonstrated that IL-4-PE has significant antitumor activity against human glioblastoma tumor model. Intratumor administration of IL-4-PE has been initiated for the treatment of malignant astrocytoma in a phase I clinical trial. (28 Refs.)

Tags: Animal, Human Descriptors: Brain Neoplasms--therapy--1H, Exotoxins--pharmacology--PD, Glioblastoma--therapy--1H, Interleukin-4--pharmacology--PD, Pseudomonas--genetics--GE, Bacterial Proteins--genetics--GE, Brain Neoplasms--metabolism--ME, Drug Design, Exotoxins--chemical synthesis--CS, Exotoxins--therapeutic use--TU, Glioblastoma--metabolism--ME, Interleukin-4--chemical synthesis--CS, Interleukin-4--therapeutic use--TU, Recombinant Fusion Proteins--chemical synthesis--CS, Recombinant Fusion Proteins--pharmacology--PD, Recombinant Fusion Proteins--therapeutic use--TU, CAS Registry No.: 0 (Bacterial Proteins), 0 (Exotoxins), 0 (IL-4-PE-40 chimeric protein), 0 (Recombinant Fusion Proteins), 20137-55-2 (Interleukin-4), Enzyme No.: EC 2.4.2.31 (exotoxin A, Pseudomonas aeruginosa)

Record Date Created: 19990729 Record Date Completed: 19990729

7/5/18 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

11847433 99288230 PMID: 10336877

High-level expression and purification of the recombinant diphtheria toxin DTGM for PHASE I clinical trials.

Frankel A. E; Ranjani A; Freely T; Delatite S; Hall P; Tagge E; Kreitman R; Willingham M

Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA.

afra@wfu.edu

Protein expression and purification (UNITED STATES) Jun 1999, 16 (1) p190-201, ISSN 1046-5928 Journal Code: 9101495 Contract/Grant No.: NIHRO176738; HR, N.H.I.B.I Document type: Clinical Trial, Clinical Trial, Phase I; Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed Subfile: INDEX MEDICUS

A genetically engineered fusion toxin targeted to acute myeloid leukemia (AML) blasts was designed with the first 388 amino acid residues of diphtheria toxin with an H-M linker fused to human granulocyte-macrophage colony-stimulating factor. The cDNA was subcloned in the pRK bacterial expression plasmid and used to transform BL21 (DE3) Escherichia coli harboring pUBS500 plasmid. Transformants were grown in Superbroth and induced with IPTG. Inclusion bodies were isolated, washed, and denatured in guanidine hydrochloride with dithioerythritol. Recombinant protein was obtained after anion-exchange size exclusion on FPLC, and polyvinylidene difluoride affinity chromatography. The final material was filter sterilized, aseptically vialled, and stored at -80 degrees C. Fifty-four 3-liter bacterial culture preparations were made and pooled into 27 batches. The final product was characterized by Coomassie Plus protein assay, Coomassie-stained SDS-PAGE, limulus amoebocyte lysate endotoxin assay, human AML HL60 cell cytotoxicity assay, HPLC TSK3000, N-terminal sequencing, E. coli DNA contamination, C57BL/6 mouse toxicity, and immunohistochemistry. Yields were 23 mg/liter bacterial culture of denatured fusion toxin. After refolding and chromatography, final yields were 24 +/- 4% or 5 mg/liter. Vialled product was sterile and 1.7 +/- 0.4 mg/ml in PBS. Purity by SDS-PAGE was 99 +/- 1%. Aggregates by HPLC were <1%. Potency revealed a 24-h IC50 of 2.7 +/- 0.5 pM on HL60 cells. Endotoxin levels were 1 EU/ml. The N-terminal sequence was confirmed and E. coli DNA was <13 pg/ml. The LD10 in mice was 110 microg/kg/day x5. There was no evidence of loss of solubility, proteolysis, aggregation, or loss of potency over 3 months at -80 and -20 degrees C. Further, the drug was stable at 4, 25, and 37 degrees C in human serum for 48 h. Drug reacted only with human monocytes, granulocytes, and myeloid precursors in frozen human tissue sections by immunohistochemistry. The synthesis of this protein drug should be useful for production for clinical phase I/II clinical trials and may be suitable for other diphtheria fusion toxins indicated for clinical development. This is the first report of the scaleup of a recombinant fusion toxin for clinical trials. Copyright 1999 Academic Press.

Tags: Animal, Human Support, Non-U.S. Gov't, Support, U.S. Gov't, P.H.S. Descriptors: Diphtheria Toxin--isolation and purification--JP, Diphtheria Toxin--therapeutic use--TU, Granulocyte-Macrophage Colony-Stimulating Factor--isolation and purification--JP, Granulocyte-Macrophage Colony-Stimulating Factor--therapeutic use--TU, Acute Disease, Amino Acid Sequence, Base Sequence, DNA, Recombinant--

genetics--GE, Diphtheria Toxin--genetics--GE, Drug Evaluation, Preclinical, Escherichia coli--genetics--GE, Gene Expression, Granulocyte-Macrophage Colony-Stimulating Factor--genetics--GE, HL-60 Cells, Lethal Dose 50, Leukemia, Myeloid--drug therapy--DT, Mice, Mice, Inbred C57BL, Molecular Sequence Data, Plasmids--genetics--GE, Recombinant Fusion Proteins--genetics--GE, Recombinant Fusion Proteins--isolation and purification--JP, Recombinant Fusion Proteins--therapeutic use--TU, CAS Registry No.: 0 (DNA, Recombinant), 0 (Diphtheria Toxin), 0 (Plasmids), 0 (Recombinant Fusion Proteins), 83693-55-1 (Granulocyte-Macrophage Colony-Stimulating Factor)

Record Date Created: 19990712 Record Date Completed: 19990712

7/7/20 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

11814001 99253640 PMID: 10321723

Cloning and cytotoxicity of fusion proteins of EGF and angiogenin.

Yoon J M; Han S H; Kwon O B; Kim S H; Park M H; Kim B K

Department of Microbial Chemistry, College of Pharmacy, Seoul National University, Kwanak-Gu, South Korea. Life sciences (ENGLAND) 1999, 64 (16) p1435-45, ISSN 0024-3205 Journal Code: 0375521 Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Targeted toxins represent a new approach to specific cytotoxic therapy. Immunotoxins based on plant and microbial toxins are very immunogenic. To develop a targeted therapy that is less immunogenic and easily invades target tissues, four fusion proteins containing human angiogenin targeted by human EGF have been constructed. EGF is a single chain polypeptide, which binds epidermal growth factor receptor (EGFR) and is known to be internalized by endocytosis. Angiogenin has been separately fused either at the amino terminus or the carboxyl terminus of EGF via linkers, giving rise to angiogenin-gly-EGF, angiogenin-gly/4s EGF and EGF-angiogenin, EGF-gly-angiogenin, respectively. The fusion proteins were over-expressed in Escherichia coli and purified from periplasmic eluents by affinity chromatography. EGF-angiogenin and EGF-gly-angiogenin maintained receptor-binding activity of EGF and RNase activity of angiogenin in a single peptide and actively inhibited growth of human EGFR-positive target cells in culture. They are expected to have a very low immunogenic potential in humans because of their endogenous origin and also to have another potential therapeutic advantage because these fusion proteins may have overcome conventional immunotoxin and possess increased ability to penetrate because of their small size. Record Date Created: 19990526 Record Date Completed: 19990526

7/7/21

DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

11799440 99238311 PMID: 10220447

Intracellular delivery of an antiviral peptide mediated by the B subunit of Escherichia coli heat-labile enterotoxin.

Loregian A; Papini E; Saini B; Marston H S; Hirst T R; Palu G

Institute of Microbiology, University of Padua, 35121 Padua, Italy.

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Apr 27 1999, 96 (p5221-6, ISSN 0027-8424 Journal Code: 7505876 Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

We report an intracellular peptide delivery system capable of targeting specific cellular compartments. In the model system we constructed a chimeric protein consisting of the nontoxic B subunit of Escherichia coli heat-labile enterotoxin (EtxB) fused to a 27-mer peptide derived from the DNA polymerase of herpes simplex virus 1. Viral DNA synthesis takes place in the nucleus and requires the interaction with an accessory factor, UL42, encoded by the virus. The peptide designated Poi is able to dissociate this interaction. The chimeric protein, EtxB-Poi, retained the functional properties of both EtxB and peptide components and was shown to inhibit viral DNA polymerase activity in vitro via disruption of the polymerase-UL42 complex. When added to virally infected cells, EtxB-Poi had no effect on adenovirus replication but specifically interfered with herpes simplex virus 1 replication. Further studies showed that the antiviral peptide localized in the nucleus, whereas the EtxB component remained associated with vesicular compartments. The results indicate that the chimeric protein entered through endosomal acidic compartments and that the Poi peptide was cleaved from the chimeric protein before being translocated into the nucleus. The system we describe is suitable for delivery of peptides that specifically disrupt protein-protein interactions and may be developed to target specific cellular compartments. Record Date Created: 19990610 Record Date Completed: 19990610

7/7/23 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

11775824 99214180 PMID: 10196187

A novel cytotoxin from Clostridium difficile serogroup F is a functional hybrid between two other large clostridial cytotoxins.

Chaves-Olarte E; Low P; Freer E; Norlin T; Weidmann M; von Eichel-Streiber C; Theisen M

Microbiology and Tumorkbiology Center, Karolinska Institutet, S-171 77 Stockholm, Sweden.

Journal of biological chemistry (UNITED STATES) Apr 16 1999, 274 (16) p1046-52, ISSN 0021-9282 Journal Code: 29851212R Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

The large clostridial cytotoxins (LCTs) constitute a group of high molecular weight, clostridial cytotoxins that inactivate cellular small GTP-binding proteins. We demonstrate that a novel LCT (TcdB-1470) from Clostridium difficile strain 1470 is a functional hybrid between "reference" TcdB-10463 and Clostridium sorcellus TcdL-1522. All three toxins had equal enzymatic potencies but were equally cytotoxic only when microinjected. When applied extracellularly TcdB-1470 and TcdB-10463 were considerably more potent cytotoxins than TcdL-1522. The small GTP-binding protein R-Ras was identified as a target for Tcd -1470 and also for TcdL-1522 but not for Tcd -10463. R-Ras is known to control integrin-extracellular mat

interactions from inside the cell. Its glucosylation may be a major determinant for the cell rounding and detachment induced by the two R-Ras-attacking toxins. In contrast, fibroblasts treated with TrcB-10463 were anchored and remained attached, with phosphotyrosine containing structures located at the cell-to-cell contacts and beta3-integrin remaining at the tips of cellular protrusions. These components were absent from cells treated with the R-Ras-inactivating toxins. The novel hybrid toxin will broaden the utility of the LCTs for clarifying the functions of several small GTPases, now including also R-Ras. Record Date Created: 19990517 Record Date Completed: 19990517

777/29 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.  
11747698 99185011 PMID: 10085027

Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells. Singh Y, Kimpel K R, Goel S, Swain P K, Leppla S H  
Centre for Biochemical Technology, Delhi 110007, India.  
Infection and immunity (UNITED STATES) Apr 1999, 67 (4) p1853-9, ISSN 0019-9567 Journal Code: 0246127  
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed  
The protective antigen (PA) protein of anthrax toxin binds to a cellular receptor and is cleaved by cell surface trypsin to produce a 63-kDa fragment (PA63). The receptor-bound PA63 oligomerizes to a heptamer and acts to translocate the catalytic moieties of the toxin, lethal factor (LF) and edema factor (EF), from endosomes to the cytosol. In this report, we used nonfluorescent gel electrophoresis to show that each PA63 subunit in the heptamer can bind one LF molecule. Studies using PA immobilized on a plastic surface showed that monomeric PA63 is also able to bind LF. The internalization of PA and LF by cells was studied with radiolabeled and biotinylated proteins. Uptake was relatively slow, with a half-time of 30 min. The number of moles of LF internalized was nearly equal to the number of moles of PA subunit internalized. The essential role of PA oligomerization in LF translocation was shown with PA protein cleaved at residues 313-314. The oligomers formed by these proteins during uptake into cells were not as stable when subjected to heat and detergent as were those formed by native PA. The results show that the structure of the toxin proteins and the kinetics of proteolytic activation, LF binding, and internalization are balanced in a way that allows each PA63 subunit to internalize an LF molecule. This set of proteins has evolved to achieve highly efficient internalization and membrane translocation of the catalytic components, LF and EF. Record Date Created: 19990426 Record Date Completed: 19990426

777/31 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.  
11720983 99157583 PMID: 10048023

Expression and properties of an aerolysin-Clostridium septicum alpha toxin hybrid protein. Diep D B, Nelson K L, Lawrence T S, Sellman B R, Tweten R K, Buckley J T  
Department of Biochemistry and Microbiology, University of Victoria, BC, Canada.  
Molecular microbiology (ENGLAND) Feb 1999, 31 (3) p785-94, ISSN 0950-382X Journal Code: 8712028  
Contract/Grant No.: A137657, AI: NIAID Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM  
Record type: Completed

Aerolysin is a bilocal channel-forming toxin secreted by *Aeromonas hydrophila*. The alpha toxin produced by *Clostridium septicum* is homologous to the large lobe of aerolysin. However, it does not contain a region corresponding to the small lobe of the *Aeromonas* toxin, leading us to ask what the function of the small lobe is. We fused the small lobe of aerolysin to alpha toxin, producing a hybrid protein that should structurally resemble aerolysin. Unlike aerolysin, the hybrid was not secreted when expressed in *Aeromonas salmonicida*. The purified hybrid was activated by proteolytic processing in the same way as both parent proteins and, after activation, it formed oligomers that corresponded to the aerolysin heptamer. Like aerolysin, the hybrid was far more active than alpha toxin against human erythrocytes and mouse T lymphocytes. Both aerolysin and the hybrid bound to human glycoprotein, and both were inhibited by preincubation with this erythrocyte glycoprotein, whereas alpha toxin was unaffected. We conclude that aerolysin contains two receptor binding sites, one for glycosyl-phosphatidylinositol-anchored proteins that is located in the large lobe and is also found in alpha toxin, and a second site, located in the small lobe, that binds a surface carbohydrate determinant. Record Date Created: 19990506 Record Date Completed: 19990506

777/32 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.  
11720819 99157408 PMID: 10047878

Differential activity of cholera toxin and *E. coli* enterotoxin: construction and purification of mutant and hybrid derivatives. Rodighiero C, Aman A T, Lencer W J, Hirst T R  
University of Bristol, Department of Pathology and Microbiology, School of Medical Sciences, UK.  
Biochemical Society transactions (ENGLAND) Nov 1998, 26 (4) pS364, ISSN 0300-5127 Journal Code: 7506897  
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed  
Record Date Created: 19990413 Record Date Completed: 19990413

777/33 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.  
11680321 99115580 PMID: 9914159

The KDEL retrieval system is exploited by *Pseudomonas* exotoxin A, but not by Shiga-like toxin-1, during retrograde transport from the Golgi complex to the endoplasmic reticulum. Jackson M E, Simpson J C, Gird A, Peppertok R, Roberts L M, Lord J M

Department of Biological Sciences, University of Warwick, Coventry, CV4 7AL, UK. m1@dnha.bio.warwick.ac.uk  
Journal of cell science (ENGLAND) Feb 1999, 112 (Pt 4) p467-75, ISSN 0021-9533 Journal Code: 0052457  
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

To investigate the role of the KDEL receptor in the retrieval of protein toxins to the mammalian cell endoplasmic reticulum (ER) lysosome variants containing AARL or KDEL C-terminal tags, or the human KDEL receptor, have been expressed in toxin-treated COS 7 and HeLa cells. Expression of the lysosome variants and the KDEL receptor was confirmed by immunofluorescence. When such cells were challenged with diphtheria toxin (DT) or *Escherichia coli* Shiga-like toxin 1 (SLT-1) there was no observable difference in their sensitivities as compared to cells which did not express these exogenous proteins, contrast, the cytotoxicity of *Pseudomonas* exotoxin A (PE) is reduced by expressing lysosome-KDEL, which causes a redistribution of the KDEL receptor from the Golgi complex to the ER, and cells are sensitised to this toxin when they express additional KDEL receptors. These data suggest that, in contrast to SLT-1, PE can exploit the KDEL receptor in order to reach ER lumen where it is believed that membrane transfer to the cytosol occurs. This contention was confirmed by microinjecting iVero cells antibodies raised against the cytoplasmically exposed tail of the KDEL receptor. Immunofluorescence confirmed that these antibodies prevented the retrograde transport of the KDEL receptor from the Golgi complex to the ER, and this in turn reduced the cytotoxicity of PE, but not that of SLT-1, to these cells. Record Date Created: 19990720 Record Date Completed: 19990720

777/36 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.  
11657978 99092760 PMID: 9876933

Stepwise translocation of an active site loop between heat-labile enterotoxins LT-II and LT-I and characterization of the obtained hybrid toxins.

Fell I K, Platas A A, van den Akker F, Reddy R, Merritt E A, Storm D R, Ho W G

Howard Hughes Medical Institute, Department of Biological Structure, University of Washington, Seattle 98195-7742, USA  
Protein engineering (ENGLAND) Nov 1998, 11 (11) p1103-9, ISSN 0269-2139 Journal Code: 8801484

Contract/Grant No.: A1 34501, AI: NIAID Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM  
Record type: Completed

Members of the cholera toxin family, including *Escherichia coli* heat-labile enterotoxins LT-I and LT-II, catalyze the covalent modification of intracellular proteins by transfer of ADP-ribose from NAD to a specific arginine of the target protein. The ADP-ribosylating activity of these toxins is located in the A-subunit, for which LT-I and LT-II share a 63% sequence identity. The flexible loop in LT-I, ranging from residue 47 to 65, closes over the active site cleft. Previous studies have shown that point mutations in this loop have dramatic effects on the activity of LT-I. Yet, in LT-II the sequence of the equivalent loop differs at 10 positions from LT-I. Therefore five mutants of the active site loop were created by a stepwise replacement of the loop sequence in LT-I with virtually all the corresponding residues in LT-II. Since we discovered that LT-II had no activity versus the artificial substrate diethylamino-benzylidene-arginoguanidine (DEABAG) while LT-I does, our active site mutants most likely probe the NAD binding, not the arginine binding region of the active site. The five hybrid toxins obtained (Q49A, F52N, Y53T, Q49V/F52 and Q49V/F52N/Y53T) show (i) great differences in holotoxin assembly efficiency, (ii) decreased cytotoxicity in Chinese hamster ovary cells, and (iii) increased *in vitro* enzymatic activity compared with wild type LT-I. The enzymatic activity of the V53T mutant is significantly higher than that of wild type LT-I. Apparently this subtle variation at position 53 is beneficial. In contrast to several other substitutions at position 53 which previously had been shown to be deleterious for activity. The most striking result of this study is that the active site loop of LT-I, despite great sensitivity for point mutations, can essentially be replaced by the active s loop of LT-II, yielding an active 'hybrid enzyme' as well as 'hybrid toxin'. Record Date Created: 19990308 Record Date Completed: 19990308

777/38 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.  
11626571 99080051 PMID: 9843379

Characterization of membrane translocation by anthrax protective antigen.

Wesche J, Elliott J L, Falnes P O, Osnes S, Collier R J

Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.  
Biochemistry (UNITED STATES) Nov 10 1998, 37 (45) p15737-46, ISSN 0006-2960 Journal Code: 0370623

Contract/Grant No.: A120271, AI: NIAID Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM  
Record type: Completed

Solving the crystallographic structure of the ring-shaped heptamer formed by protective antigen (PA), the B moiety of anthrax toxin, has focused attention on understanding how this oligomer mediates membrane translocation of the toxins A moieties. We have developed an assay for translocation in which radiolabeled ligands are bound to proteolytically activated PA (PA63) at the surface of CHO or L6 cells, and translocation across the plasma membrane is induced by lowering the pH. The cells are then treated with Pronase E to degrade residual surface-bound material, and protected ligands are quantified after fractionation by SDS-PAGE. Translocation was most efficient (35%-50%) with LFN, the N-terminal PA binding domain of the anthrax lethal fac (LF). Intact LF, edema factor (EF), or fusion proteins containing LFN fused to certain heterologous proteins [the diphtheria toxin A chain (DTA) or dihydropyridine reductase (DHRF)] were less efficiently translocated (15%-20%), and LFN fusions to several other proteins were not translocated at all. LFN with different N-terminal residues was found to be degraded according to the N end rule by the proteasome, and translocation of LFN fused to a mutant form of DHRF with a low affinity for methotrexate (MTF



protected cells from the effects of MTX. Both results are consistent with a cytosolic location of protected proteins. Evidence that a protein must unfold to be translocated was obtained in experiments showing that (i) translocation of LFNDR1A was blocked by introduction of an artificial disulfide into the DTA moiety, and (ii) translocation of LFNDR1A was blocked by their ligands (MTX and adenine, respectively). These results demonstrate that the acid-induced translocation by anthrax toxin closely resembles that of diphtheria toxin, despite the fact that these two toxins are unrelated and form pores by different mechanisms. Record Date Created: 19981221 Record Date Completed: 19981221

777/39 DIALOG(R)/File 155/MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.  
15606274 99039034 PMID: 9821593

Positive selection vectors to generate fused genes for the expression of his-tagged proteins.  
Van Reeth T; Dieze P L; Szpirer C; Gabant P  
Université Libre de Bruxelles, Rhode-Saint-Genese, Belgium.

Biotechniques (UNITED STATES) Nov 1998, 25 (5) p898-904, ISSN 0736-6205 Journal Code: 8306785  
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed  
Epitope tagging simplifies detection, characterization and purification of proteins. Gene fusion to combine the coding region of a well-characterized epitope with the coding region for a protein of interest generally requires several subcloning steps. Alternatively, a PCR strategy can be used to generate such a chimeric gene. In addition to its simplicity, this approach allows one to limit the size of the multiple cloning sites present in conventional expression vectors, thus reducing the introduction of artifactual amino-acid sequences into the fused protein. In this communication, we describe new vectors that allow PCR cloning and selection of chimeric genes coding for N- or C-terminal His-tagged proteins. These vectors are based on the control of cell death CcdB direct selection technology and are well adapted to the cloning of blunt-ended PCR products that were generated by using thermostable polymerases that provide proofreading activity. Record Date Created: 19990119 Record Date Completed: 19990119

775/52 DIALOG(R)/File 155/MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.  
11368088 98248937 PMID: 9587386

Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology  
Immunotoxins recombinantes et toxines chimères pour une thérapie ciblée en oncologie.

Chiron M F  
Rhône-Poulenc Roier Genocell, Centre de recherche de Vitry-Affronville, France.  
Bulletin du cancer (FRANCE) Dec 1997, 84 (12) p135-40, ISSN 0007-4551 Journal Code: 0072416  
Document type: Journal Article, Review, Review, Tutorial, English Abstract Languages: FRENCH  
Main Citation Owner: NLM Record type: Completed Subfile: INDEX MEDICUS

Immunotoxins and chimeric toxins are hybrid molecules constituted of antibodies, growth factor or cytokines coupled to peptide toxins. They are designed to selectively eliminate tumor cells. Some of these chimera have been shown to induce complete tumor regressions of human tumor xenografts in immunodeficient mice. In clinical trials, higher anti tumor responses were observed in lymphoma, brain tumor, breast and colon cancers. Problems arose with normal tissue toxicity and the production of neutralising antibodies. Should the latest recombinant toxins conceived by rational design, solved these problems, chimeric toxins would be an alternative approach to target tumor cells and vascular endothelial cells in solid tumors. (37 Refs.)  
Tags: Animal; Human Descriptors: Antigen-Presenting Cells--drug effects--DE; Immunotoxins--therapeutic use--TU; Neoplasms--Experimental--therapy--TH; Recombinant Fusion Proteins--therapeutic use--TU; Antibodies, Monoclonal--pharmacology--PD; Antibodies, Monoclonal--therapeutic use--TU; Bacterial Toxins--pharmacology--PD; Bacterial Toxins--therapeutic use--TU; Cytotoxicity, Immunologic; Exotoxins--pharmacology--PD; Exotoxins--therapeutic use--TU; Immunotherapy--methods--MT; Immunotoxins--pharmacology--PD; Immunotoxins--toxicity--TO; Mice; Recombinant Fusion Proteins--pharmacology--PD; Recombinant Fusion Proteins--toxicity--TO; CAS Registry No.: 0 (Antibodies, Monoclonal); 0 (Bacterial Toxins); 0 (Exotoxins); 0 (Immunotoxins); 0 (Recombinant Fusion Proteins)  
Record Date Created: 19980602 Record Date Completed: 19980602

775/55 DIALOG(R)/File 155/MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.  
113337192 98217169 PMID: 9558086

Increasing immunogenicity of antigens fused to Ig-binding proteins by cell surface targeting  
Leonetti M; Thali R; Cotton J; Leroy S; Drevet P; Ducanceau F; Boublain J C; Menezes A  
Département d'ingénierie et de l'études des protéines, C. E. Saday, Gif-Sur-Yvette, France. leonetti@cea.fr  
Journal of immunology (Baltimore, Md. : 1950) (UNITED STATES) Apr 15 1999, 160 (8) p3820-7, ISSN 0022-1767  
Journal Code: 2985117R Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM

Record type: Completed Subfile: AIM; INDEX MEDICUS  
Fusion of antigenic proteins to Ig-binding proteins such as protein A from *Staphylococcus aureus* and its derived ZZ fragment is known to increase immunogenicity of the fused Ag in vivo. To shed light on the origin of this effect, we used snake toxins as Ags and observed that 1) fusion of toxins to ZZ enhanced their presentation to a toxin-specific T cell hybridoma (T1B2), using A20 B lymphoma cells, splenocytes, or peritoneal exudate cells as APCs; 2) this enhancement further increased when the number of fused Ig-binding domains varied from two with ZZ to five with protein A; and 3) the phenomenon vanished when the fusion protein was preincubated with an excess of free ZZ or when P388D1 monocytes cells were used as APCs. Therefore, ZZ-fused toxins are likely to be targeted to surface Ig of APCs by their ZZ moiety. Furthermore, ZZ-alpha and toxin alpha stimulated similar profiles of toxin-specific T cells in BALB/c mice, suggesting a comparable processing and presentation in vivo for both

toxin forms. To improve the targeting efficiency, ZZ-alpha was noncovalently complexed to various Igs directed to different cell surface components of APCs. The resulting complexes were up to 10(3)-fold more potent than the free toxin at stimulating T1B. Also, they elicited both a T cell and an Ab response in BALB/c mice, without the need of any adjuvant. This simple approach may find practical applications by increasing the immunogenicity of recombinant proteins without the use of adjuvant.

Tags: Animal; In Vivo Descriptors: Antigens--metabolism--ME; Carrier Proteins--immunology--IM; Carrier Proteins--metabolism--ME; Immunoglobulins--metabolism--ME; Recombinant Fusion Proteins--immunology--IM; Recombinant Fusion Proteins--metabolism--ME; Antibody Formation; Antigen Presentation; Antigen-Presenting Cells--immunology--IM; Cell Membrane--immunology--IM; Erythrocytes--immunology--IM; Hybridomas; Immunization; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Peptide Fragments--immunology--IM; Peptide Fragments--metabolism--ME; Staphylococcal Protein A--immunology--IM; Staphylococcal Protein A--metabolism--ME; T-Lymphocytes--immunology--IM; CAS Registry No.: 0 (Antigens); 0 (Carrier Proteins); 0 (Erythrocytes); 0 (Immunoglobulins); 0 (Peptide Fragments); 0 (Recombinant Fusion Proteins); 0 (Staphylococcal Protein A); 11094-614 (erythrocyte A)  
Record Date Created: 19980504 Record Date Completed: 19980504

777/63 DIALOG(R)/File 155/MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.  
11274724 98153210 PMID: 9485477

Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1.  
Landgraf R; Pegram M; Slamon D J; Eisenberg D  
Department of Chemistry and Biochemistry and Division of Hematology-Oncology, University of California--Los Angeles, Box 951570, Los Angeles, California 90095-1570, USA.  
Biochemistry (UNITED STATES) Mar 3 1998, 37 (9) p3220-8, ISSN 0006-2960 Journal Code: 0370623  
ContractGrant No.: 1K12 CA01714; CA; NCI; GM31299; GM; NIGMS Document type: Journal Article  
Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

As a step in the design of directed toxins aimed at cells that overexpress HER receptors, particularly breast carcinoma cells, we studied the properties of a chimera of diphtheria toxin (DT) and heregulin beta1. The EGF-like growth hormone heregulin is ligand for the HER3 and HER4 receptors and their heterodimers with HER2. The 60-residue EGF-like domain (hrg) of heregulin elicits a biological response and binds to these receptors primarily through its N terminus. We tested a fusion protein in which replaces the C-terminal receptor-binding domain of DT (DT(389)hrg) and an alternative design in which this domain is fused to the N terminus of DT(389). Of those two constructs, the N-terminal fusion was not active as a directed toxin but elicited a growth response. The C-terminal fusion of hrg to DT(389) yielded a functional toxin and showed cell line specific cytotoxicity that is consistent with heregulin specificity. The binding of hrg to its cognate receptor is not impaired as shown by receptor activation direct binding, and competition with free hrg. Cytotoxicity is dependent on high-affinity binding of DT(389)hrg to HER3 and HE receptors and is not mediated by HER2 overexpression alone. For those cell lines exhibiting high-affinity binding sites, the level of cytotoxicity correlates with the rate of internalization. Thus DT(389)hrg chimeras offer a possible avenue toward directed toxins against cells that overexpress HER receptors. Record Date Created: 19980403 Record Date Completed: 19980403

777/65 DIALOG(R)/File 155/MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.  
11269315 98147722 PMID: 9486398

Chimeric clostridial cytotoxins: identification of the N-terminal region involved in protein substrate recognition.  
Hofmann F; Busch C; Aktories K  
Institut für Pharmakologie und Toxikologie der Albert-Ludwigs-Universität Freiburg, Germany.

Infection and immunity (UNITED STATES) Mar 1998, 66 (3) p1076-81, ISSN 0019-9567 Journal Code: 0246127  
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed  
Clostridium sordellii lethal toxin is a member of the family of large clostridial cytotoxins that glucosylate small GTPases. In contrast to Clostridium difficile toxins A and B, which exclusively modify Rho subfamily proteins, C. sordellii lethal toxin also glucosylates Ras subfamily proteins. By deletion analysis and construction of chimeric fusion proteins of C. sordellii lethal toxin and C. difficile toxin B, we localized the enzyme activity of the lethal toxin to the N terminus of the holotoxin and identified the region involved in protein substrate specificity. The toxin fragment of the N-terminal 546 amino acid residues of C. sordellii lethal toxin glucosylated Rho and Ras subfamily proteins, as the holotoxin did. Deletion of a further 30 amino acid residues from the terminus of this active fragment drastically reduced glucotransferase activity and blocked glycosyltransferase activity. Exchange of amino acid residues 364 through 516 of lethal toxin for those in the active toxin B fragment (1 to 546) allowed glucosylation of Ras subfamily proteins. In contrast, the chimera with amino acids 1 to 364 from toxin B, 365 to 468 from lethal toxin, and 469 to 546 from toxin B exhibited markedly reduced modification of Ras subfamily proteins, whereas modification of Rac and Cdc42 was hardly changed. The data indicate that the region of amino acid residues 364 through 516 primarily defines the substrate specificity of C. sordellii lethal toxin. Record Date Created: 19980312 Record Date Completed: 19980312

777/92 DIALOG(R)/File 155/MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.  
10866676 97218154 PMID: 9068515

In vitro effects of a recombinant toxin, mSCF-PE40, targeting c-kit receptors ectopically expressed in small cell lung cancers  
Nishida K; Seto M; Takahashi T; Oshima Y; Asano S; Tojo A; Ueda R  
Laboratory of Chemotherapy, Aichi Cancer Center Research Institute, Nagoya, Japan.  
Cancer letters (IRELAND) Feb 26 1997, 113 (1-2) p153-8, ISSN 0304-3835 Journal Code: 7600053  
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Most small cell lung cancers (SCLCs) ectopically express high levels of the c-kit receptor. We have examined if the receptor can serve as a target for a chimeric toxin, mSCF-PE40 composed of murine stem cell factor (SCF) genetically fused to the N terminus of a modified form of Pseudomonas exotoxin (PE) lacking its cell recognition domain. Selective cytotoxicity was found for human c-kit receptor-negative cells. This agent thus warrants further evaluation for therapy of human SCLCs. Record Date Created: 19970407 Record Date Completed: 19970407

77/96 DIALOG(R)File 155;MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.  
10819657 97109563 PMID: 8951823

Pseudomonas exotoxin exhibits increased sensitivity to furin when sequences at the cleavage site are mutated to resemble the arginine-rich loop of diphtheria toxin.

Chiron M.F.; Ogata M.; Fitzgerald D.J.

Biotherapy Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA

Molecular microbiology (ENGLAND) Nov 1996, 22 (4) p769-78, ISSN 0950-382X Journal Code: 8712028

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

To be toxic for mammalian cells, Pseudomonas exotoxin (PE) requires proteolytic cleavage between Arg-279 and Gly-280.

Cleavage, which is mediated by the cellular protease furin, generates an active C-terminal fragment which translocates to the cytosol and inhibits protein synthesis. In vitro, furin-mediated cleavage is optimal at pH 5.5 with a relatively slow turnover rate.

Within cells, only 5-10% of cell-associated PE is cleaved. To investigate the reasons for this inefficient cleavage, the amino acid composition near the cleavage site was altered to resemble more closely the arginine-rich sequence from the functionally similar region of diphtheria toxin (DT). Four PE-DT mutants were generated, whereby 1, 5, 6 or 8 amino acids at the PE-cleavage site

were changed to amino acids found at the DT-cleavage site. Mutant proteins were expressed in *Escherichia coli*, purified and then analysed for their susceptibility to cleavage by furin and trypsin, susceptibility to cell-mediated cleavage, and cytotoxic activity relative to wild-type PE. At pH 5.5, the rate of both furin-mediated cleavage and trypsin-mediated cleavage increased

dramatically when amino acids in PE were altered to resemble the DT sequence. This increase did not alter the pH optimum for furin-mediated cleavage of PE toxins, which remained at pH 5.0-5.5. When radioactive versions of selected PE-DT proteins

were added to intact cells, an increase in the percentage of molecules that were cleaved relative to wild-type PE was also seen. However, changes that favoured increased proteolysis apparently interfered with other important toxin functions because none of the PE-DT proteins exhibited enhanced toxicity for cells when compared with the activity of wild-type PE. Record Date Created: 19970331 Record Date Completed: 19970331

106/1 14408705 22309410 PMID: 12421321  
SlyE allows secretion of YopE-DHFR hybrids by the *Yersinia enterocolitica* type III Ysc system. Nov 2002

106/2 11633291 99067023 PMID: 9651698  
Determinants of the fidelity of processing glucanase-lysozyme fusions by *Aspergillus niger*. Nov 15 1998

106/3 10701557 97050825 PMID: 8895554  
Status of YopM and YopN in the *Yersinia* Yop virulon: YopM of *Y. enterocolitica* is internalized inside the cytosol of PU-5.8 macrophages by the YopB, D, N delivery apparatus. Oct 1 1996

106/4 09859120 21671924 PMID: 11812232  
Purification of recombinant human epidermal growth factor secreted from the methylotrophic yeast *Hansenula polymorpha*. Feb 2002

106/5 09795539 21602927 PMID: 11737648  
The type III secretion chaperone LcrH co-operates with YopD to establish a negative, regulatory loop for control of Yop synthesis in *Yersinia pseudotuberculosis*. Nov 2001

106/6 08156965 94222840 PMID: 8169210  
The IcrB (YscN) gene cluster of *Yersinia pseudotuberculosis* is involved in Yop secretion and shows high homology to the spa gene clusters of *Shigella flexneri* and *Salmonella typhimurium*. May 1994

106/7 07723384 93178658 PMID: 8440393  
Purification and characterization of the trefoil peptide human spasmodic polypeptide (hSP) produced in yeast. Mar 8 1993

106/8 07520216 92383946 PMID: 1514325  
Efficient secretion in yeast based on fragments from K1 killer prepro toxin. Apr 1992

106/9 07461533 92325077 PMID: 1624469  
Structure and regulation of the *Yersinia pestis* yscBCDEF operon. Jul 1992

106/10 06967208 91207691 PMID: 1367012  
Efficient KEX2-like processing of a glucanase-interleukin-6 fusion protein by *Aspergillus nidulans* and secretion of mature interleukin-6. Apr 1991

106/11 06441772 90066461 PMID: 2885554  
Regulation of alpha-factor production in *Saccharomyces cerevisiae*: alpha-factor phenotype-induced expression of the MF alpha 1 and STE13 genes. Oct 1989

105/7 DIALOG(R)File 155;MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

07723384 93178658 PMID: 8440393

Purification and characterization of the trefoil peptide human spasmodic polypeptide (hSP) produced in yeast.

Thim L.; Noms K.; Noms F.; Nielsen P.F.; Bom S.E.; Christensen M.; Petersen J.

Department of Protein Chemistry, Pharmaceuticals Research, Novo Nordisk, Novo Alle, Bagsvaerd, Denmark.

FEBS letters (NETHERLANDS) Mar 8 1993, 318 (3) p345-52, ISSN 0014-5793 Journal Code: 0155157

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Subline: INDEX/MEDICUS

Recombinant human spasmodic polypeptide (h-SP) has been produced in relatively large amounts in *Saccharomyces cerevisiae*. The two intronless trefoil domains of the hSP-DNA were cloned separately by PCR from human genomic DNA, and the remaining parts of the gene synthesized. Recombinant plasmids were constructed to encode a fusion protein consisting of

hybrid leader sequence and the hSP sequence. The leader sequence serves to direct the fusion protein into the secretory pathway of the cell and to expose it to the Kex 2 processing enzyme system. The secreted h-SP was found in a glycosylated and an non-glycosylated form. The two forms of h-SP were purified from the yeast fermentation broth by a combination of ion exchange chromatography and preparative HPLC. The overall yield from 8 litres of fermentation broth was 160 mg h-SP and 219 mg glycosylated h-SP corresponding to 50% and 34%, respectively. The structure of the h-SP and the glycosylated h-SP

was determined by amino acid analysis and carbohydrate composition analysis as well as by peptide mapping, amino acid sequencing and mass spectrometric analysis.

Tags: Human Descriptors: Peptides--isolation and purification--IP; \* Recombinant Fusion Proteins--isolation and purification--IP; \*Saccharomyces cerevisiae--metabolism--ME; Amino Acid Sequence; Amino Acids--analysis--AN; Base Sequence; Carbohydrates--analysis

AN; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Cloning, Molecular; DNA--genetics--GE; Glycosylation; Growth Substances--chemistry--CH; Growth Substances--genetics--GE; Molecular Sequence Data; Peptide Mapping; Peptides--chemistry--CH; Peptides--genetics--GE; Plasmids; Polymerase Chain Reaction; Recombinant Fusion Proteins--biosynthesis--BI; Recombinant Fusion

Proteins--chemistry--CH; Saccharomyces cerevisiae--genetics--GE; Spectrum Analysis; Mass CAS Registry No.; 0 (Amino Acids); 0 (Carbohydrates); 0 (Growth Substances); 0 (Peptides); 0 (Plasmids); 0 (Recombinant Fusion Proteins); 146046-78-8 (trefoil factor); 8298

77-7 (pancreatic spasmodic polypeptide); 9007-49-2 (DNA)

Record Date Created: 19930330 Record Date Completed: 19930330

126/1 11130131 98004523 PMID: 9342362  
Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. Oct 2 1997

126/2 10729076 97078529 PMID: 8919453  
Identification and characterization of an extracellular protease activity produced by the marine *Vibrio* sp. 60. Feb 1 1996

126/3 08567217 95255518 PMID: 7737376  
Role of processing and intracellular transport for optimal toxicity of Shiga toxin and toxin mutants. May 1995

126/4 08370202 95058175 PMID: 7366513  
Proteolytic cleavage at arginine residues within the hydrophilic disulphide loop of the *Escherichia coli* Shiga-like toxin I A subunit is not essential for cytotoxicity. Oct 1993

126/5 08332655 95020625 PMID: 7394910  
Genetic identification of exported proteins in *Streptococcus pneumoniae*. Sep 1993

126/6 08171538 94237439 PMID: 8181710  
Efficient extracellular production of hybrid *E. coli* heat-labile enterotoxin B subunits in a marine *Vibrio*. Mar 15 1994

126/7 07905627 93386458 PMID: 8359916  
Expression of the *Pasteurella haemolytica* leukotoxin is inhibited by a locus that encodes an ATP-binding cassette homology. Sep 1993

126/8 07468879 92332425 PMID: 1629152  
Secretion of CygA-PtB and HlyA-PtB fusion proteins in *Escherichia coli*: involvement of the glycine-rich repeat domain of *Erwinia chrysanthemi* protease B. Aug 1992

126/9 05844070 88198014 PMID: 3129403  
Association of degradation and secretion of three chimeric polypeptides in *Escherichia coli*. May 1988

166/1 10064164 22008109 PMID: 12011465  
The gamma-secretase-generated intracellular domain of beta-amyloid precursor protein binds Numb and inhibits Notch signaling. May 14 2

166/2 08627536 95316063 PMID: 7795711  
SecA-dependence of the translocation of a large periplasmic loop in the *Escherichia coli* MalF inner membrane protein is a function of sequence context. Apr-Jun 1995

166/3 08542996 95231294 PMID: 7715449



Topological and mutational analysis of KpsM, the hydrophobic component of the ABC-transporter involved in the export of polyisaltic acid in *Escherichia coli* K1. Dec 1994

18/6/1 15677795 2287703 PMID: 12853446  
Caspase-activated PAK-2 is regulated by subcellular targeting and proteasomal degradation. 07 09 2003

18/6/2 15413188 22787241 PMID: 12904216  
Why green fluorescent fusion proteins have not been observed in the vacuoles of higher plants. Aug 2003

18/6/3 14599955 22423774 PMID: 12535522  
ATP hydrolysis by the proteasome regulatory complex PAN serves multiple functions in protein degradation. Jan 2003

18/6/4 14599946 22423765 PMID: 12535513  
Dissecting various ATP-dependent steps involved in proteasomal degradation. Jan 2003

18/6/5 14197767 22267310 PMID: 12177052  
PZD domains facilitate binding of high temperature requirement protease A (HtrA) and tail-specific protease (Tsp) to heterologous substrates through recognition of the small stable RNA A (ssrA)-encoded peptide. Oct 18 2002

18/6/6 14104297 22297623 PMID: 12408919  
Multiple associated proteins regulate proteasome structure and function. Sep 2002

18/6/7 13957875 22220065 PMID: 12234933  
Alternating translocation of protein substrates from both ends of ClpXP protease. Sep 16 2002

18/6/8 11880069 99321840 PMID: 10393320  
Multi-ubiquitination of a nascent membrane protein produced in a rabbit reticulocyte lysate. Jul 1999

18/6/9 11626266 99059723 PMID: 9843491  
Characterization of intermediates in the process of plant peroxisomal protein import. Dec 1 1998

18/6/10 11530405 98421510 PMID: 9748263  
UDP-galactose 4-epimerase is a class I integral membrane protein of the endoplasmic reticulum. Oct 2 1998

18/6/11 11516471 98406098 PMID: 9733748  
Prodomain-dependent nuclear localization of the caspase-2 (Nedd2) precursor. A novel function for a caspase prodomain. Sep 18 1998

18/6/12 11130131 98004523 PMID: 9342362  
Tagging HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-antitoxin fusion protein. Oct 28 1997

18/6/13 11098716 97392455 PMID: 9250669  
Anionic phospholipids are determinants of membrane protein topology. Jul 16 1997

18/6/14 11038716 97392455 PMID: 9250669  
Anionic phospholipids are determinants of membrane protein topology. Jul 16 1997

18/6/15 10846212 97197505 PMID: 9045801  
Regulation of the proteinase B structural gene PRB1 in *Saccharomyces cerevisiae*. Mar 1997

18/6/16 10417616 96223976 PMID: 8626744  
Ricin A chain fused to a chloroplast-targeting signal is unfolded on the chloroplast surface prior to import across the envelope membranes. Feb 23 1996

18/6/17 10412427 96218725 PMID: 8636058  
Stabilization of a Hema-Laz hybrid protein against proteolysis during carbon starvation in alp mutants of *Salmonella typhimurium*. Apr 1996

18/6/18 10405531 96211529 PMID: 8648731  
Properties of the protein encoded by the UL32 open reading frame of herpes simplex virus 1. Jun 1996

18/6/19 10404174 96210138 PMID: 8625976  
Proteasome inhibitors block VCAM-1 and ICAM-1 gene expression in endothelial cells without affecting nuclear translocation of nuclear factor-kappa B. Apr 1996

18/6/20 10396906 96202337 PMID: 8643690  
Signal transduction by activated rNhoct: importance of proteolytic processing and its regulation by the extracellular domain. Feb 20 1996

18/6/21 10394860 96200283 PMID: 8634315  
Rapid transmembrane movement of C6-NBD-labeled phospholipids across the inner membrane of *Escherichia coli*. Apr 3 1996

18/6/22 10394680 96200102 PMID: 8631709

Topological characterization of the essential *Escherichia coli* cell division protein FtsN. Mar 1996

18/6/23 10113842 22080068 PMID: 12085229  
Analysing c-Mit internalization using a functional c-Mit-EGFP chimera containing the fluorochrome within the extracellular domain. Jul 4 2002

18/6/24 09866371 21668973 PMID: 11809791  
Role for the adaptor protein Gcd10 in the activation of Akt. Feb 2002

18/6/25 09573677 21356495 PMID: 11454738  
Hydroxamate-inducible factor-1 alpha (HIF-1 alpha) escapes O2-driven proteasomal degradation irrespective of its subcellular localization: nucleus or cytoplasm. Jul 2001

18/6/26 09483802 21260031 PMID: 11359933  
Ligand-dependent degradation of Sme3 by a ubiquitin ligase complex of ROC1 and associated proteins. May 2001

18/6/27 09461606 21234971 PMID: 11336669  
The human peroxisomal targeting signal receptor, Pex5p, is translocated into the peroxisomal matrix and recycled to the cytosol. Apr 20 2001

18/6/28 09453302 21225521 PMID: 11325926  
Fosrespore-specific transcription of the lonB gene during sporulation in *Bacillus subtilis*. May 2001

18/6/29 09382476 21145823 PMID: 11248057  
The nucleoporin Nup88 associates with the intranuclear filamentous protein network of TPR. Mar 13 2001

18/6/30 09374452 21137192 PMID: 11238907  
Proteasome inhibition induces nuclear translocation and transcriptional activation of the dioxin receptor in mouse embryo primary fibroblasts the absence of xenobiotics. Mar 2001

18/6/31 09186681 20493582 PMID: 10922368  
The amino-terminal domain of apolipoprotein B does not undergo retrograde translocation from the endoplasmic reticulum to the cytosol. Proteasomal degradation of nascent apolipoprotein B begins at the carboxyl terminus of the protein, while apolipoprotein B is still in its original translocon. Oct 13 2000

18/6/32 09186694 20493281 PMID: 11038175  
Characterization of the signal that directs Tom20 to the mitochondrial outer membrane. Oct 16 2000

18/6/33 08590412 95278726 PMID: 7758939  
C-terminal glycine-histidine tagging of the outer membrane protein Iga beta of *Neisseria gonorrhoeae*. Apr 1 1996

18/6/34 08575242 95263544 PMID: 7744847  
Import of transcription factor MTF1 into the yeast mitochondria takes place through an unusual pathway. May 19 1995

18/6/35 08370202 95058175 PMID: 766513  
Proteolytic cleavage at arginine residues within the hydrophilic disulphide loop of the *Escherichia coli* Shiga-like toxin I: A subunit is not essential for cytotoxicity. Oct 1993

18/6/36 08367435 95045406 PMID: 7957078  
Molecular chaperones cooperate with PIM1 protease in the degradation of misfolded proteins in mitochondria. Nov 1 1994

18/6/37 08332655 95020625 PMID: 7934910  
Genetic identification of exported proteins in *Streptococcus pneumoniae*. Sep 1993

18/6/38 08321998 95009968 PMID: 7925307  
Translocation of N-terminal tails across the plasma membrane. Oct 3 1994

18/6/39 07932600 93393433 PMID: 8379852  
Semliki Forest virus capsid protein expressed by a baculovirus recombinant. 1993

18/6/40 07536266 92404727 PMID: 2136629  
Nuclear transport of plant polyviral proteins. Oct 1990

18/6/41 07501464 92365167 PMID: 1501298  
Regulation of nuclear transport of a plant polyvirus protein by autophagy. Sep 1992

18/6/42 07469940 92324486 PMID: 1321129  
Carboxy-terminal sequences can influence the in vitro import and intragaugellar targeting of chloroplast protein precursors. Jul 15 1992

18/6/43 07453560 92317095 PMID: 1377688  
Seque nial translocation of an artificial precursor protein across the two mitochondrial membranes. Jul 5 1992

18/6/44 07426279 92289698 PMID: 1600950

Selective extracellular release of cholera toxin B subunit by *Escherichia coli*: dissection of *Neisseria* Iga beta-mediated outer membrane transport. Jun 1992

186/45 07411152 922724449 PMID: 1350514

Cytochromes c1 and b2 are sorted to the intermembrane space of yeast mitochondria by a stop-transfer mechanism. May 29 1992

186/46 07179559 92041980 PMID: 1657948

Protein import into the yeast mitochondrial matrix. A new translocation intermediate between the two mitochondrial membranes. Nov 5 1991

186/47 06973915 91214407 PMID: 2151020

Aberrant mitochondrial processing of chimeric import precursors containing subunits 8 and 9 of yeast mitochondrial ATP synthase. Dec 1990

186/48 06638675 90264273 PMID: 2188944

SecY, a multispanning integral membrane protein, contains a potential leader peptidase cleavage site. Jun 1990

186/49 06019639 89304426 PMID: 3053734

Topogenic analysis of the human immunodeficiency virus type 1 envelope glycoprotein, gp160, in microsomal membranes. Nov 1988

186/50 06902842 88257183 PMID: 3290220

Signal and membrane anchor functions overlap in the type II membrane protein I gamma CAT. Jun 1988

187/20 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

10396906 96202337 PMID: 8643690

Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain.

Kopan R, Schroeder E H; Weintraub H; Wee J S

Division of Dermatology, Department of Molecular Biology and Pharmacology, Washington University, St. Louis, MO 63110, USA.

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Feb 20 1996, 93 (4)

p1683-8, ISSN 0027-8424 Journal Code: 7505876 Document type: Journal Article Languages: ENGLISH

Main Citation Owner: NLM Record type: Completed

Previous studies imply that the intracellular domain of Notch1 must translocate to the nucleus for its activity. In this study, we

demonstrate that a mNotch1 mutant protein that lacks its extracellular domain but retains its membrane-spanning region

becomes proteolytically processed on its intracellular surface and, as a result, the activated intracellular domain (mNotchIC) is

released and can move to the nucleus. Proteolytic cleavage at an intracellular site is blocked by protease inhibitors. Intracellular

cleavage is not seen in cells transfected with an inactive variant, which includes the extracellular lin-Notch-glp repeats.

Collectively, the studies presented here support the model that mNotch1 is proteolytically processed and the cleavage product is

translocated to the nucleus for mNotch1 signal transduction. Record Date Created: 19960717 Record Date Completed:

19960717

187/21 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

10394860 96200283 PMID: 8634315

Rapid transmembrane movement of C6-NBD-labeled phospholipids across the inner membrane of *Escherichia coli*.

Huijbregts R P; de Kroon A I; de Kruijff B

Department Biochemistry of Membranes, Centre for Biomembranes and Lipid Enzymology, Institute of Biomembranes, Utrecht University, The Netherlands.

Biochimica et biophysica acta (NETHERLANDS) Apr 3 1996, 1280 (1) p41-50, ISSN 0006-3002 Journal Code: 0217513

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

In this study we have investigated the transmembrane movement of short chain fluorescently labeled phospholipids across the

inner membrane of *Escherichia coli*. Exogenously added C6-NBD-labeled phospholipids rapidly flip across the inner membrane

of *E. coli*, as was shown by a diffusion reduction assay applied to inverted inner membrane vesicles (ILMV) isolated from wild

type *E. coli* cells. The rate of transmembrane movement of the phospholipid probes incorporated into ILMV is temperature

dependent, and shows no phospholipid head group specificity. C6-NBD-labeled phospholipids translocate across the membrane

of ILMV incubated at 37 degrees C with a t(1/2 of 7 min. After the incorporation into ILMV C6-NBD-PG is partially converted to CL

by CL-synthase. If ILMV are pretreated with proteinase K the conversion of this fluorescent probe to C6-NBD-CL is not observed

any more, suggesting that the catalytic domain of CL-synthase is at the cytoplasmic site of the plasma membrane of *E. coli*.

Newly synthesized C6-NBD-CL also flips across the inner membrane although at a slower rate than the other phospholipid

probes. The transmembrane movement occurs in both directions and is not influenced by treatment of the ILMV with a sulphydryl

reagent or a proteinase, nor by the presence of ATP, or a delatph across the membrane of the ILMV. However, the

transmembrane movement of the C6-NBD-labeled phospholipid probes is not observed in LUVETs (large unilamellar vesicles

made by extrusion technique) prepared of wild type *E. coli* lipids, indicating that the rapid transmembrane movement of

phospholipids across the inner membrane of *E. coli* is a protein-mediated process. Record Date Created: 19960710 Record Date

Completed: 19960710

187/33 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.

08370202 95058175 PMID: 7968513

Proteolytic cleavage at arginine residues within the hydrophilic disulphide loop of the *Escherichia coli* Shiga-like toxin I A subunit is not essential for cytotoxicity.

Burgess B J; Roberts L M

Department of Biological Sciences, University of Warwick, Coventry, UK.

Molecular microbiology (ENGLAND) Oct 1993, 10 (1) p171-9, ISSN 0950-382X Journal Code: 8712028

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

*Escherichia coli* Shiga-like toxin I is a type II ribosome-inactivating protein composed of an A subunit with RNA-specific N-

glycosidase activity, non-covalently associated with a pentamer of B subunits possessing affinity for galactose-containing

glycolipids. The A subunit contains a single intrachain disulphide bond encompassing a hydrophobic sequence containing two

tryptophan-sensitive arginine residues. By analogy with other bacterial toxins it has been proposed that proteolytic nicking, deemed

essential for a cytotoxic effect, occurs within this disulphide-bonded loop to generate the A1 and A2 fragments. Reduced A1 is

then believed to translocate an internal membrane to inactivate protein synthesis in the cytosol. In this report, the disulphide-lo

arginines of the SLT I A subunit were mutated to block the specific proteolysis presumed to occur. However, the mutant

generated remained an effective toxin having similar catalytic activity to wild-type toxin and only a marginally reduced cytotoxic

towards cultured cells. We conclude that the disulphide-loop arginine residues are not the unique and essential processing site

previously assumed, but that processing may occur at alternative accessible sites to compensate for loss of target sites within

the loop. Record Date Created: 19941129 Record Date Completed: 19941129

20/67 16123688 PMID: 14642278

Regulating the conducting states of a mammalian serotonin transporter. Oct 30 2003

20/62 15440652 22793392 PMID: 12913111

Rho-specific Bacillus cereus ADP-ribosyltransferase C3ser cloning and characterization. Aug 19 2003

20/63 15377227 22613949 PMID: 12722723

Expression, purification, and efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation domain variants. May 2003

20/64 15348009 22765599 PMID: 12750364

Entrapment of Rho ADP-ribosylated by Clostridium botulinum C3 exoenzyme in the Rho-guanine nucleotide dissociation inhibitor-1 complex. 05

2003

20/65 15377414 22773060 PMID: 12890789

Reversible suppression of glutamatergic neurotransmission of cerebellar granule cells in vivo by genetically manipulated expression of

tetanus neurotoxin light chain. Jul 30 2003

20/66 15311407 22758990 PMID: 12853568

Intra actions between synaptic vesicle fusion proteins explored by atomicforce microscopy. 07 09 2003

20/67 15120030 22538130 PMID: 12850831

Prostaglandin F(2alpha) stimulation of cyclooxygenase-2 promoter activity by the FP(2B) prostanoid receptor. Mar 28 2003

20/68 15004649 22617621 PMID: 12731878

Channel formation by the binding component of Clostridium botulinum C2 toxin: glutamate 307 of C2II affects channel properties in vitro a

pH-dependent C2I translocation in vivo. May 13 2003

20/69 14937497 22435559 PMID: 12547349

A single dose of recombinant Salmonella typhimurium induces specific humoral immune responses against heterologous *Elmerria lenella*

antigens in chicken. Jan 2003

20/610 14928003 22331471 PMID: 12444490

The uptake machinery of clonidine actin ADP-ribosylating toxins--a cell delivery system for fusion proteins and polypeptide drugs. 09 24 2002

20/611 14915304 22576820 PMID: 12691734

The Rho/RACK pathway mediates neurite growth-inhibitory activity associated with the chondroitin sulfate proteoglycans of the CNS glial scar.

Mar 2003

20/612 14790045 22560265 PMID: 12672406

Characterization of antibody responses to endogenous and exogenous antigen in the nonobese diabetic mouse. Feb 2003

20/613 14712165 22482024 PMID: 12593858

Activation of phospholipase D1 by ADP-ribosylated RhoA. Feb 28 2003

20/614 14706307 22148892 PMID: 12154081

Leukotriene D(4) induces stress-fibre formation in intestinal epithelial cells via activation of RhoA and PkCdelta. Sep 1 2002

20/615 14667953 22477381 PMID: 12588974

Inhibitory and stimulatory regulation of Rac and cell motility by the G12/13-Rho and Gi pathways: integrated downstream of a single G

protein-coupled sphingosine-1-phosphate receptor isoform. Mar 2003

- 206/6 146/19818 22516246 PMID: 12629174  
A regulated interaction of syntaxin 1A with the antidepressant-sensitive norepinephrine transporter establishes catecholamine clearance capacity. Mar 1 2003
- 206/17 14554070 22443989 PMID: 12555333  
Tetanus toxin abolishes exocytosis of ROMK1 induced by inhibition of protein tyrosine kinase. 12 30 2002
- 206/18 14546728 22135753 PMID: 12140265  
Plasma membrane targeting of SNAP-25 increases its local concentration and is necessary for SNARE complex formation and regulated exocytosis. Aug 15 2002
- 206/19 14464053 22127360 PMID: 12126902  
Recombinant *Lactobacillus johnsonii* as a mucosal vaccine delivery vehicle. Jul 26 2002
- 206/20 14387371 22012452 PMID: 12018391  
Cdc42 antagonizes inductive action of cAMP on cell shape, via effects of the myotonic dystrophy kinase-related Cdc42-binding kinase (MRCK) on myosin light chain phosphorylation. Apr 2002
- 206/21 14283907 22332362 PMID: 12237298  
Sarcolipin overexpression in rat slow twitch muscle inhibits sarcoplasmic reticulum  $Ca^{2+}$  uptake and impairs contractile function. 09 16 2002
- 206/22 14236806 22313557 PMID: 12221101  
Clostridium perfringens iota toxin Mapping of the Ia domain involved in docking with Ib and cellular internalization. 09 06 2002
- 206/23 14150739 22278759 PMID: 12391613  
Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and carntine. Nov 1 2002
- 206/24 14124259 22316781 PMID: 12429212  
Hybrid tetanus toxin C fragment-diphtheria toxin translocation domain allows specific gene transfer into PC12 cells. Sep 2002
- 206/25 14106775 21960967 PMID: 11963655  
EphA4 catalytic activity causes inhibition of RhoA GTPase in *Xenopus laevis* embryos. Mar 2002
- 206/26 13966482 22233515 PMID: 12296860  
Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B - restoration by exogenous interleukin-12. Oct 2002
- 206/27 13963781 22223651 PMID: 12244189  
Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen. Oct 1 2002
- 206/28 13954466 22213398 PMID: 12225361  
Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses. Sep 2002
- 206/29 13948465 22202601 PMID: 12213444  
In vivo neuronal tracing with GFP-TTC gene delivery. Aug 2002
- 206/30 11981772 99426801 PMID: 10496883  
Humoral and cellular immune responses in mice immunized with recombinant *Mycobacterium bovis* Bacillus Calmette-Guerin producing a pertussis toxin- tetanus toxin hybrid protein. Oct 1999
- 206/31 11974144 99419034 PMID: 10488092  
GalpA(13) stimulates Rho-dependent activation of the cyclooxygenase-2 promoter. Sep 24 1999
- 206/32 11974124 99419014 PMID: 10488072  
Neosynthesis and activation of Rho by *Escherichia coli* cytotoxic necrotizing factor (CNF1) reverse cytopathic effects of ADP-ribosylated Rho. Sep 24 1999
- 206/33 11966074 99410778 PMID: 10479698  
Relative contribution of endogenous neurotrophins in hippocampal long-term potentiation. Sep 15 1999
- 206/34 11962231 99406730 PMID: 10477565  
Human dendritic cells very efficiently present a heterologous antigen expressed on the surface of recombinant gram-positive bacteria to CD4+ T lymphocytes. Sep 15 1999
- 206/35 11948316 99392459 PMID: 10463173  
Antigenic variants in *Bordetella pertussis* strains isolated from vaccinated and unvaccinated children. Aug 1999
- 206/36 11945831 99388884 PMID: 10450261  
Neuropil pattern formation and regulation of cell adhesion molecules in *Drosophila* optic lobe development depend on synaptobrevin. Sep 1 1999
- 206/37 11942945 99388886 PMID: 10456940  
Cell surface-exposed tetanus toxin fragment C produced by recombinant *Bacillus anthracis* protects against tetanus toxin. Sep 1999
- 206/38 11925624 99369242 PMID: 10442633  
The Src family tyrosine kinase is involved in Rho-dependent activation of c-Jun N-terminal kinase by Galpha12. Aug 5 1999
- 206/39 11909065 99352288 PMID: 10423269  
Rho-kinase (ROK) promotes CD44v3-6-10j-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. 1999
- 206/40 11853824 99294858 PMID: 10364548  
Rapid spine delivery and redistribution of AMPA receptors after synaptic NMDA receptor activation. Jun 11 1999
- 206/41 11853404 99294410 PMID: 10367944  
Instruments for oral disease-intervention strategies: recombinant *Lactobacillus casei* expressing tetanus toxin fragment C for vaccination or myelin proteins for oral tolerance induction in multiple sclerosis. Apr 23 1999
- 206/42 11847220 99288017 PMID: 10359565  
The IL-1 receptor and Rho directly associate to drive cell activation in inflammation. Jun 1999
- 206/43 11837792 99278135 PMID: 10346912  
Enhancement of the endopeptidase activity of botulinum neurotoxin by its associated proteins and diethiothreitol. May 25 1999
- 206/44 11803560 99242792 PMID: 10225867  
Immunogenicity of a *Salmonella typhimurium*  $\alpha$ roA  $\alpha$ roD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. May 1999
- 206/45 11759317 99199333 PMID: 10094832  
Activation of protein kinase C by phorbol esters modulates alpha2beta1 integrin on MC-7 breast cancer cells. Apr 10 1999
- 206/46 11722801 99160459 PMID: 10049679  
Recombinant and truncated tetanus neurotoxin light chain: cloning, expression, purification, and proteolytic activity. Mar 1999
- 206/47 11700499 99140154 PMID: 10206702  
Expression of disulphide-bridge-dependent conformational epitopes and immunogenicity of the carboxy-terminal 19 kDa domain of Plasmodium yoelii merozoite surface protein-1 in live attenuated *Salmonella* vaccine strains. Jan 1999
- 206/48 11620461 99053650 PMID: 9839925  
Monitoring of scFv selected by phage display using detection of scFv-P11 fusion proteins in a microtiter scale assay. Nov 1 1998
- 206/49 11602353 99035056 PMID: 9816208  
Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients. Mar 1998
- 206/50 11593846 99026267 PMID: 9806860  
Conjugative transfer of the *Escherichia coli*-Clostridium perfringens shuttle vector pJIR1457 to Clostridium botulinum type A strains. Nov 1
- 206/51 11592988 99025406 PMID: 9809552  
DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nov 1998
- 206/52 11497567 98381840 PMID: 9717740  
Production of an expression system for a synaptobrevin fragment to monitor cleavage by botulinum neurotoxin B. Jul 1998
- 206/53 11496293 98380521 PMID: 9712698  
Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins. Aug 1998
- 206/54 11438327 98321222 PMID: 9647788  
Localization of RhoA GTPase to endoltrial caveolae-enriched membrane domains. Jun 29 1998
- 206/55 11425098 98307523 PMID: 9645616  
Soluble human lymphocyte activation gene-3 modulates allospecific T cell responses. May 1998
- 206/56 11415320 98297359 PMID: 9635436  
The small GTP-binding protein RhoA regulates a delayed rectifier potassium channel. Jun 12 1998
- 206/57 11383536 98264620 PMID: 9603457  
MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation. May 1998
- 206/58 11350223 98230504 PMID: 9570577  
Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. Feb 1 1998
- 206/59 11335876 98215725 PMID: 9548730

- Rho-mediated contractility exposes a cryptic site in fibronectin and induces fibronectin matrix assembly. Apr 20 1998
- 206/60 11335865 98215714 PMID: 9548719  
Association of the myosin-binding subunit of myosin phosphatase and moesin: dual regulation of moesin phosphorylation by Rho-associated kinase and myosin phosphatase. Apr 20 1998
- 206/61 11308636 98187903 PMID: 9529054  
The N-terminal part of the enzyme component (C2) of the binary Clostridium botulinum C2 toxin interacts with the binding component 2II and functions as a carrier system for a Rho ADP-ribosylating C3-like fusion toxin. Apr 1998
- 206/62 11272296 98150766 PMID: 9491802  
The small GTP-binding protein Rho1 is a multifunctional protein that regulates actin localization, cell polarity, and septum formation in the fission yeast *Schizosaccharomyces pombe*. Nov 1997
- 206/63 11209393 98086179 PMID: 9426210  
Transient expression of botulinum neurotoxin C1 light chain differentially inhibits calcium and glucose induced insulin secretion in clonal beta-cells. Dec 9 1997
- 206/64 11139735 98015419 PMID: 9353935  
Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro. Oct 1997
- 206/65 11129343 98003598 PMID: 9343703  
Temperature-induced expression of human-mouse chimeric Fab 1997
- 206/66 11120921 97415331 PMID: 9271130  
Identification of a recombinant synaptobrevin-thioredoxin fusion protein by capillary zone electrophoresis using laser-induced fluorescence detection. Jul 18 1997
- 206/67 11110175 97404407 PMID: 9256494  
Construction of hybrid proteins that migrate retrogradely and transsynaptically into the central nervous system. Aug 19 1997
- 206/68 11106181 97400359 PMID: 9257853  
DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. Aug 15 1997
- 206/69 11067813 97422537 PMID: 9278305  
Impaired class II expression and antigen uptake in monocyte cells after HIV-1 infection. Sep 1 1997
- 206/70 11060921 97415331 PMID: 9271130  
Identification of a recombinant synaptobrevin-thioredoxin fusion protein by capillary zone electrophoresis using laser-induced fluorescence detection. Jul 18 1997
- 206/71 11050175 97404407 PMID: 9256494  
Construction of hybrid proteins that migrate retrogradely and transsynaptically into the central nervous system. Aug 19 1997
- 206/72 11046181 97400359 PMID: 9257853  
DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. Aug 15 1997
- 206/73 11019908 97373354 PMID: 9223983  
Heterologous expression of the cuticular-glutathione peroxidase of lymphatic filariae in an attenuated vaccine strain of Salmonella typhimurium abrogates H-2 restriction of specific antibody responses. Jun 1995
- 206/74 11008552 97361879 PMID: 9218840  
Isolation of human anti-c-erbB-2. Fabs from a lymph node-derived phage display library. Jul 1997
- 206/75 10994209 97347435 PMID: 9202074  
Rho proteins play a critical role in cell migration during the early phase of mucosal restitution. Jul 1 1997
- 206/76 10961209 97313862 PMID: 9170263  
Cleavage of the synaptobrevin-vesicle-associated membrane protein (VAMP) of the mouse brain by the recombinant light chain of Clostridium botulinum type B toxin. May 15 1997
- 206/77 10960533 97313177 PMID: 9169781  
Expression and immunogenicity of an *Echinococcus granulosus* fatty acid-binding protein in live attenuated *Salmonella* vaccine strains. Jun 1997
- 206/78 10824716 97175716 PMID: 9023371  
Binding of the synaptic vesicle v-SNARE, synaptobrevin, to the plasma membrane t-SNARE, SNAP-25, can explain docked vesicles at neurotoxin-treated synapses. Feb 4 1997
- 206/79 10790005 97140301 PMID: 8986782  
Insulin-stimulated translocation of GLUT4 glucose transporters requires SNARE-complex proteins. Dec 24 1995
- 206/80 10698443 97047696 PMID: 8926085  
Expression and immunogenicity of pertussis toxin S1 subunit: tetanus toxin fragment C fusions in *Salmonella typhi* vaccine strain CVD 908. Oct 1996
- 206/81 10662431 97011151 PMID: 8859161  
Regulation mechanism of ERK (extracellular/signal transduction kinase) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway. Oct 1996
- 206/82 10600306 96417858 PMID: 8820649  
A *Salmonella typhimurium* thirA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection. Feb 1996
- 206/83 10590509 96405413 PMID: 8809553  
Factors affecting the immunogenicity of tetanus toxin fragment C expressed in *Lactococcus lactis*. Jun 1996
- 206/84 10421671 96228050 PMID: 8647268  
Botulinum neurotoxin light chains inhibit both Ca(2+)-induced and GTP- analogue-induced catecholamine release from permeabilised adren chromaffin cells. May 20 1996
- 206/85 10389160 96194531 PMID: 8617948  
Herpesvirus saimiri open reading frame 14, a protein encoded by T lymphotropic herpesvirus, binds to MHC class II molecules and stimulates T cell proliferation. May 1 1996
- 206/86 103693907 96174811 PMID: 8599324  
Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. Feb 1 1996
- 206/87 10362180 96165391 PMID: 8571127  
Identification of a putative target for Rho as the serine-threonine kinase protein kinase N. Feb 2 1995
- 206/88 10361266 96164477 PMID: 8578848  
Expression of fragment C of tetanus toxin used to a carboxyl-terminal fragment of diphtheria toxin in *Salmonella typhi* CVD 908 vaccine strain Nov 1995
- 206/89 10348836 96151333 PMID: 8599190  
Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen. Oct 1995
- 206/90 10310362 96112457 PMID: 8678289  
Detection of arginine-ADP-ribosylated protein using recombinant ADP-ribosylarginine hydrolase. Oct 10 1995
- 206/91 10271008 96072756 PMID: 7578132  
Expression and purification of the light chain of botulinum neurotoxin A: a single mutation abolishes its cleavage of SNAP-25 and neurotoxic after reconstitution with the heavy chain. Nov 21 1995
- 206/92 10248273 96049754 PMID: 7486581  
Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs. Sep 29 1995
- 206/93 10228878 96030146 PMID: 7476431  
Purification and assay of recombinant C3 transferase. 1995
- 206/94 10149075 22140381 PMID: 12145319  
Amsin, a novel syntaxin-binding protein that may regulate SNARE complex assembly. Aug 2 2002
- 206/95 10148812 22140034 PMID: 12145198  
Calmodulin and lipid binding to synaptobrevin regulates calcium-dependent exocytosis. Aug 1 2002
- 206/96 10144823 22133754 PMID: 12114537  
Retrograde trans-synaptic transfer of green fluorescent protein allows the genetic mapping of neuronal circuits in transgenic mice. Jul 23 2000
- 206/97 10092697 22048404 PMID: 12052960  
Trans-synaptic Eph receptor-ephrin signaling in hippocampal mossy fiber LTP. Jun 7 2002
- 206/98 099863262 21909309 PMID: 11912151  
Vaccination with DNA encoding a single-chain TCR fusion protein induces antitumor immunity and protects against T-cell lymphoma. Mar 2002
- 206/99 09916932 21826459 PMID: 11741886  
The binary Clostridium botulinum C2 toxin as a protein delivery system: identification of the minimal protein region necessary for interaction toxin components. Feb 15 2002

205/100 09860389 21673341 PMID: 11814247  
Structure-function analysis of the Rho-ADP-ribosylating exoenzyme CstIIa2 from *Staphylococcus aureus*. Feb 5 2002

205/624 DIALOG(R)File 155.MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.  
14124259 22316781 PMID: 12429212

Hydriδ tetanus toxin C fragment-diphtheria toxin translocation domain allows specific gene transfer into PC12 cells.

Barati Shahrani, Chegini Fariba, Hurtado Plinio, Rush Robert A, et al

Department of Human Physiology, Centre for Neuroscience, Flinders Medical Research Institute, Flinders University of South Australia, Adelaide, Australia. Shahrani.Barati@post.flinders.edu.au

Experimental neurology (United States) Sep 2002 177 (1) p75-87, ISSN 0014-4886 Journal Code: 0370712

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed Subfile: INDEX MEDICUS

To study the mechanism by which genes can efficiently be transferred into specific cell types, we have constructed several novel, single-chain multicomponent proteins by recombining the nontoxic C fragment of tetanus toxin and the translocation domain of diphtheria toxin together with the DNA-binding fragment of GAL4 transcription factor, for transposition of plasmid DNA into neuronal cells. The C fragment of tetanus toxin provided neuronal selectivity, the translocation domain of diphtheria toxin permitted endosomal escape, and the GAL4 domain provided binding to DNA. To assess the cellular tasks of each component in gene transfer, different combinations of these fragments were produced by polymerase chain reaction, expressed in *Escherichia coli*, and purified under native conditions from the soluble proteins. We show that only fusion proteins bearing the C fragment of tetanus toxin bind to gangliosides and, followed by their specific binding to differentiated PC12 cells, are internalized within 10 min. These proteins delivered the green fluorescence protein gene to PC12 cells, with the highest transfection efficiency achieved with proteins containing both the C fragment and the translocation domain. Addition of chloroquine elevated the transfection efficiency, which was further increased by incorporation of a nuclear localization signal in the delivery system. In addition, the effect of different DNA-condensing materials (poly-L-lysine, protamine, lysine(γ=8)-tyrosylphenyl(ε=2)-lysine(γ=8)) on gene transfer was investigated.

Tags: Animal, Support, Non-U.S. Gov't Descriptors: Diphtheria Toxin--genetics--GE, Gene Transfer Techniques--Peptide Fragments--genetics--GE, \*Tetanus Toxin--genetics--GE, Amino Acid Sequence--genetics--GE, Binding Sites--genetics--GE, Cattle, Cell Line; Diphtheria Toxin--metabolism--ME, Gene Transfer Techniques--trends--ID, Mice, Molecular Sequence Data, PC12 Cells, Peptide Fragments--metabolism--ME, Protein Transport--genetics--GE, Rats, Recombinant Fusion Proteins--genetics--GE, Recombinant Fusion Proteins--metabolism--ME, Saccharomyces cerevisiae Proteins--genetics--GE, Saccharomyces cerevisiae Proteins--metabolism--ME, Tetanus Toxin--metabolism--ME, Transfection Factors--genetics--GE, Transfection Factors--metabolism--ME, CAS Registry No.: 0 (Diphtheria Toxin), 0 (GAL4 protein, S cerevisiae), 0 (Peptide Fragments), 0 (Recombinant Fusion Proteins), 0 (Saccharomyces cerevisiae Proteins), 0 (Tetanus Toxin), 0 (Transfection Factors), 0 (tetanus toxin fragment C)

Record Date Created: 20021113 Record Date Completed: 20021209

205/27 DIALOG(R)File 155.MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.  
13963781 22223951 PMID: 12244189

Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.

Rice Jason, Buchan Sarah, Stevenson Freda K, et al

Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals Trust, Southampton, United Kingdom. j.rice@soton.ac.uk

Journal of immunology (Baltimore, Md. : 1950) (United States) Oct 1 2002 169 (7) p3908-13, ISSN 0022-1767 Journal Code: 2985117R Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed Subfile: AIM, INDEX MEDICUS

DNA vaccines can activate immunity against tumor Ags expressed as MHC class I-associated peptides. However, priming of CD8(+) CTL against weak tumor Ags may require adjuvant molecules. We have used a pathogen-derived sequence from tetanus toxin (fragment C (F(C))) fused to tumor Ag sequences to promote Ab and CD4(+) T cell responses. For induction of CD8(+) T cell responses, the F(C) sequence has been engineered to remove potentially competitive MHC class I-binding epitopes and to improve presentation of tumor epitopes. The colon carcinoma CT26 expresses an endogenous retroviral gene product, gp70, containing a known H2-L(d)-restricted epitope (AHI1). A DNA vaccine encoding gp70 alone was a poor inducer of CTL, and performance was not significantly improved by fusion of full-length F(C). However, use of a minimized domain of F(C), with the AHI1 sequence fused to the 3' position, led to rapid induction of high levels of CTL. IFN-gamma-producing epitope-specific CTL were detectable ex vivo and these killed CT26 targets in vitro. The single epitope vaccine was more effective than GM-CSF-transfected CT26 tumor cells in inducing an AHI1-specific CTL response and equally effective in providing protection against tumor challenge. Levels of AHI1-specific CTL in vivo were increased following injection of tumor cells, and CTL expanded in vitro were able to kill CT26 cells in tumor bearers. Pre-existing immunity to tetanus toxin had no effect on the induction of AHI1-specific CTL. These data demonstrate the power of epitope-specific CTL against tumor cells and illustrate a strategy for priming immunity via a dual component DNA vaccine.

Tags: Animal, Support, Non-U.S. Gov't Descriptors: Antigens, Neoplasm--immunology--IM, \*Cancer Vaccines--immunology--IM, \*Cytotoxicity, Immunology, \*Epitopes, T-Lymphocyte Activation, \*Recombinant Fusion Proteins--immunology--IM, T-Lymphocytes, Cytotoxic--immunology--IM, Vaccines, DNA--immunology--IM, Antigens, Neoplasm--administration and dosage--AD, Cancer Vaccines--administration and dosage--AD, Cancer Vaccines--chemical synthesis--CS, Cancer Vaccines--

genetics--GE, Colonic Neoplasms--immunology--IM, Colonic Neoplasms--pathology--PA, Colonic Neoplasms--prevention and control--PC, Cytotoxicity, Immunologic--genetics--GE, Epitopes, T-Lymphocyte--administration and dosage--AD, Epitopes, T-Lymphocyte--genetics--GE, Growth Inhibitors--administration and dosage--AD, Growth Inhibitors--chemical synthesis--CS, Growth Inhibitors--genetics--GE, Growth Inhibitors--immunology--IM, Injections, Intramuscular, Interferon Type II--biosynthesis--BI, Lymphocyte Activation--genetics--GE, Mice, Mice, Inbred BALB C, Neoplasm Transplantation, Recombinant Fusion Proteins--administration and dosage--AD, Recombinant Fusion Proteins chemical synthesis--CS, Recombinant Fusion Proteins--genetics--GE, Retroviridae Proteins, Oncogenic--administration and dosage--AD, Retroviridae Proteins, Oncogenic--genetics--GE, Retroviridae Proteins, Oncogenic--immunology--IM, T-Lymphocytes, Cytotoxic--transplantation--TR, tetanus Toxoid--administration and dosage--AD, Tetanus Toxoid--immunology--IM, Vaccin DNA--administration and dosage--AD, Vaccines, DNA--chemical synthesis--CS, Vaccines, DNA--genetics--GE, Viral Envelope Proteins--administration and dosage--AD, Viral Envelope Proteins--genetics--GE, Viral Envelope Proteins--immunology--IM, CAS Registry No.: 0 (Antigens, Neoplasm), 0 (Cancer Vaccines), 0 (Epitopes, T-Lymphocyte), 0 (Growth Inhibitors), 0 (Recombinant Fusion Proteins), 0 (Retroviridae Proteins, Oncogenic), 0 (Tetanus Toxoid), 0 (Vaccines, DNA), 0 (Viral Envelope Proteins), 0 (glycoprotein gp70, leukemia virus envelope protein), 8211562-6 (Interferon Type II)

Record Date Created: 20020923 Record Date Completed: 20021112

205/38 DIALOG(R)File 155.MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.  
11925624 99869242 PMID: 10442633

The Src family tyrosine kinase is involved in Rho-dependent activation of c-Jun N-terminal kinase by Galpha12.

Nagao M, Kazuo Y, Itoh H

Faculty of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Japan.

Oncogene (ENGLAND) Aug 5 1999, 18 (31) p4425-34, ISSN 0950-9232 Journal Code: 8711562

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed Subfile: INDEX MEDICUS

G12t, a member of alpha subunit of heterotrimeric G protein G12 subfamily, has been shown to stimulate c-Jun N-terminal kinase (JNK) activity through the low molecular weight GTP-binding proteins Ras, Rac, and Cdc42. In this study using the transient expression of a constitutively activated mutant of Galpha12 (Galpha12Q229L) in human embryonic kidney (HEK) 293 cells, we found that Rho and Src family kinase are also involved in the Galpha12-induced activation of JNK. The activation of JNK by Galpha12Q229L was inhibited by dominant-negative RhoA(G14V), and butanolium C3 exoenzyme which specifically inactivates Rho. In addition, the expression of activated RhoA(G14V) elevated JNK activity in HEK 293 cells. The Galpha12Q229L-stimulated activation of JNK was blocked by a specific inhibitor of protein tyrosine kinases (PP2), and C-terminal Src kinase (Csk). Moreover, we observed that Galpha12Q229L stimulated Src family kinase activity and v-Src induce JNK activation. Interestingly, the v-Src-induced activation of JNK was inhibited by dominant-negative RhoA(T19N). In contrast Csk did not inhibit the JNK activation by activated RhoA(G14V). These results suggest that Rho and Src family kinase are required for the Galpha12-induced JNK activation, and that Src family kinase acts upstream of Rho activation in the JNK pathway.

Tags: Animal, Human, Support, Non-U.S. Gov't Descriptors: \*Ca(2+)-Calmodulin Dependent Protein Kinase--metabolism--ME, GTP-Binding Proteins--metabolism--ME, \*Protein-Tyrosine Kinase--metabolism--ME, \*Proto-Oncogene Proteins--metabolism--ME, 3T3 Cells, Amino Acid Substitution, COS Cells, Cell Line, DNA Primers, Enzyme Activation, GTP-Binding Proteins--genetics--GE, Mice, Mutagenesis, Site-Directed, Polysome Chain Reaction, Proto-Oncogene Proteins--genetics--GE, Rats, Recombinant Fusion Proteins--metabolism--ME, Transfection, rDNA GTP-Binding Protein, Src Homology Domains CAS Registry No.: 0 (DNA Primers), 0 (G12-alpha protein), 0 (Proto-Oncogene Proteins), 0 (Recombinant Fusion Proteins), Enzyme No.: EC 2.7.1.112 (Protein-Tyrosine Kinase), EC 2.7.1.123 (Ca(2+)-Calmodulin Dependent Protein Kinase), EC 2.7.10.- (c-Jun amino-terminal kinase), EC 3.6.1.- (GTP-Binding Proteins), EC 3.6.1.- (moa GTP-Binding Protein)

Record Date Created: 19990830 Record Date Completed: 19990830

207/61 DIALOG(R)File 155.MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.  
11592988 99025406 PMID: 9809552

DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma.

King C. A, Spellenberg M, B, Zhu D, Rice J, Sahota S S, Thompson A R, Hamblin T J, Rad J, Stevenson F K

Tenovus Laboratory, Southampton University Hospitals Trust, England.

Nature medicine (UNITED STATES) Nov 1998, 4 (11) p1281-6, ISSN 1078-8956 Journal Code: 9502015

Comment in: Nat Med. 1998 Nov 4;1(11) 1239-40. Comment in: PMID 9809542 Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Vaccination with idiotypic protein protects against B-cell lymphoma, mainly through anti-idiotypic antibody. For use in patients DNA vaccines containing single-chain Fv derived from tumor provide a convenient alternative vaccine delivery system. However single-chain Fv sequence alone induces low anti-idiotypic response and poor protection against lymphoma. Fusion of the gene encoding fragment C of tetanus toxin to single-chain Fv substantially promotes the anti-idiotypic response and induces strong protection against B-cell lymphoma. The same fusion design also induces protective immunity against a surface Ig-negative myeloma. These findings indicate that fusion to a pathogen sequence allows a tumor antigen to engage diverse immune mechanisms that suppress growth. This fusion design has the added advantage of overcoming potential tolerance to tumor th may exist in patients. Record Date Created: 19981130 Record Date Completed: 19981130

207/61 DIALOG(R)File 155.MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.  
11308636 98187903 PMID: 9529054



The N-terminal part of the enzyme component (C2) of the binary Clostridium botulinum C2 toxin interacts with the binding component C2I and functions as a carrier system for a Rho ADP-ribosylating C3-like fusion toxin.

Barth H, Hofmann F, Olenik C, Just I, Aktories K  
Institut für Pharmakologie und Toxikologie der Albert-Ludwigs-Universität Freiburg, Germany.

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Aug 19 1997, 94 (17) p4000-5, ISSN 0027-8424 Journal Code: 7505876 Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

The binary actin-ADP-ribosylating Clostridium botulinum C2 toxin consists of the enzyme component C2I and the binding component C2II, which are separate proteins. The active component C2I enters cells through C2II by receptor-mediated endocytosis and membrane translocation. The N-terminal part of C2I (C2IN), which consists of 225 amino acid residues but lacks ADP-ribosyltransferase activity, was identified as the C2II contact site. A fusion protein (C2IN-C3) of C2IN and the full-length C3-like ADP-ribosyltransferase from Clostridium limosum was constructed. The fusion protein C2IN-C3 ADP-ribosylated Rho but not actin in CHO cell lysates. Together with C2II, C2IN-C3 induced complete rounding up of CHO and HeLa cells after incubation for 3 h. No cell rounding was observed without C2II or with the original C3-like transferase from C. limosum. The data indicate that the N-terminal 225 amino acid residues of C2I are sufficient to cause the cellular uptake of C. limosum transferase via the binding component of C2II, thereby increasing the cytotoxicity of the C3-like exoenzyme several hundred-fold. Record Date Created: 19980409 Record Date Completed: 19980409

207/67 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.  
11101075 97404407 PMID: 9256494

Construction of hybrid proteins that migrate retrogradely and transsynaptically into the central nervous system.

Coen L, Osta R, Maury M, Brulet P  
Unité d'Embryologie Moléculaire, Unité de Recherche Associée 1947, Centre National de la Recherche Scientifique, Institut Pasteur, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France.

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Aug 19 1997, 94 (17) p4000-5, ISSN 0027-8424 Journal Code: 7505876 Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

The nontoxic proteolytic C fragment of tetanus toxin (TTC peptide) has the same ability to bind nerve cells and be retrogradely transported through a synapse as the native toxin. We have investigated its potential use as an in vivo neurotropic carrier. In this work we show that a hybrid protein encoded by the lacZ-TTC gene fusion retains the biological functions of both proteins in vivo, i.e., retrograde transsynaptic transport of the TTC fragment and beta-galactosidase enzymatic activity. After intramuscular injection, enzymatic activity could be detected in motoneurons and connected neurons of the brainstem areas. This strategy could be used to deliver a biological activity to neurons from the periphery to the central nervous system. Such a hybrid protein could also be used to map synaptic connections between neural cells. Record Date Created: 19970917 Record Date Completed: 19970917

207/68 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.  
11106181 97400359 PMID: 9257853

DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C.

Speleberg M B, Zhu D, Thompson A, King C A, Hamblin T J, Stevenson F K

Tenovus Laboratory, Southampton University Hospitals, United Kingdom.

Journal of Immunology (Baltimore, Md. - 1950) (UNITED STATES) Aug 15 1997, 159 (4) p1885-92, ISSN 0022-1767 Journal Code: 2985117R Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Idiotypic determinants can act as tumor-associated Ags for B cell lymphoma. Vaccination with idiotypic protein and adjuvant is known to induce specific protection against lymphoma challenge in mice, largely mediated by anti-idiotypic Ab. For facilitating the approach for patients, the V(H) and V(L) genes used to encode the individual idiotypic determinants of each tumor can be obtained by PCR and assembled as single chain Fv (scFv). DNA vaccines containing scFv sequences alone induce low and poorly reproducible levels of anti-idiotypic Ab, likely to be insufficient to suppress tumor in patients. In addition, it may be necessary to break tolerance to Id in tumor bearers. By using the gene for fragment C of tetanus toxin to the C terminus of human scFv, we have promoted the anti-scFv Ab response in mice by >50-fold in three of three cases. The induced Abs are mainly against idiotypic determinants, and react specifically with patients' tumor cells, indicating optimal folding of the scFv molecule in the fusion protein. For both antigenic components of the DNA vaccine, the IgG subclass distribution showed a relative increase in IgG2a as compared with vaccination with IgM protein in adjuvant. In patients, the fusion gene should both promote anti-idiotypic Ab and induce Abs against fragment C of tetanus toxin. The latter response would provide a potentially useful comparative measure of the ability of patients to respond to conventional Ag delivered via DNA. Record Date Created: 19970828 Record Date Completed: 19970828

207/71 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.  
11050175 97404407 PMID: 9256494

Construction of hybrid proteins that migrate retrogradely and transsynaptically into the central nervous system.  
Coen L, Osta R, Maury M, Brulet P

Unité d'Embryologie Moléculaire, Unité de Recherche Associée 1947, Centre National de la Recherche Scientifique, Institut Pasteur, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France.

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Aug 19 1997, 94 (17) p4000-5, ISSN 0027-8424 Journal Code: 7505876 Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

The nontoxic proteolytic C fragment of tetanus toxin (TTC peptide) has the same ability to bind nerve cells and be retrogradely transported through a synapse as the native toxin. We have investigated its potential use as an in vivo neurotropic carrier. In this work we show that a hybrid protein encoded by the lacZ-TTC gene fusion retains the biological functions of both proteins in vivo, i.e., retrograde transsynaptic transport of the TTC fragment and beta-galactosidase enzymatic activity. After intramuscular injection, enzymatic activity could be detected in motoneurons and connected neurons of the brainstem areas. This strategy could be used to deliver a biological activity to neurons from the periphery to the central nervous system. Such a hybrid protein could also be used to map synaptic connections between neural cells. Record Date Created: 19970917 Record Date Completed: 19970917

207/76 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.  
10961209 97313862 PMID: 9170263

Cleavage of the synaptobrevin/vesicle-associated membrane protein (VAMP) of the mouse brain by the recombinant light chain of Clostridium botulinum type B toxin.

Rhee S D, Jung H H, Yang G H, Moon Y S, Yang K H

Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Taejeon, South Korea.

FEMS microbiology letters (NETHERLANDS) May 15 1997, 150 (2) p203-8, ISSN 0378-1097 Journal Code: 7705721

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

The light chain of Clostridium botulinum type B toxin was expressed in Escherichia coli using the expression vector pET-3a containing phage T7 promoter. The expressed protein was then purified by DEAE-cellulose and phosphocellulose chromatography and the proteolytic activity of the purified light chain was studied. The purified recombinant light chain cleaved synaptobrevin when mixed with the mouse brain microsome and the proteolytic activity of the light chain was inhibited if a metal chelating agent such as EDTA or 2,2'-dipyridyl was added. The recombinant light chain cleaved synaptobrevin more effectively than the native type B toxin. When the native toxin was tryptolyzed and was reduced with DTT, its proteolytic activity was similar to that of the recombinant light chain. Record Date Created: 19970714 Record Date Completed: 19970714

207/88 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.  
10361266 96164477 PMID: 8578848

Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in Salmonella typhi CVD 908 vaccine strain.

Gomez-Duane O G, Galen J, Chatfield S N, Rappuoli R, Eideals L, Levine M M

Department of Medicine, University of Maryland School of Medicine, Baltimore 21201, USA.

Vaccine (ENGLAND) Nov 1995, 13 (16) p1596-602, ISSN 0264-410X Journal Code: 8406899 Contract/Grant No.: NO1 A15096; AI, NIAID; NO1 A45251; AI, NIAID; RO1 A129471; PHS Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

We report the expression of fragment C of tetanus toxin (FC) fused to the eukaryotic cell binding domain (the carboxyl-terminus) of diphtheria toxin (FC-bD-T fusion) in attenuated Salmonella typhi live vector vaccine strain CVD 908. The FC-bD-T fusion was constructed using plasmid pET17c1r15 which carries the gene encoding FC under control of the n1B promoter (n1Bp). The open reading frame for FC was modified to incorporate an in-frame glycine-proline hinge region and a set of four restriction sites at the 3' end of the FC gene. A 482 bp DNA fragment encoding the eukaryotic cell binding domain of diphtheria toxin was then inserted at the 3' end of the modified FC gene to create an in-frame FC-bD-T fusion gene. The resulting plasmid, pOG215, was able to express the FC-bD-T fusion protein in both Escherichia coli DH5a and S. typhi CVD 908, as evidenced by Western immunoblots using anti-FC and anti-C-terminal diphtheria toxin monoclonal antibodies. Maximum expression of the FC-bD-T fusion protein was achieved by growing CVD 908(pOG215) at the low oxidation-reduction potential of thioglycollate broth, i.e., conditions that activate n1Bp and drive transcription of the FC-bD-T fusion gene. Whereas maximum expression of FC alone was also observed using thioglycollate broth, expression of bD-T alone was unsuccessful using a variety of growth conditions. FC fusions constitute one strategy to 'rescue' expression of proteins which are otherwise difficult to express. Record Date Created: 19960312 Record Date Completed: 19960312

207/82 DIALOG(R)File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.  
10600306 96417858 PMID: 8620649

A Salmonella typhimurium h7a live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection.

Chabagoty J A, Khan C M, Nash A A, Hommaechi C E

Department of Microbiology, University of Newcastle, Newcastle upon Tyne, UK.

Molecular microbiology (ENGLAND) Feb 1996, 19 (4) p791-801, ISSN 0950-382X Journal Code: 8712028 Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Multiple tandem copies of an immunogenic epitope comprising amino acids 8-23 of glycoprotein D of herpes simplex virus (HSV) were expressed as C-terminal fusions to tetanus toxin fragment C (TeC) in different *Salmonella typhimurium* live vaccine strains. Expression of the longer fusions was best in strains harbouring a lesion in *htrA*, a stress protein gene. SL3261, an *araA* strain, did not effectively express the longer fusions. Mice immunised with an S. typhimurium C5 *htrA* mutant expressing fusions with two or four copies of the peptide made an antibody response to both the peptide and TeC, whereas constructs expressing one copy of the peptide only elicited antibody to TeC. A non-immunogenic octameric fusion underwent rearrangements in vivo resulting in a predominantly monomeric fusion. In contrast, the S. typhimurium SL3261 *araC* vaccine expressing the TeC-tetrameric fusion did not elicit antibody to the peptide. Sera from mice immunised with a single dose of the dimer and tetramer fusions in the *htrA* strain neutralised HSV in vitro, and the mice were protected from HSV infection as measured by a reduction in virus load in the ear pinna. We have previously shown that mice vaccinated with salmonella expressing TeC are protected against tetanus toxin and virulent salmonella challenge. These results suggest that it may be possible to develop a multivalent vaccine against salmonellosis, tetanus and HSV. Record Date Created: 19961216 Record Date Completed: 19961216

207/88 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

10361266 96164477 PMID: 8578848

Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in *Salmonella typhi* CVD 908 vaccine strain.

Gomez-Duarte O G, Galen J, Chatfield S N, Rappuoli R, Eideis L, Levine M M

Department of Medicine, University of Maryland School of Medicine, Baltimore 21201, USA.

Vaccine (ENGLAND) Nov 1995, 13 (16) p1596-602, ISSN 0264-410X Journal Code: 8406899

Contract/Grant No.: NO1 AI15096; AI; NIAID; NO1 AI45251; AI; NIAID; RO1 AI29471; PHS Document type: Journal Article

Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

We report the expression of fragment C of tetanus toxin (FC) fused to the eukaryotic cell binding domain (the carboxyl-terminus) of diphtheria toxin (FC-bD-t fusion) in attenuated *Salmonella typhi* live vector vaccine strain CVD 908. The FC-bD-t protein fusion was constructed using plasmid pTETnrl15 which carries the gene encoding FC under control of the *ntrB* promoter (ntrBP). The open reading frame for FC was modified to incorporate an in-frame glycine-proline hinge region and a set of four restriction sites at the 3' end of the FC gene. A 482 bp DNA fragment encoding the eukaryotic cell binding domain of diphtheria toxin was then inserted at the 3' end of the modified FC gene to create an in-frame FC-bD-t fusion gene. The resulting plasmid, pOG215, was able to express the FC-bD-t fusion protein in both *Escherichia coli* DH5a and S. typhi CVD 908, as evidenced by Western immunoblots using anti-FC and anti-C-terminal diphtheria toxin monoclonal antibodies. Maximum expression of the FC-bD-t fusion protein was achieved by growing CVD 908 (pOG215) at the low oxidation-reduction potential of thioglycollate broth, i.e. in conditions that activate *ntrBP* and drive transcription of the FC-bD-t fusion gene. Whereas maximum expression of FC alone was also observed using thioglycollate broth, expression of bD-t alone was unsuccessful using a variety of growth conditions. FC fusions constitute one strategy to "rescue" expression of proteins which are otherwise difficult to express. Record Date Created: 19960312 Record Date Completed: 19960312

207/89 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

10348836 96151333 PMID: 8539190

Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen.

LaPerriere H F, Clayton M A, Middlebrook J L

Toxinology Division, U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702-5011, USA.

Toxicon - official journal of the International Society on Toxinology (ENGLAND) Oct 1995, 33 (10) p1383-6, ISSN 0041-0101 Journal Code: 1307333 Document type: Journal Article; Review; Tutorial Languages: ENGLISH

Main Citation Owner: NLM Record type: Completed

Using the polymerase chain reaction, a large fragment of botulinum toxin was placed in two expression systems, one designed to produce a fusion protein product and another designed to produce only the toxin fragment. Expression of the fragment in the latter system was inconsistent. Expression of the fusion protein was easily measurable by ELISA. Mice were vaccinated with crude fusion protein, then challenged with native toxin. Mice receiving two immunizations were partially protected from up to 1200 LD50, suggesting that this toxin fragment may be a good vaccine candidate to replace the currently used toxoid. (8 Refs) Record Date Created: 19960419 Record Date Completed: 19960419

207/99 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

09916932 21826459 PMID: 11741886

The binary Clostridium botulinum C2 toxin as a protein delivery system: identification of the minimal protein region necessary for interaction of toxin components.

Barth Hojger, Roebeling Robert, Fritz Michaela, Aktories Klaus

Institut für Experimentelle und Klinische Pharmakologie und Toxikologie der Albert-Ludwigs-Universität Freiburg, Albertstrasse 25, D-79104 Freiburg Germany. barthh@uni-freiburg.de

Journal of biological chemistry (United States) Feb 15 2002, 277 (7) p5074-81, ISSN 0021-9258 Journal Code: 2985121R

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

The binary Clostridium botulinum C2 toxin is composed of the enzyme component C2I and the binding component C2II, which are individual and non-linked proteins. Activated C2IIa mediates cell binding and translocation of C2I into the cytoplasm. C2I

ADP-ribosylates G-actin at Arg-177 to depolymerize actin filaments. A fusion toxin containing the N-terminal domain of C2I (residues 1-225) transports C3 ADP-ribosyltransferase from Clostridium limosum into cells (Barth, H., Hofmann, F., Olenik, C. Just, L., and Aktories, K. (1998) Infect. Immun. 66, 1364-1369). We characterized the adaptor function of C2I and its interaction with C2IIa. The fusion toxin GST-C2I(1-225)-C3 was efficiently transported by C2IIa, indicating that C2IIa translocates proteins into the cytosol even when the C2I(1-225) adaptor was positioned in the middle of a fusion protein. Amino acid residues 1-87 of C2I were sufficient for interaction with C2IIa and for translocation of C2I fusion toxins into HeLa cells. Residues 1-87 were the minimal part of C2I to bind to C2IIa on the cell surface, as detected by fluorescence-activated cytometry. An excess of C2I(1-8 but not of further truncated C2I fragments) competed with Alexa488-labeled C2I for binding to C2IIa. Also, the fragment C2I(3-431) and the fusion toxin C2I(30-225)-C3 competed with C2I-Alexa488 for binding to C2IIa. C2I(30-225)-C3 did not induce cytotoxic effects on cells when applied together with C2IIa, indicating that amino acid residues 1-29 are involved in translocation of C2I but are not absolutely essential for binding to C2IIa. Record Date Created: 20020211 Record Date Completed: 2002032

21/6/1 14464053 22127360 PMID: 12126902

Recombinant Lactobacillus johnsonii as a mucosal vaccine delivery vehicle. Jul 26 2002

21/6/2 11139735 98015419 PMID 9333335

Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro. Oct 1997

21/6/3 10600306 96417658 PMID: 8820649

A *Salmonella typhimurium* *htrA* live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection. Feb 1996

21/6/4 10271008 96072756 PMID: 7578132

Expression and purification of the light chain of botulinum neurotoxin A: a single mutation abolishes its cleavage of SNAP-25 and neurotoxic after reconstitution with the heavy chain. Nov 21 1995

21/6/5 08198098 94284020 PMID: 7911329

A single mutation in the recombinant light chain of tetanus toxin abolishes its proteolytic activity and removes the toxicity seen after reconstitution with native heavy chain. Jun 7 1994

20/6/101 09786731 21593241 PMID: 11757697

New strategies for vaccination and immunomodulation in N-HL. 2001

20/6/102 09784644 21590899 PMID: 11733320

DNA fusion vaccines against B-cell tumors. Dec 2001

20/6/103 09784045 21590233 PMID: 11733060

Remodelling of synaptic actin induced by photoconductive stimulation. Nov 30 2001

20/6/104 09694092 21486508 PMID: 11507098

Activation of protein kinase D by signaling through Rho and the alpha subunit of the heterotrimeric G protein G13. Oct 19 2001

20/6/105 09683906 21475804 PMID: 11591816

Rho-dependent transfer of Citron-kinase to the cleavage furrow of dividing cells. Sep 2001

20/6/106 09683875 21475773 PMID: 11591673

Surface display of recombinant proteins on *Bacillus subtilis* spores. Nov 2001

20/6/107 09588715 21372433 PMID: 11479570

Plant viral genes in DNA icosahedral vaccines activate linker CD4+ T-cell mediated immunity against B-cell malignancies. Aug 2001

20/6/108 09576600 21359546 PMID: 11466377

DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines. Aug 1 2001

20/6/109 09574549 21357442 PMID: 11464916

Lactic acid bacteria as live vaccines. Jan 2000

20/6/110 09570645 21353021 PMID: 11447282

Antibodies with infinite affinity. Jul 17 2001

20/6/111 09544048 21324877 PMID: 11431570

Conditional restoration of hippocampal synaptic potentiation in GluA-deficient mice. Jun 29 2001

20/6/112 09572530 21290769 PMID: 11397774

Human uterolisin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Jun 8 2001

20/6/113 09490505 21267040 PMID: 11356871

A common exocytotic mechanism mediates axonal and dendritic outgrowth. Jun 1 2001



206/114 09481963 21268150 PMID: 11356482  
Neuronal targeting of cardiotrophin-1 by coupling with tetanus toxin C fragment. May 2001

206/115 09445588 21217457 PMID: 11321160  
Heterologous gene expression in bacterial systems under reduced oxygen tensions. Small-scale optimization precedes industrial fermentation. Feb 2001

206/116 09414709 21181853 PMID: 11285284  
Restriction of secretory granule motion near the plasma membrane of chromaffin cells. Apr 2 2001

206/117 09410039 21176902 PMID: 11281322  
Sup3p yeast prion-like protein as an adapter for production of the Gag-p55 antigen of HIV-1 and the L-chain of botulinum neurotoxin in *Saccharomyces cerevisiae*. Jan-Feb 2001

206/118 09384540 21148517 PMID: 11253870  
Recombinant vaccines against infectious hematopoietic necrosis virus: production by the *Caulobacter crescentus* S-layer protein secretion system and evaluation in laboratory trials. Jan 26 2001

206/119 09382538 21145885 PMID: 11248119  
Genetically altered AMPA-type glutamate receptor kinetics in interneurons disrupt long-range synchrony of gamma oscillation. Mar 13 2001

206/120 09355316 21116968 PMID: 11179324  
Efficacy of two alternate vaccines based on *Plasmodium falciparum* merozoite surface protein 1 in an Aotus challenge trial. Mar 2001

206/121 08342103 21101372 PMID: 11165271  
Assessment of a vaccinia virus vectored multi-epitope live vaccine candidate for *Plasmodium falciparum*. Jan 2001

206/122 09341772 21100916 PMID: 11168632  
Low concentrations of lipopolysaccharide synergize with peptides to augment human T-cell proliferation and can prevent the induction of non-responsiveness by CTLA-4g. Jan 2001

206/123 09292031 21029392 PMID: 11191108  
RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Sep-Oct 2000

206/124 09182865 20489211 PMID: 11036518  
Rho GTPases: secretion and actin dynamics in permeabilized mast cells. 2000

206/125 09149087 20451065 PMID: 10995446

206/126 09112657 20411243 PMID: 10954418  
Membrane localization and biological activity of SNAP-25 cysteine mutants in insulin secreting cells. Sep 2000

206/127 09104452 20402597 PMID: 10944231  
Ca2+-dependent regulation of synaptic SNARE complex assembly via a calmodulin- and phospholipid-binding domain of synaptobrevin. Aug 15 2000

206/128 09092184 20389730 PMID: 10930684  
Cloning, expression and evaluation of a recombinant sub-unit vaccine against *Clostridium botulinum* type F toxin. Sep 15 2000

206/129 09030890 20324939 PMID: 10865133  
Measurement of exocytosis by amperometry in adrenal chromaffin cells: effects of clostridial neurotoxins and activation of protein kinase C on fusion pore kinetics. May 2000

206/130 09002366 20294906 PMID: 10833399  
Cloning, expression, and one-step purification of the minimal essential domain of the light chain of botulinum neurotoxin type A. Jun 2000

206/131 08996880 20289121 PMID: 10830309  
The activation of phospholipase D by endothelin-1, angiotensin II, and platelet-derived growth factor in vascular smooth muscle A10 cells is mediated by small G proteins of the ADP-ribosylation factor family. Jun 2000

206/132 08990056 20281858 PMID: 10820215  
Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C fragment: a potential vector for delivering heterologous proteins to neurons. Jun 2000

206/133 08953915 20243570 PMID: 10779774  
Characterization of human inducible costimulator ligand expression and function. May 1 2000

206/134 08942669 20231879 PMID: 10769020  
EpHrin-Δ5 induces collapse of growth cones by activating Rho and Rho kinase. Apr 17 2000

206/135 08942573 20231782 PMID: 10768937  
Tetanus toxin fragment C expressed in live *Salmonella* vaccines enhances antibody responses to its fusion partner Schistosoma haematobium glutathione S-transferase. May 2000

206/136 08922959 20211255 PMID: 10744952  
High-level expression of tetanus toxin fragment C-thioreconin fusion protein in *Escherichia coli*. Apr 2000

206/137 08915837 20203748 PMID: 10741704  
Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy. Mar 2000

206/138 08914955 20202759 PMID: 10736202  
Ectopic expression of NCAM in skeletal muscle of transgenic mice results in terminal sprouting at the neuromuscular junction and altered structure but not function. Mar 2000

206/139 08912838 20200471 PMID: 10734125  
Rho family proteins modulate rapid apoptosis induced by cytotoxic T lymphocytes and Fas. Mar 31 2000

206/140 08900494 20187498 PMID: 10722622  
Immunogenicity and efficacy in aotus monkeys of four recombinant *Plasmodium falciparum* vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. Apr 2000

206/141 08900479 20187483 PMID: 10722607  
Linkage of exogenous T-cell epitopes to the 19-kilodalton region of *Plasmodium yoelii* merozoite surface protein 1 (MSP-1(19)) can enhance protective immunity against malaria and modulate the immunoglobulin subclass response to MSP-1(19). Apr 2000

206/142 08883909 20170179 PMID: 10707906  
A somatic gene transfer approach using recombinant fusion proteins to map muscle-motoneuron projections in *Xenopus* spinal cord. Nov 1999

206/143 08873167 20158951 PMID: 10692440  
G protein modulation of N-type calcium channels is facilitated by physical interactions between syntaxin 1A and Gbetagamma. Mar 3 2000

206/144 08865185 20141225 PMID: 10676534  
Identification and characterization of functional subunits of *Clostridium botulinum* type A progenitor toxin involved in binding to intestinal microvilli and erythrocytes. Feb 11 2000

206/145 08766143 20047427 PMID: 10582602  
Botulinum neurotoxin E-insensitive mutants of SNAP-25 fail to bind VAMP but support exocytosis. Dec 1999

206/146 08715029 99403634 PMID: 7673393  
Generation of an expression library in the baculovirus expression vector system. Jun 1995

206/147 086659250 99347847 PMID: 7622252  
Characterization of recombinant tetanus toxin derivatives suitable for vaccine development. Aug 1995

206/148 08649251 99337845 PMID: 7613218  
Cloning of human anti-IgE autoantibodies and their role in the regulation of IgE synthesis. May-Jun 1995

206/149 08638422 99326951 PMID: 7603339  
Enginee ring human monoclonal antibody fragments: a recombinant enzyme-linked Fab. Apr 1995

206/150 08621485 99310012 PMID: 7790070  
Influence of preimmunization with tetanus toxoid on immune responses to tetanus toxin fragment C-guest antigen fusions in a *Salmonella* vaccine carrier. Jul 1995

206/151 08548161 99236461 PMID: 7720079  
Utilization of soluble fusion proteins for induction of T cell proliferation. Feb 1995

206/152 08608902 99197178 PMID: 7534271  
Immunogenic combinations of HIV-1 B- and heterologous T-cell epitopes. Oct 1994

206/153 08490963 99179179 PMID: 7874174  
Autosomal dominant hypocalcaemia caused by a  $Ca^{2+}$ -sensing receptor gene mutation. Nov 1994

206/154 08393632 99081611 PMID: 7527446  
Construction, expression, and immunogenicity of multiple tandem copies of the Schistosoma mansoni peptide 115-131 of the P28 glutathione S-transferase expressed as C-terminal fusions to tetanus toxin fragment C in a live attenuated vaccine strain of *Salmonella*. Dec 15 1994

206/155 08363150 99051122 PMID: 7962205  
Probing the action of *Clostridium difficile* toxin B in *Xenopus* laevis oocytes. Jun 1994

206/156 08326441 99014411 PMID: 7929302

Activation of rat liver phospholipase D by the small GTP-binding protein RhoA. Oct 21 1994

20/6/157 08323681 95011651 PMID: 7926831  
Phage display of a human antibody against Clostridium tetani toxin. Oct 11 1994

20/6/158 08289729 94355968 PMID: 8075533  
Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain VACs. May 1994

20/6/159 08248894 94314916 PMID: 7913711  
Autoantigen-specific T cell proliferation induced by the ribosomal P2 protein in patients with systemic lupus erythematosus. Jul 1994

20/6/160 08217913 94283856 PMID: 8013871  
Cloning, sequencing and expression in *Escherichia coli* of the gene encoding component S of the coenzyme B12-dependent glutamate mutase from *Clostridium coccleatum*. May 1 1994

20/6/161 08214919 94280880 PMID: 8011337  
A post-docking role for synaptobrevin in synaptic vesicle fusion. Jun 1994

20/6/162 08198098 94264020 PMID: 7911329  
A single mutation in the recombinant light chain of tetanus toxin abolishes its proteolytic activity and removes the toxicity seen after reconstitution with native heavy chain. Jun 7 1994

20/6/163 08193553 94259475 PMID: 8200692  
Assays for adjuvanticity of new formulations and of carrier proteins for inducing antibody responses to selected immunogens in the squirrel monkey *Samir sciurus*. Apr 1994

20/6/164 08065830 94131577 PMID: 7507893  
Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein. Feb 1994

20/6/165 08043965 94109700 PMID: 8282204  
Cloning in a bacteriophage lambda vector for the display of binding proteins on filamentous phage. Dec 27 1993

20/6/166 07907600 93368431 PMID: 8361360  
Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge. Jun 1993

20/6/167 07882039 93342856 PMID: 8393605  
Comparison of the effects of adjuvants and adjuvant doses on the quantitative and qualitative antibody response to selected antigens in New World squirrel monkeys *Samir sciurus*. 1993

20/6/168 07845929 93301597 PMID: 7686212  
Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. Jul 1 1993

20/6/169 07843212 93258880 PMID: 8518367  
Recombinant human antibodies: linkage of an Fab fragment from a combinatorial library to an Fc fragment for expression in mammalian cell culture. Apr 1993

20/6/170 07829910 93265459 PMID: 8508952  
A bacteriophage lambda vector for the cloning and expression of immunoglobulin Fab fragments on the surface of filamentous phage. Jun 15 1993

20/6/171 07753752 93209239 PMID: 8458345  
A chimeric toxin to study the role of the Z1 KDa GTP binding protein rho in the control of actin microfilament assembly. Mar 1993

20/6/172 07707454 93162704 PMID: 1286873  
Therapeutic human antibodies derived from PCR amplification of B-cell variable regions. Dec 1992

20/6/173 07386559 92249751 PMID: 1577256  
Cloning of a *Clostridium botulinum* type B toxin gene fragment encoding the N-terminus of the heavy chain. Feb 1 1992

20/6/174 07351768 92214527 PMID: 1805685  
Effects of a soluble CDA and CDA-Pseudomonas exotoxin A chimeric protein on human peripheral blood lymphocytes: lymphocyte activation and anti-HIV activity in vitro. Oct 1991

20/6/175 07134855 91376069 PMID: 1896445  
Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Sep 15 1991

20/6/176 07131767 91372981 PMID: 1910014  
Characterization of the C3 gene of *Clostridium botulinum* types C and D and its expression in *Escherichia coli*. Oct 1991

20/6/177 06865780 91105879 PMID: 1988163  
Inhibition of human antigen-specific memory B cell response in vitro by a diphtheria toxin-related interleukin 2 fusion protein. Feb 1991

20/6/178 06410899 90035423 PM D: 2478475  
Expression of tetanus toxin subfragments in vitro and characterization of epitopes. Nov 1989

20/7/136 DIALOG(R)File 155;MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.  
089229395 20211255 PMID: 10744952  
High-level expression of tetanus toxin fragment C-thioredoxin fusion protein in *Escherichia coli*.  
Rivas A V; Ho P L; Tanizaki M M; Raw I; Nascimento A L  
Center of Biotechnology, Instituto Butantan, Av. Vital Brasil, 1500, CEP 05503-900, Sao Paulo, SP, Brazil.  
Biotechnology and applied biochemistry (ENGLAND) Apr 2000, 31 ( Pt 2) p91-4, ISSN 0885-4513 Journal Code: 860946  
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed  
An insert of *Clostridium tetani* DNA corresponding to fragment C of tetanus toxin was amplified by PCR. This 1.4 kb fragment was cloned into the high-expression vector DE132a, under control of the T7 promoter. Expression of this plasmid in *Escherichia coli* BL21(DE3) resulted in the production of a fusion protein (approximately 62 kDa) consisting of 112 amino acids of thioredoxin and approximately 450 amino acids of fragment C. This fusion protein was recognized by anti-tetanus toxin antiserum in an ELISA and an immunoblot. The recombinant fragment-C-thioredoxin protein was purified significantly in one step by Ni(2+)-chelex Sepharose, the final yield being approximately 35 mg/l. Immunization of animals with the recombinant protein produce antibodies that were able to recognize the tetanus toxin. By using this gene-fusion expression system we produced soluble fragment C of tetanus toxin in a high yield, preventing many problems inherent in the use of other expression systems that produce either insoluble fragment C in inclusion bodies, or a soluble form, but in low yield, using *E. coli* as the expression host Record Date Created: 20000525 Record Date Completed: 20000525

20/7/132 DIALOG(R)File 155;MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.  
089900056 20281859 PMID: 10820215  
Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment potential vector for delivering heterologous proteins to neurons.  
Francis J W; Brown R H; Figueiredo D; Remington M P; Castillo O; Schwarzschild M A; Fishman P S; Murphy J R; van der Spek J C  
Cecil B. Day Center for Neuromuscular Research, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA. francis@helix.harvard.edu  
Journal of neurochemistry (UNITED STATES) Jun 2000, 74 (6) p2528-36, ISSN 0022-3042 Journal Code: 2985190R  
Contract/Grant No.: 1P01NS31248-02; NS; NINDS; 5F32HS10064; HS; AHCPR; R01 NS3679-01; NS; NINDS  
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed  
This study describes the expression, purification, and characterization of a recombinant fusion toxin, DAB(389)TTC, composed of the catalytic and membrane translocation domains of diphtheria toxin (DAB(389)) linked to the receptor binding fragment of tetanus toxin (C-fragment). As determined by its ability to inhibit cellular protein synthesis in primary neuron cultures, DAB(389)TTC was approximately 1,000-fold more cytotoxic than native diphtheria toxin or the previously described fusion toxin DAB(389)MSh. The cytotoxic effect of DAB(389)TTC on cultured cells was specific toward neuronal-type cells and was blocked by coinubation of the chimeric toxin with tetanus antitoxin. The toxicity of DAB(389)TTC, like that of diphtheria toxin, was dependent on passage through an acidic compartment and ADP-ribosyltransferase activity of the DAB(389) catalytic fragment. These results suggest that a catalytically inactive form of DAB(389)TTC may be useful as a nonviral vehicle to deliver exogenous proteins to the cytosolic compartment of neurons. Record Date Created: 20000602 Record Date Completed: 20000602

20/7/114 DIALOG(R)File 155;MEDLINE(R) (c) format only 2004 The Dialog Corp. All rts. reserv.  
09481983 21258150 PMID: 11359482  
Neuronal targeting of cardiotrophin-1 by coupling with tetanus toxin C fragment.  
Bordet T; Caselhan-Parkline L; Fauchereau F; Floucourt G; Kalin A; Haase G  
INSERM U 129, Institut Cochin de Genetique Moleculaire, 24, Rue du Faubourg St Jacques, 75014 Paris, France.  
Molecular and cellular neurosciences (United States) May 2001, 17 (5) p842-54, ISSN 1044-7431 Journal Code: 910009  
Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed  
Cardiotrophin-1 (CT-1) is a potent neurotrophic factor for motoneurons but its clinical use in motor neuron diseases is precluded by side effects on the heart and liver. We explored the possibility of targeting CT-1 to neurons by coupling with the tetanus toxin fragment C. Genetic fusion proteins between CT-1 or GFP and TTC were produced in *Escherichia coli* and assayed in vitro contrast to uncoupled CT-1 or GFP. TTC-coupled proteins bound with high affinity to cerebral neurons and spinal cord motoneurons and were rapidly internalized. Glia, hepatocytes, or cardiomyocytes did not show detectable binding or uptake of TTC-coupled proteins. Similar to CT-1, TTC-coupled CT-1 induced IL-6 secretion by KB cells, activated Reg-2 gene expression and promoted motoneuron survival in a dose-dependent manner. In vivo studies will test whether TTC-coupled CT-1 might be targeted to degenerating spinal cord or brain-stem motoneurons and migrate trans-synaptically to cortical motoneurons, which are also affected in amyotrophic lateral sclerosis. Copyright 2001 Academic Press. Record Date Created: 20010518 Record Date Completed: 20010809

Tags: Animal; Human; Support; Non-U.S. Gov't Descriptors: Cells; Cultured--drug effects--DE; \*Cytokines--pharmacology--PD; \*Motor Neuro Disease--drug therapy--DT; \*Motor Neurons--drug effects--DE; \*Nerve Growth Factors--pharmacology--PD; \*Peptide Fragments--pharmacology--PD; \*Recombinant Fusion Proteins--pharmacology--PD; \*Tetanus Toxin--pharmacology--PD; Brain--cytology--CY; Brain-

drug effects-DE; Brain-metabolism-ME; Cell Survival-drug effects-DE; Cell Survival-physiology-PH; Cells, Cultured-cytology-CY; Cells, Cultured-metabolism-ME; Cytokines-genetics-GE; Dose-Response Relationship, Drug; Escherichia coli-genetics-GE; Feus; Gene Expression-drug effects-DE; Gene Expression-physiology-PH; Heart-drug effects-DE; Heart-physiology-PH; Hepatocytes-cytology-CY; Hepatocytes-drug effects-DE; Hepatocytes-metabolism-ME; Interleukin-6-genetics-GE; Interleukin-6-metabolism-ME; Interleukin-6-secretion-SE; Luminescent Proteins-antibodies-AV; Luminescent Proteins-genetics-GE; Motor Neuron Disease-metabolism-ME; Motor Neuron Disease-physiology-PH; Motor Neurons-cytology-CY; Motor Neurons-metabolism-ME; Nerve Growth Factors-genetics-GE; Peptide Fragments-genetics-GE; Protein Engineering-methods-MT; Recombinant Fusion Proteins-clinical synthesis-CS; Recombinant Fusion Proteins-genetics-GE; Signal Transduction-drug effects-DE; Signal Transduction-genetics-GE; Spinal Cord-cytology-CY; Spinal Cord-drug effects-DE; Spinal Cord-metabolism-ME; Tetanus Toxin-genetics-GE; CAS Registry No.: 0 (Cytokines); 0 (Interleukin-6); 0 (Luminescent Proteins); 0 (Nerve Growth Factors); 0 (Peptide Fragments); 0 (Recombinant Fusion Proteins); 0 (Tetanus Toxin); 0 (Dactinophin 1); 0 (Tetanus toxin fragment C); 147336-22-9 (green fluorescent protein)

207/151 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

08548161 95256461 PMID: 7720079

Utilization of soluble fusion proteins for induction of T cell proliferation.

Kirschman D. A.; De Cieshi P. A.; Bono C. P.; Zachris M. L.; Schwartz B. D.; Wouffe S. L.

Department of Immunology and Glycobiology, Monsanto Corporate ResearchG, D. Seate, St. Louis, Missoun 63198, USA.

Cellular immunology (UNITED STATES) Feb 1995, 160 (2) p193-8, ISSN 0008-8749 Journal Code: 1246405

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

A peptide display library was evaluated as a means to identify peptide binding motifs for class II molecules. Peptides expressed as part of a soluble fusion protein with a maltose binding protein (malE) were produced by *Escherichia coli*. Constructs containing the high-affinity binding influenza hemagglutinin peptide 307W-319 (mal-HA) or the low-affinity binding tetanus toxoid peptide 830-843 (mal-TT) were used as controls. mal-HA, but not mal-TT, inhibited synthetic biotinylated-HA peptide from binding to purified DR4 Dwt4 molecules in a dose-dependent manner. The fusion-peptide presentation system was also evaluated for its ability to induce antigen-specific T cell proliferation. DR4 Dwt4-B cells pulsed with mal-HA, but not mal-TT, induced dose-dependent proliferation of an HA-specific DR4 Dwt4-restricted T cell line to the same extent as synthetic HA peptide. Using this type of peptide display library, it may be possible to determine the antigenic specificity of T cell clones isolated from patients with autoimmune diseases. Record Date Created: 19950522 Record Date Completed: 19950522

207/164 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

08065830 9431577 PMID: 7507893

Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein.

Boucher P.; Sato H.; Sato Y.; Locht C.

Laboratoire de Microbiologie Genetique et Moleculaire, Institut Pasteur de Lille, France.

Infection and immunity (UNITED STATES) Feb 1994, 62 (2) p449-56, ISSN 0019-9567 Journal Code: 0246127

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

The currently available diphtheria-tetanus-whole-cell pertussis (DTP) vaccines are associated with a variety of problems, including undesirable side effects and inconsistent efficacy. These problems are probably related to the poor definition of such vaccines, especially with respect to the whole-cell component against pertussis. Ideal vaccines should include only immunoprotective antigens with no toxin activity. As an initial step towards obtaining a well-defined and simplified DTP vaccine, a pertussis toxin-tetanus toxin chimera protein was constructed. A soluble form of the pertussis toxin ST subunit was fused to the protective fragment C of tetanus toxin, and the recombinant hybrid protein was produced in *Escherichia coli*. The 75-kDa fusion protein (p75) was overexpressed as a soluble molecule and purified to near homogeneity by two consecutive chromatographic steps. Purified p75 retained its ability to bind to ganglioside GT1b, the receptor for tetanus toxin, and to be recognized by protective and neutralizing anti-pertussis toxin antibodies specific for conformational epitopes. When administered to mice, the hybrid protein was found to be non-toxic but immunogenic. In addition, it was capable of inducing strong protection against tetanus and some protection against pertussis, as well as eliciting a pertussis toxin-neutralizing antibody response. Although the levels of anti-pertussis toxin antibodies were rather low, neutralizing titers of the immunized mice correlated well with anti-pertussis toxin titers, indicating that protective epitopes are conserved in the recombinant protein. Record Date Created: 19940304 Record Date Completed: 19940304

237/1 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

11119318 97413668 PMID: 9270054

Postischemic infusion of Cu/Zn superoxide dismutase or SOD-1e451 reduces cerebral infarction following focal ischemia/reperfusion in rats.

Francis J. W.; Ren J.; Warren L.; Brown R. H.; Finkbein S. P.

Cecil B. Day Laboratory for Neuromuscular Research, Massachusetts General Hospital, Charlestown 02129, USA.

Experimental neurology (UNITED STATES) Aug 1997, 146 (2) p435-43, ISSN 0014-4886 Journal Code: 0370712

Contract/Grant No.: 1P01AG12992-01; AG; NIA; 1P01NS31248-04; NS; NINDS; P01 NS 10828; NS; NINDS

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Oxygen-free radicals play a major role in neuronal cell injury following cerebral ischemia/reperfusion. The free-radical scavenging enzyme, Cu/Zn superoxide dismutase (SOD-1), ameliorates various types of brain injury resulting from temporary CNS ischemia. We have compared the cerebroprotective properties of human SOD-1 (hSOD-1) with a novel recombinant SOD-1

hybrid protein, SOD-1e451, composed of hSOD-1 linked to the neuronal binding fragment of tetanus toxin (TTXc). Following of temporary middle cerebral artery occlusion, rats infused with equivalent activities of either hSOD-1 or SOD-1e451 for the initial 3 h of reperfusion showed reductions in cerebral infarct volume of 43 and 57%, respectively, compared to saline-treated controls ( $P < 0.01$ ). Serum hSOD-1 concentrations in rats receiving SOD-1e451 were seven-fold higher than those in rats receiving the native enzyme. Animals treated with SOD-1e451 also demonstrated an extended persistence of hSOD-1 in the bloodstream during drug washout as compared to animals given free enzyme. Immunohistochemical examination of brain sections from an SOD-1e451-treated ischemic rat showed positive immunoreactivity in the ipsilateral cerebral cortex using eit anti-TTXc or anti-human SOD-1 antibodies. Our results document that both hSOD-1 and SOD-1e451 significantly reduce bra infarct volume in a model of transient focal ischemia/reperfusion in rats. Additionally, our findings suggest that the cerebroprotective effects of SOD-1 may be enhanced by neuronal targeting as seen with the hybrid protein SOD-1e451. Reco Date Created: 19970919 Record Date Completed: 19970919

237/2 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

11056318 97413668 PMID: 9270054

Postischemic infusion of Cu/Zn superoxide dismutase or SOD-1e451 reduces cerebral infarction following focal ischemia/reperfusion in rats.

Francis J. W.; Ren J.; Warren L.; Brown R. H.; Finkbein S. P.

Cecil B. Day Laboratory for Neuromuscular Research, Massachusetts General Hospital, Charlestown 02129, USA.

Experimental neurology (UNITED STATES) Aug 1997, 146 (2) p435-43, ISSN 0014-4886 Journal Code: 0370712

Contract/Grant No.: 1P01AG12992-01; AG; NIA; 1P01NS31248-04; NS; NINDS; P01 NS 10828; NS; NINDS

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

Oxygen-free radicals play a major role in neuronal cell injury following cerebral ischemia/reperfusion. The free-radical scavenging enzyme, Cu/Zn superoxide dismutase (SOD-1), ameliorates various types of brain injury resulting from temporary CNS ischemia. We have compared the cerebroprotective properties of human SOD-1 (hSOD-1) with a novel recombinant SOD hybrid protein, SOD-1e451, composed of hSOD-1 linked to the neuronal binding fragment of tetanus toxin (TTXc). Following of temporary middle cerebral artery occlusion, rats infused with equivalent activities of either hSOD-1 or SOD-1e451 for the initial 3 h of reperfusion showed reductions in cerebral infarct volume of 43 and 57%, respectively, compared to saline-treated controls ( $P < 0.01$ ). Serum hSOD-1 concentrations in rats receiving SOD-1e451 were seven-fold higher than those in rats receiving the native enzyme. Animals treated with SOD-1e451 also demonstrated an extended persistence of hSOD-1 in the bloodstream during drug washout as compared to animals given free enzyme. Immunohistochemical examination of brain sections from an SOD-1e451-treated ischemic rat showed positive immunoreactivity in the ipsilateral cerebral cortex using eit anti-TTXc or anti-human SOD-1 antibodies. Our results document that both hSOD-1 and SOD-1e451 significantly reduce bra infarct volume in a model of transient focal ischemia/reperfusion in rats. Additionally, our findings suggest that the cerebroprotective effects of SOD-1 may be enhanced by neuronal targeting as seen with the hybrid protein SOD-1e451. Reco Date Created: 19970919 Record Date Completed: 19970919

237/3 DIALOG(R)/File 155:MEDLINE(R) (c) format only 2004 The Dialog Corp. All its. reserv.

08990066 20281858 PMID: 10820215

Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: potential vector for delivering heterologous proteins to neurons.

Francis J. W.; Brown R. H.; Figueiredo D.; Remington M. P.; Castillo O.; Schwarzschild M. A.; Fishman P. S.; Murphy J. R.; van der Spek J. C.

Cecil B. Day Center for Neuromuscular Research, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown MA 02129, USA. frances@helix.mgh.harvard.edu

Journal of neurochemistry (UNITED STATES) Jun 2001, 74 (6) p2528-36, ISSN 0022-3042 Journal Code: 2985190R

Contract/Grant No.: 1P01NS31248-02; NS; NINDS; 5F32HS10064; HS; AHCPR; R01 NS38679-01; NS; NINDS

Document type: Journal Article Languages: ENGLISH Main Citation Owner: NLM Record type: Completed

This study describes the expression, purification, and characterization of a recombinant fusion toxin, DAB(389)TTTC, compose of the catalytic and membrane translocation domains of diphtheria toxin (DAB(389)) linked to the receptor binding fragment of tetanus toxin (C-fragment). As determined by its ability to inhibit cellular protein synthesis in primary neuron cultures, DAB(389)TTTC was approximately 1,000-fold more cytotoxic than native diphtheria toxin or the previously described fusion toxin DAB(389)MSH. The cytotoxic effect of DAB(389)TTTC on cultured cells was specifically toward neuronal-type cells and was blocked by concoluation of the chimeric toxin with tetanus antitoxin. The toxicity of DAB(389)TTTC, like that of diphtheria toxin, was dependent on passage through an acidic compartment and ADP-ribosyltransferase activity of the DAB(389) catalytic fragment. These results suggest that a catalytically inactive form of DAB(389)TTTC may be useful as a nonviral vehicle to deliver exogenous proteins to the cytosolic compartment of neurons. Record Date Created: 20000602 Record Date Completed: 20000602

Tags: Animal; Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, Non-P.H.S.; Support, U.S. Gov't, P.H.S. Descriptors: Hippocampus-metabolism-ME; Immunotoxins-metabolism-ME; Neurons-metabolism-ME; Peptide Fragments-metabolism-ME; Superoxide Dismutase-metabolism-ME; Tetanus Toxin-metabolism-ME; Base Sequence; Biological Transport; Blotting, Western; Cell Line; Cells, Cultured; Cloning Molecular; DNA Primers; Electrophoresis; Polysaccharide Gel; Immunohistochemistry; Immunotoxins-administration and dosage-AD; Kinetics Molecular Sequence Data; Peptide Fragments-administration and dosage-AD; Peptide Fragments-biosynthesis-BI; Polymerase Chain Reaction; Protein Hybridization; Rats; Restriction Mapping; Superoxide Dismutase-administration and dosage-AD; Superoxide Dismutase-

biosynthesis-B; Tetanus Toxin--administration and dosage-AD; Tetanus Toxin--biosynthesis-B (CAS Registry No.: 0 (DNA Primers); 0 (Immunotoxins); 0 (Peptide Fragments); 0 (Tetanus Toxin); 0 (Tetanus toxin fragment C); Enzyme No.: EC 1.15.1.1 (Superoxide Dismutase)

09Jan04 12:55:17 User208600 Session D1604.3

File 34:SciSearch(R) Cited Ref Sci 1990-2004Jan W1 (c) 2004 Inst for Sci Info

Set Items Description

\*\*\* \*\*\*\*\*

Ref Items Index:term  
E1 1 CR=FRANCIS J, 1994, V40, P829, J AM GERIATR SOC  
E2 1 CR=FRANCIS J, 1994, V99, P395, J GEOPHY'S RES  
E3 0 CR=FRANCIS J, 1995  
E4 1 CR=FRANCIS J, 1995, BERICHT KARTZEHN  
E5 1 CR=FRANCIS J, 1995, BLOOD CONSERVATION A  
E6 1 CR=FRANCIS J, 1995, P26, WORLD INGREED MAR  
E7 1 CR=FRANCIS J, 1995, P34, WORLD INGREED SEP  
E8 2 CR=FRANCIS J, 1995, P7, TRANSFORMATION TROP  
E9 1 CR=FRANCIS J, 1995, V19, P383, J ACCOUNT ECON  
E10 1 CR=FRANCIS J, 1995, V329, P208, NEW ENGL J MED  
E11 4 CR=FRANCIS J, 1995, V43, P565, J AM GERIATR SOC  
E12 1 CR=FRANCIS J, 1995, V50, P581, PHARMACOL BIOCHEM  
E13 6 CR=FRANCIS J, 1995, V50, P581, PHARMACOL BIOCHEM  
E14 1 CR=FRANCIS J, 1996, DRAUGHT ANIMAL POWER  
E15 1 CR=FRANCIS J, 1996, P26, NATURAL FOOD COLORAN  
E16 1 CR=FRANCIS J, 1996, P67, IMPROVING RUMINANT P  
E17 3 CR=FRANCIS J, 1996, P917, GERIATRIC MED  
E18 1 CR=FRANCIS J, 1996, V125, P421, ANN INTERN MED  
E19 6 CR=FRANCIS J, 1996, V5, P103, CNS DRUGS

E20 1 CR=FRANCIS J, 1996, V77, PS290, OXYGEN ISOTOPIC Z  
E21 1 CR=FRANCIS J, 1996, V9, P861, COLLOID SURF A  
E22 1 CR=FRANCIS J, 1997, INTERDISCIPLINARY SU  
E23 1 CR=FRANCIS J, 1997, J PROCESSES MECH ENG  
E24 1 CR=FRANCIS J, 1997, J JOURNEY ARUSHA SEYCH

Ref Items Index:term  
E1 3 CR=FRANCIS JW, 1996, V112, P317, J MOL CATAL A-CH  
E2 1 CR=FRANCIS JW, 1996, V26, P192, J COLL SCI TEACH  
E3 0 CR=FRANCIS JW, 1997  
E4 12 CR=FRANCIS JW, 1997, V146, P435, EXP NEUROL  
E5 1 CR=FRANCIS JW, 1997, V23, SOC NEUR ABSTR  
E6 29 CR=FRANCIS JW, 1998, V95, P6492, P NATL ACAD SCI  
E7 2 CR=FRANCIS JW, 2000, V62, P90, AM BIOL TEACH  
E8 7 CR=FRANCIS JW, 2000, V74, P2528, J NEUROCHEM  
E9 1 CR=FRANCIS K, UNPUB  
E10 1 CR=FRANCIS K, V92, P3616, BLOOD  
E11 1 CR=FRANCIS K, 1995, V45, AM J PUBLIC HLTH 2 S  
E12 1 CR=FRANCIS K, 1971, NZ KIWI

E7 1 CR=FRANCIS JW, 1995, V270, P5434, J BIOL CHEM  
E8 1 CR=FRANCIS JW, 1995, V99, P77, J MOL CATAL  
E9 13 CR=FRANCIS JW, 1995, V99, P77, J MOL CATAL A-CHEM  
E10 1 CR=FRANCIS JW, 1996, V101, P317, J MOL CATAL A-CH  
E11 3 CR=FRANCIS JW, 1996, V112, P317, J MOL CATAL A-CH  
E12 1 CR=FRANCIS JW, 1996, V26, P192, J COLL SCI TEACH  
E13 12 CR=FRANCIS JW, 1997, V23, SOC NEUR ABSTR  
E14 1 CR=FRANCIS JW, 1997, V23, SOC NEUR ABSTR  
E15 29 CR=FRANCIS JW, 1998, V95, P6492, P NATL ACAD SCI  
E16 2 CR=FRANCIS JW, 2000, V62, P90, AM BIOL TEACH  
E17 7 CR=FRANCIS JW, 2000, V74, P2528, J NEUROCHEM  
E18 1 CR=FRANCIS K, UNPUB  
E19 1 CR=FRANCIS K, V92, P3616, BLOOD  
E20 1 CR=FRANCIS K, 1995, V45, AM J PUBLIC HLTH 2 S  
E21 1 CR=FRANCIS K, 1971, NZ KIWI  
E22 1 CR=FRANCIS K, 1979, V35, P23, EXPERIENTIA  
E23 1 CR=FRANCIS K, 1982, V52, P11, P NATL ACAD SCI IND  
E24 6 CR=FRANCIS K, 1985, V26, P1195, PLANT CELL PHYSIO

23/6/4 08629500 95318117 PMID: 7797532  
Cultn superoxide dismutase (SOD-1); Tetanus toxin fragment C; hybrid protein for targeted delivery of SOD-1 to neuronal cells; Jun 23 1995

3/6/1 11080385 Genuine Article#: 602XU Number of References: 129  
Title: Clostridial neurotoxins (ABSTRACT AVAILABLE) Publication date: 20020000

3/6/2 09710099 Genuine Article#: 437OE Number of References: 58  
Title: Neuronal targeting of cardiotrophin-1 by coupling with tetanus toxin C fragment (ABSTRACT AVAILABLE) Publication date: 20010500

3/6/3 08930221 Genuine Article#: 345OX Number of References: 46  
Title: Protective effect of supplemental superoxide dismutase on survival of neuronal cells during starvation - Requirement for cytosolic distribution (ABSTRACT AVAILABLE) Publication date: 20000500

3/6/4 08657931 Genuine Article#: 312XG Number of References: 52  
Title: Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: A potential vector for delivering heterologous proteins to neurons (ABSTRACT AVAILABLE) Publication date: 20000600

3/6/5 08654608 Genuine Article#: 306PP Number of References: 26  
Title: High-level expression of tetanus toxin fragment C-phlorodxin fusion protein in Escherichia coli (ABSTRACT AVAILABLE) Publication date: 20000400

3/6/6 08346824 Genuine Article#: 274MM Number of References: 41  
Title: A somatic gene transfer approach using recombinant fusion proteins to map muscle-motoneuron projections in Xenopus spinal cord (ABSTRACT AVAILABLE) Publication date: 19931100

3/6/7 07482407 Genuine Article#: 171LB Number of References: 149  
Title: Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses (ABSTRACT AVAILABLE) Publication date: 19990228

3/6/8 07199829 Genuine Article#: 135NQ Number of References: 42  
Title: Tracing axons (ABSTRACT AVAILABLE) Publication date: 19981000

3/6/9 06171745 Genuine Article#: YA203 Number of References: 30  
Title: Structure of the receptor binding fragment H-C of tetanus neurotoxin (ABSTRACT AVAILABLE) Publication date: 19971000

3/6/10 06055012 Genuine Article#: XRT65 Number of References: 41  
Title: Construction of hybrid proteins that migrate retrogradely and transsynaptically into the central nervous system (ABSTRACT AVAILABLE) Publication date: 19970819

3/6/11 05946700 Genuine Article#: XJ537 Number of References: 50  
Title: Delivery of recombinant tetanus-superoxide dismutase proteins to central nervous system neurons by retrograde axonal transport (ABSTRACT AVAILABLE) Publication date: 19970600

3/7/7 DIALOG(R)/File 34:SciSearch(R) Cited Ref Sci (c) 2004 Inst for Sci Info. All rts. reserv.  
07482407 Genuine Article#: 171LB Number of References: 149

Title: Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses  
Author(s): Pelizzari R, Rossetto O, Schiavo G, Montecucco C (REPRINT)  
Corporate Source: UNIV PADUA,CTR BIOMEMBRANE, CNR, VIA G COLOMBO 31-35100 PADUA/ITALY (REPRINT); UN PADUA,CTR BIOMEMBRANE, CNR/35100 PADUA/ITALY; UNIV PADUA,DIPARTIMENTO SCI BIOMED/35100 PADUA/ITALY; IMPERIAL CANC RES FUND LAB NEUROBIOPATHOLOGY LONDON WC2A 3PX/ENGLAND/  
Journal: PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES  
1999, V354, N1381 (FEB 28), P259-268 ISSN: 0952-8436 Publication date: 19990228  
Publisher: ROYAL SOC LONDON, 6 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND  
Language: English Document Type: ARTICLE

Abstract: The clostridial neurotoxins responsible for tetanus and botulism are proteins consisting of three domains endowed w different functions: neurospecific binding, membrane translocation and proteolysis for specific components of the neuroexocytosis apparatus. Tetanus neurotoxin (TeNT) binds to the presynaptic membrane of the neuromuscular junction, is internalized and transported retroaxonally to the spinal cord. The spastic paralysis induced by the toxin is due to the blockade neurotransmitter release from spiral inhibitory interneurons. In contrast, the seven serotypes of botulinum neurotoxins (BoNT act at the periphery by inducing a flaccid paralysis due to the inhibition of acetylcholine release at the neuromuscular junction TeNT and BoNT serotypes B, D, F and G cleave specifically at single but different peptide bonds, of the vesicle associated membrane protein (VAMP) synaptobrevin, a membrane protein of small synaptic vesicles (SSVs). BoNT types A, C and E cleave SNAP-25 at different sites located within the carboxy-terminus, while BoNT type C: additionally cleaves syntaxin. The remarkable specificity of BoNT's is exploited in the treatment of human diseases characterized by a hyperfunction of cholinergic terminals.

3/7/11 DIALOG(R)/File 34:SciSearch(R) Cited Ref Sci (c) 2004 Inst for Sci Info. All rts. reserv.

05946700 Genuine Article#: XJ537 Number of References: 50

Title: Delivery of recombinant tetanus-superoxide dismutase proteins to central nervous system neurons by retrograde axonal transport

5/6/1 09361245 Genuine Article#: 396BM Number of References: 33  
Title: Interaction of tetanus toxin derived hybrid proteins with neuronal cells (ABSTRACT AVAILABLE) Publication date: 20001100

5/6/2 07912310 Genuine Article#: 23EZ Number of References: 43  
Title: Hybrid enzymes (ABSTRACT AVAILABLE) Publication date: 19990800

5/6/3 07467070 Genuine Article#: 169FN Number of References: 35  
Title: Non-viral neuronal gene delivery mediated by the H-C fragment of tetanus toxin (ABSTRACT AVAILABLE) Publication date: 19990200

5/6/4 06042440 Genuine Article#: XR256 Number of References: 47  
Title: Postischemic infusion of Cu/Zn superoxide dismutase or SOD-Tet451 reduces cerebral infarction following focal ischemiareperfusion in rats (ABSTRACT AVAILABLE) Publication date: 19970800

Author(s): Beguin P (REPRINT)

15//FRANCE (REPRINT)  
Journal: CURRENT OPINION IN BIOTECHNOLOGY, 1999, V10, N4 (AUG), P336-340 ISSN: 0958-1669 Publication date 19990800 Publisher: CURRENT BIOLOGY LTD, 34-42 CLEVELAND STREET, LONDON W1P 6LE, ENGLAND  
Language: English Document Type: REVIEW

5/7/3 DIALOG/R/FILE 34;SciSearch(R) Cited Ref Sci (c) 2004 Inst for Sci Info. All rts. reserv.  
0746/070 Genuine Article#: 169FN Number of References: 35  
Title: Non-viral neuronal gene delivery mediated by the H-C fragment of tetanus toxin  
Author(s): Knight A. (REPRINT); Carvajal J.; Schneider H.; Coultie C.; Chamberlain S.; Fairweather N  
Corporate Source: UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED SCH MED CYST FIBROSIS GENE THERAPY  
RES GRP/LONDON SW7 2AZ/ENGLAND; (REPRINT); UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED SCH MED  
GENE THERAPY RES GRP, SECT MOL GENET/LONDON/ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL &  
MED SCH MED, ATAXIA GRP, SECT MOL GENET, DIV BIOMED SCI/LONDON/ENGLAND; UNIV LONDON IMPERIAL  
COLL SCI TECHNOL & MED DEPT, BIOCHEM/LONDON/ENGLAND/  
Journal: EUROPEAN JOURNAL OF BIOCHEMISTRY, 1999, V259, N3 (FEB), P762-769 ISSN: 0014-2956 Publication date:  
19990220 Publisher: SPRINGER VERLAG, 175 FIFTH AVE, NEW YORK, NY 10010 Language: English Document Type:  
ARTICLE

**Abstract:** Many inherited neurological diseases and cancers could potentially benefit from efficient targeted gene delivery to neurons of the central nervous system. The nontoxic fragment C (H-C) of tetanus toxin retains the specific nerve cell binding and transport properties of tetanus holotoxin. The H-C fragment has previously been used to promote the uptake of attached proteins such as horseradish peroxidase, beta-galactosidase and superoxide dismutase into neuronal cells *in vitro* and *in vivo*. We report the use of purified recombinant H-C fragment produced in yeast and covalently bound to polylysine [poly(K)] to enable binding of DNA. We demonstrate that when used to transfect cells, this construct results in nonviral gene delivery and marker gene expression *in vitro* in N18 RE 105 cells (a neuroblastoma x glioma mouse/rat hybrid cell line) and F98 (a glioma cell line). Transfection was dependent on H-C and was neuronal cell type specific. H-C may prove a useful targeting ligand to future neuronal gene therapy.

Mark a special word or phrase in this record:

**Mark!**All organism  
Clostridium tetani

Select one or more organism in this record:

**Submit****EC NUMBER COMMENTARY**

3.4.24.68

**RECOMMENDED NAME** GeneOntology No.**Tentoxilysin****GO:0000000****SYSTEMATIC NAME**

No entries in this field

**SYNONYMS**

More

**Tentoxilysin****Tetanus neurotoxin****ORGANISM COMMENTARY LITERATURE**

cf. EC 3.4.24.69

SwissProt

**CAS REGISTRY NUMBER COMMENTARY**

107231-12-9

**REACTION**Synaptobrevin + H<sub>2</sub>O = hydrolyzed synaptobrevin**COMMENTARY**

Clostridium tetani: structure and mechanism &lt;2, 5, 6&gt;

**REACTION TYPE**

hydrolysis of peptide bond

**ORGANISM COMMENTARY LITERATURE****ORGANISM****Clostridium**  
**tetani****COMMENTARY**


toxigenic strains N3911 &lt;1&gt;; E 88 (non-sporulating) &lt;3&gt;; Harvard &lt;6&gt;; all toxigenic strains synthesize only one type of neurotoxin &lt;5, 6&gt;


**LITERATURE****1-6****SUBSTRATE****PRODUCT****REACTION  
DIAGRAM****ORGANISM****COMMENTARY/**Substrate  
r:=reversible  
ir:=irreversible**LITERATURE/**  
Substrate**COMMENTARY/**  
Product**LITERATURE/**  
Product

More

?

Clostridium  
tetanino substrates are rat  
<4,5>; or chicken  
<5>; synaptobrevin-1  
(with Val76 instead of  
Gln76) or short  
peptides containing  
the cleavage site of  
the target protein  
<5,6>; catalytic  
activity requires  
reduction of the  
single interchain  
disulfide bond of the  
neurotoxin <4>i.e. VAMP <5,6>;  
neuronal vesicle-  
associated**4, 5, 6**

Synaptobrevin + H2O	Hydrolyzed synaptobrevin		Clostridium tetani	membrane protein, MW 19000 <4>; with 2 isoforms in human <4>; chicken <5>; or rat brain <4,5>; ; synaptobrevin/VAMP-1 and synaptobrevin/VAMP-2, cleaves at Gln76-Phe77, the same site as botulin neurotoxin B <5,6>	<u>1</u> , <u>2</u> , <u>3</u> , <u>4</u> , <u>5</u> , <u>6</u>	2 peptide fragments, MW 12000 and MW 7000	<u>4</u>
---------------------	--------------------------	---	--------------------	---	---	---	----------

NATURAL SUBSTRATE	NATURAL PRODUCT	REACTION DIAGRAM	ORGANISM	COMMENTARY SUBSTRATE	LITERATURE (Substrate)	COMMENTARY PRODUCT	LITERATURE (Product)	ORGANISM (Product)
Synaptobrevin + H2O	-		Clostridium tetani	i.e. VAMP, neuronal vesicle-associated membrane protein, predominantly exposed to cytosol <5>; neurotoxin blocks neurotransmitter release in Aplysia neurons <4>; tetanus neurotoxin receptors are located on the motor neuron plasmalemma at neuromuscular junction, after binding the toxin is internalized inside vesicles of unknown nature and then translocated across the vesicle membrane <5>; enzyme disables neuroexocytosis apparatus, acts at spinal inhibitory interneurons, blocking release of various neurotransmitters to produce spastic paralysis, clostridial neurotoxins are described as the most toxic substances known	<u>4</u> , <u>5</u> , <u>6</u>	-	-	-




#### COFACTOR ORGANISM COMMENTARY LITERATURE IMAGE

No entries in this field

METAL IONS	ORGANISM	COMMENTARY	LITERATURE
Cobalt	Clostridium tetani	zinc-dependent endoproteinase, can replace zinc	<u>5</u>
Nickel	Clostridium tetani	zinc-dependent endoproteinase, can replace zinc	<u>5</u>
Zinc	Clostridium tetani	zinc-dependent endoproteinase <2,4,5,6>; L-chain: form of zinc-endopeptidase, 0.8-1 gatom zinc/mol toxin, bound to light or L-chain <6>; 1 atom zinc per molecule toxin, zinc-binding motif: His-Glu-X-X-His, nickel or cobalt can replace zinc <5>; toxin surface topography of His-residues <2>	<u>2</u> , <u>4</u> , <u>5</u> , <u>6</u>

INHIBITORS	ORGANISM	COMMENTARY	LITERATURE	IMAGE
Ala-Ser-Gln-Phe-Glu-Thr-Ser	Clostridium tetani	synthetic peptide containing cleavage site of synaptobrevin, inhibits toxin action on buccal ganglion of Aplysia californica	<u>4</u>	● <u>2D-image</u>
	Clostridium			● <u>2D-</u>



Captopril	tetani	-	4, 5	<a href="#">image</a>
EDTA	Clostridium tetani	-	4	
Gln-Phe-Glu-Thr	Clostridium tetani	synthetic peptide containing cleavage site of synaptobrevin, inhibits toxin action on buccal ganglion of Aplysia californica	4	
NaOCl	Clostridium tetani	inactivation	6	

ACTIVATING COMPOUND	ORGANISM	COMMENTARY	LITERATURE	IMAGE
Proteases	Clostridium tetani	activation by rapid cleavage within an exposed loop of the single inactive MW 150000 polypeptide chain and generation of active di-chain neurotoxin <5,6>; bacterial <5,6>; or tissue proteases <5>	5,6	-

KM VALUE [mM] KM VALUE [mM] Maximum SUBSTRATE ORGANISM COMMENTARY LITERATURE IMAGE

No entries in this field

Ki VALUE [mM] Ki VALUE [mM] Maximum INHIBITOR ORGANISM COMMENTARY LITERATURE IMAGE

No entries in this field

TURNOVER NUMBER TURNOVER NUMBER MAXIMUM SUBSTRATE ORGANISM COMMENTARY LITERATURE IMAGE

No entries in this field

SPECIFIC ACTIVITY [μM/min/mg]	SPECIFIC ACTIVITY MAXIMUM	ORGANISM	COMMENTARY	LITERATURE
additional information	-	Clostridium tetani	in neurotoxin-injected Aplysia neurons 4-10 molecules of L-chains are sufficient to cause blockade of neurotransmitter release with a t1/2 of 20-40 min at 20°C	5

pH OPTIMUM pH MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

pH RANGE pH RANGE MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

TEMPERATURE OPTIMUM	TEMPERATURE OPTIMUM MAXIMUM	ORGANISM	COMMENTARY	LITERATURE
37	-	Clostridium tetani	assay at	4, 6

TEMPERATURE RANGE TEMPERATURE MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

SOURCE TISSUE	ORGANISM	COMMENTARY	LITERATURE
culture supernatant	Clostridium tetani	-	6

LOCALIZATION	ORGANISM	COMMENTARY	GeneOntology No.	LITERATURE
cytosol	Clostridium tetani	accumulates until bacterial lysis	GO:0005829	5, 6

ACCESSION CODE ENTRY NAME ORGANISM NO. OF AA MOLECULAR WEIGHT[Da] SOURCE Sequence

No entries in this field

PDB	ORGANISM
<a href="#">1A8D</a> , <a href="#">download</a>	Clostridium tetani

[1AF9, download](#) Clostridium tetani  
[1DFQ, download](#) Clostridium tetani  
[1DIW, download](#) Clostridium tetani  
[1DLL, download](#) Clostridium tetani  
[1FV2, download](#) Clostridium tetani

MOLECULAR WEIGHT	MOLECULAR WEIGHT MAXIMUM	ORGANISM	COMMENTARY	LITERATURE
150700	-	Clostridium tetani	Clostridium tetani, calculated from amino acid sequence	<u>6</u>
additional information	-	Clostridium tetani	amino acid sequence homologies between tetanus toxin TeNT and botulinum toxins BoNT/A, B and E	<u>3</u>

SUBUNITS	ORGANISM	COMMENTARY	LITERATURE
More	Clostridium tetani	the enzyme consists of a heavy (H) chain and a light (L) chain <2,3>; held together by a single disulfide bond and non-covalent forces <2>; MW 52288 (L-chain) and MW 98300 (H-chain), calculated from amino acid sequence <3>	<u>2</u> , <u>3</u>

#### POSTTRANSLATIONAL MODIFICATION ORGANISM COMMENTARY LITERATURE

No entries in this field

#### Crystallization/COMMENTARY ORGANISM LITERATURE

No entries in this field

#### pH STABILITY pH STABILITY MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

#### TEMPERATURE STABILITY TEMPERATURE STABILITY MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

#### GENERAL STABILITY ORGANISM LITERATURE

No entries in this field

#### ORGANIC SOLVENT ORGANISM COMMENTARY LITERATURE

No entries in this field

#### OXIDATION STABILITY ORGANISM LITERATURE

- Clostridium tetani 6

STORAGE STABILITY	ORGANISM	COMMENTARY	LITERATURE
-80°C, in 10 mM HEPES buffer, pH 7.2, 50 mM NaCl, after freezing in liquid N2, stable	Clostridium tetani	-	<u>6</u>

Purification/COMMENTARY	ORGANISM	LITERATURE
single-chain, two-chain and L-chain form <6>; very toxic! Booster injection of tetanus toxoid before starting research with tetanus toxin advisable, human anti-tetanus neurotoxin antibodies available <6>	Clostridium tetani	<u>2</u> , <u>6</u>

Cloned/COMMENTARY	ORGANISM	LITERATURE
Clostridium tetani <1,3>; expressed in Escherichia coli JM101 using three different plasmid vectors <3>	Clostridium tetani	<u>1</u> , <u>3</u>

#### ENGINEERING ORGANISM COMMENTARY LITERATURE

No entries in this field

## Renatured/COMMENTARY ORGANISM LITERATURE

No entries in this field

## APPLICATION ORGANISM COMMENTARY LITERATURE

No entries in this field

## DISEASE TITLE OF PUBLICATION LINK TO PUBMED

No entries in this field

REF.	AUTHORS	TITLE	JOURNAL	VOL.	PAGES	YEAR	ORGANISM	COMMENTARY	LINK TO PUBMED
<a href="#">1</a>	Fairweather, N.F.; Lyness, V.A.	The complete nucleotide sequence of tetanus toxin	Nucleic Acids Res.	14	7809- 7813	1986	Clostridium tetani	-	● <a href="#">PubMed</a>
<a href="#">2</a>	Rossetto, O.; Schiavo, G.; Polverino de Laureto, P.; Fabbiani, S.; Montecucco, C.	Surface topography of histidine residues of tetanus toxin probed by immobilized-metal-ion affinity chromatography	Biochem. J.	285	9-12	1992	Clostridium tetani	-	● <a href="#">PubMed</a>
<a href="#">3</a>	Eisel, U.; Jarusch, W.; Goretzki, K.; Henschen, A.; Engels, J.; Weller, U.; Hudel, M.; Habermann, E.; Niemann, H.	Tetanus toxin: primary structure, expression in E. coli, and homology with botulinum toxins	EMBO J.	5	2495- 2502	1986	Clostridium tetani	-	● <a href="#">PubMed</a>
<a href="#">4</a>	Schiavo, G.; Benfenati, F.; Poulain, B.; Rossetto, O.; Polverino de Laureto, P.; DasGupta, B.R.; Montecucco, C.	Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin [see comments]	Nature	359	832- 835	1992	Clostridium tetani	-	● <a href="#">PubMed</a>
<a href="#">5</a>	Montecucco, C.; Schiavo, G.	Mechanism of action of tetanus and botulinum neurotoxins	Mol. Microbiol.	13	1-8	1994	Clostridium tetani	review	● <a href="#">PubMed</a>
<a href="#">6</a>	Schiavo, G.; Montecucco, C.	Tetanus and botulism neurotoxins: isolation and assay	Methods Enzymol.	248	643- 652	1995	Clostridium tetani	review	● <a href="#">PubMed</a>

## LINKS TO OTHER DATABASES (specific for EC-Number 3.4.24.68)

[ExPASy](#)

[Online Mendelian Inheritance in Man](#)

[KEGG](#)

NCBI: [PubMed](#), [Protein](#), [Nucleotide](#), [Structure](#), [Genome](#), [OMIM](#), [Domains](#)

[IUBMB Enzyme Nomenclature](#)

[WIT database](#)

[EMP Project](#)

[PDB database\(3D structure\)](#)

[PROSITE Database of protein families and domains](#)

[SYSTEMS](#)

[Protein Mutant Database](#)

Mark a special word or phrase in this record:

**Mark!**

All organism  
 Clostridium barati  
 Clostridium botulinum  
 Clostridium butyricum  
 Clostridium sp.

Select one or more organism in this record:

**Submit****EC NUMBER COMMENTARY****3.4.24.69****RECOMMENDED NAME** GeneOntology No.**Bontoxilysin****GO:0000000****SYSTEMATIC NAME**

No entries in this field

**SYNONYMS****ORGANISM COMMENTARY LITERATURE**

BoNT	-	-	-
BoNT/B	-	SwissProt	-
BoNT/C1	-	SwissProt	-
BoNT/D	-	SwissProt	-
BoNT/E	-	SwissProt	-
BoNT/F	-	SwissProt	-
BoNT/G	-	SwissProt	-
Bontoxilysin C1	-	SwissProt	-
<b>Botulinum neurotoxin</b>	-	-	-
More	-	cf. EC 3.4.24.68	-

**CAS REGISTRY NUMBER COMMENTARY**

107231-12-9

**REACTION****COMMENTARY**Protein + H<sub>2</sub>O = hydrolyzed protein

Clostridium botulinum: mechanism &lt;4&gt;; Clostridium botulinum, Clostridium barati, Clostridium butyricum: structure/function relationship &lt;5&gt;









**REACTION TYPE****ORGANISM COMMENTARY LITERATURE**

hydrolysis of peptide bond

**ORGANISM****COMMENTARY****LITERATURE****Clostridium barati****5****Clostridium botulinum**

strains 62A (serotype A) or Beluga (serotype E) &lt;10&gt;; type G strain &lt;15&gt;; 7 serologically different neurotoxin types: BoNT/A-G &lt;2, 3, 5, 6&gt;; serotypes BoNT/A, BoNT/B &lt;1, 4, 8, 15&gt;; BoNT/C, BoNT/D &lt;15&gt;; BoNT/E &lt;1, 4, 8&gt;

**1-10, 12, 15****Clostridium butyricum****5****Clostridium sp.** serotypes BoNT/A, B, D, E <13>; F <13, 14>**6, 11, 13, 14**

SUBSTRATE	PRODUCT	REACTION DIAGRAM	ORGANISM	Substrate r:=reversible ir:=irreversible	LITERATURE/ Substrate	COMMENTARY/ Product	LITERATURE/ Product
More	?		Clostridium botulinum	catalytic activity requires reduction of the single interchain disulfide bond of the neurotoxin <4,15>; activating protease activity is localized on light or L-chain of neurotoxin <4>; the clostridial neurotoxins differ from other proteases in the recognition of the tertiary structure of the target rather than the sequence of the peptide bond to be cleaved <15>; neuroparalytic activity tested by intravenous injection into Balb/c mice <1>; no hydrolysis of short peptides spanning the respective cleavage sites of the target proteins <5,6>; synaptotagmin, synaptophysin <15>	<u>1</u> , <u>4</u> , <u>5</u> , <u>6</u> , <u>15</u>	-	-
More	?		Clostridium barati	no hydrolysis of short peptides spanning the respective cleavage sites of the target proteins <5>	<u>5</u>	-	-
More	?		Clostridium butyricum	no hydrolysis of short peptides spanning the respective cleavage sites of the target proteins <5>	<u>5</u>	-	-
More	?		Clostridium sp.	the botulinum neurotoxins are divided into two groups: the A-E type and the B-D-F- tetanus toxin type <13>; no hydrolysis of short peptides spanning the respective cleavage sites of the target proteins <6>; N- ethylmaleimide sensitive factor (i.e. NSF), alpha/beta-SNAP or gamma-SNAP <13>	<u>6</u> , <u>13</u>	-	-
Proteins of neuroexocytosis apparatus + H2O	?		Clostridium botulinum	-	<u>2</u> , <u>3</u> , <u>5</u> , <u>6</u>	-	-
Proteins of neuroexocytosis apparatus + H2O	?		Clostridium barati	-	<u>5</u>	-	-
Proteins of neuroexocytosis apparatus + H2O	?		Clostridium butyricum	-	<u>5</u>	-	-
Proteins of neuroexocytosis apparatus + H2O	?		Clostridium sp.	-	<u>6</u>	-	-
Recombinant glutathione S- methyltransferase	Hydrolyzed recombinant glutathione S-		Clostridium	-	<u>15</u>	2 proteolytic fragments. MW	<u>15</u>

VAMP-2 fusion  
protein + H<sub>2</sub>O

methyltransferase  
VAMP-2 fusion protein



botulinum

36000 and MW  
6000

i.e. VAMP <5,6,12,15>;  
synaptic vesicle-  
associated membrane  
protein <4,6,15>; MW  
19000 <4>; two  
isoforms in human <4>;  
chicken <5>; or rat  
brain <4,5>; ;  
synaptobrevin/VAMP-1  
(VAMP-1 from chicken,  
#Clostridium  
botulinum,5#Clostridium  
barati,o#Clostridium  
butyricum# <5> or rat  
brain, #Clostridium  
botulinum,n#Clostridium  
barati,l#Clostridium  
butyricum# <4, 5>  
carrying Val76 instead  
of Gln76 is not  
hydrolyzed by serotype  
BoNT/B, #Clostridium  
botulinum,o#Clostridium  
barati,i#Clostridium  
butyricum# <4, 5>)

Synaptobrevin +  
H<sub>2</sub>O

Hydrolyzed  
synaptobrevin



Clostridium  
botulinum

<4,5,6,15>; both  
isoforms are cleaved at  
the same rate <15>;  
highly specific  
neurotoxins <4,5,6,15>;  
serotype BoNT/B:  
cleavage at Ser-Gln-+-  
Phe-Glu (at the same  
site as the tetanus  
neurotoxin) <5>; or  
Gln76-Phe77 <4>; or  
Gln-Lys-+-Leu-Ser <5>;  
or-Asp-Gln-+-Lys-Leu-,  
serotype BoNT/G:  
cleavage at Ala83-  
Ala84 (VAMP-1), Ala81-  
Ala82 (VAMP-2) <15>;  
or Ser-Ala-+-Ala-Lys  
<5>; hydrolyzed by  
serotypes BoNT/B  
<4,5,6>; D, F or G  
<5,6>; in vitro, in  
synaptosomes and in  
injected Aplysia  
neurons <5>; no  
substrate of serotype  
BoNT/A or E <4,12>;  
the term -+- depicts the  
points of cleavage

4 , 5 , 6 , 15

2 proteolytic  
fragments, MW  
12000 and MW  
7000 <4>; MW  
13000 and MW  
6000 <15>

4 , 15

i.e. VAMP <6,13,14>;  
synaptic vesicle-  
associated membrane  
protein <6,13,14>; ;  
synaptobrevin/VAMP-1  
(VAMP-1 from chicken,  
#Clostridium  
botulinum,t#Clostridium  
barati,r#Clostridium  
butyricum# <5> or rat  
brain, #Clostridium  
botulinum,y#Clostridium  
barati,n#Clostridium  
butyricum# <4, 5>  
carrying Val76 instead

Synaptobrevin +  
H2O      Hydrolyzed  
synaptobrevin



Clostridium  
sp.

of Gln76 is not hydrolyzed by serotype BoNT/B, #Clostridium botulinum, r#Clostridium barati, n#Clostridium butyricum# <4, 5> <13>; and synaptobrevin/VAMP-2 <6, 13>; both isoforms are cleaved at the same rate <13, 14>; highly specific neurotoxins <6, 13, 14>; serotype BoNT/D: cleavage at Lys61-Leu62 <13>; serotype BoNT/F: cleavage at Gln-Lys <14>; hydrolyzed by serotypes BoNT/B <6>; D, F or G <6>; the term +- depicts the points of cleavage

6, 13, 14

MW 8000 and  
MW 9000 <13>

13

i.e. VAMP <5>; chicken <5>; or rat brain <5>; ; synaptobrevin/VAMP-1 (VAMP-1 from chicken, #Clostridium botulinum, k#Clostridium barati, #Clostridium butyricum# <5> or rat brain, #Clostridium botulinum, o#Clostridium barati, m#Clostridium butyricum# <4, 5> carrying Val76 instead of Gln76 is not hydrolyzed by serotype BoNT/B, #Clostridium botulinum, >#Clostridium barati, e#Clostridium butyricum# <4, 5>) <5>; and

5

Synaptobrevin +  
H2O      Hydrolyzed  
synaptobrevin













Clostridium  
barati

synaptobrevin/VAMP-2 <5>; highly specific neurotoxins <5>; serotype BoNT/B: cleavage at Ser-Gln+-Phe-Glu (at the same site as the tetanus neurotoxin) <5>; or Gln-Lys+-Leu-Ser <5>; or Ser-Ala+-Ala-Lys <5>; hydrolyzed by serotypes BoNT/B <5>; D, F or G <5>; in vitro, in synaptosomes and in injected Aplysia neurons <5>; the term +- depicts the points of cleavage

i.e. VAMP <5>; chicken <5>; or rat brain <5>; ; synaptobrevin/VAMP-1 (VAMP-1 from chicken, #Clostridium botulinum, d#Clostridium barati, d#Clostridium butyricum# <5> or rat brain, #Clostridium botulinum, i#Clostridium barati, i#Clostridium butyricum# <4, 5> carrying Val76 instead



Synaptobrevin + H2O	Hydrolyzed synaptobrevin		Clostridium butyricum	<p>of Gln76 is not hydrolyzed by serotype BoNT/B, #Clostridium botulinum, u#Clostridium barati, u#Clostridium butyricum# &lt;4, 5&gt; &lt;5&gt;; and synaptobrevin/VAMP-2 &lt;5&gt;; highly specific neurotoxins &lt;5&gt;; serotype BoNT/B: cleavage at Ser-Gln-+-Phe-Glu (at the same site as the tetanus neurotoxin) &lt;5&gt;; or Gln-Lys-+-Leu-Ser &lt;5&gt;; or Ser-Ala-+-Ala-Lys &lt;5&gt;; hydrolyzed by serotypes BoNT/B &lt;5&gt;; D, F or G &lt;5&gt;; in vitro, in synaptosomes and in injected Aplysia neurons &lt;5&gt;; the term -+- depicts the points of cleavage</p> <p>i.e. SNAP 25, protein of presynaptic membrane &lt;5&gt;; MW 25000 &lt;5&gt;; native and recombinant protein &lt;12&gt;; highly specific neurotoxins &lt;12&gt;; serotype BoNT/A: cleavage at Gln197-Arg198 &lt;12&gt;; or Asn-Gln-+-Arg-Ala &lt;5&gt;; serotype BoNT/E: cleavage at Arg180-Ile181 &lt;12&gt;; or Asp-Arg-+-Ile-Met &lt;5&gt;; serotype BoNT/A and E &lt;5,6,12&gt;; in vitro, in isolated synaptosomes &lt;5,12&gt;; and in injected Aplysia neurons &lt;5&gt;; no substrate of serotype BoNT/G &lt;15&gt;; the term -+- depicts the points of cleavage</p> <p>i.e. SNAP 25, protein of presynaptic membrane &lt;5&gt;; MW 25000 &lt;5&gt;; or Asn-Gln-+-Arg-Ala &lt;5&gt;; or Asp-Arg-+-Ile-Met &lt;5&gt;; serotype BoNT/A and E &lt;5&gt;; in vitro, in isolated synaptosomes &lt;5&gt;; and in injected Aplysia neurons &lt;5&gt;; the term -+- depicts the points of cleavage</p> <p>i.e. SNAP 25, protein of presynaptic membrane &lt;5&gt;; MW 25000 &lt;5&gt;; or Asn-Gln-+-Arg-Ala &lt;5&gt;; or Asp-Arg-+-Ile-Met &lt;5&gt;; serotype BoNT/A and E &lt;5&gt;; in vitro, in isolated synaptosomes &lt;5&gt;; and in injected Aplysia neurons &lt;5&gt;; the term -+- depicts the points of cleavage</p>	5		
Synaptosome-associated protein + H2O	Hydrolyzed synaptosome-associated protein		Clostridium botulinum		5, 6, 12	2 proteolytic fragments, MW 20500 and MW 3000 (serotype BoNT/E) or MW 22500 and MW 1000 (serotype BoNT/A)	12
Synaptosome-associated protein + H2O	Hydrolyzed synaptosome-associated protein		Clostridium barati		5	2 proteolytic fragments, MW 20500 and MW 3000 (serotype BoNT/E) or MW 22500 and MW 1000 (serotype BoNT/A)	
Synaptosome-associated protein + H2O	Hydrolyzed synaptosome-associated protein		Clostridium butyricum		5	2 proteolytic fragments, MW 20500 and MW 3000 (serotype BoNT/E) or MW 22500 and MW 1000 (serotype BoNT/A)	

Synaptosome-associated protein + H <sub>2</sub> O	Hydrolyzed synaptosome-associated protein		Clostridium sp.	i.e. SNAP 25, protein of presynaptic membrane <13>; serotype BoNT/A and E <6,13>; the term +- depicts the points of cleavage	6, 13		2 proteolytic fragments, MW 20500 and MW 3000 (serotype BoNT/E) or MW 22500 and MW 1000 (serotype BoNT/A)	-
Syntaxin + H <sub>2</sub> O	?		Clostridium botulinum	serotype BoNT/C <5,6>; in vitro, in synaptosomes and in injected Aplysia neurons <5>; no substrate of serotype BoNT/G <15>	5, 6		-	-
Syntaxin + H <sub>2</sub> O	?		Clostridium barati	serotype BoNT/C <5>; in vitro, in synaptosomes and in injected Aplysia neurons <5>	5		-	-
Syntaxin + H <sub>2</sub> O	?		Clostridium butyricum	serotype BoNT/C <5>; in vitro, in synaptosomes and in injected Aplysia neurons <5>	5		-	-
Syntaxin + H <sub>2</sub> O	?		Clostridium sp.	serotype BoNT/C <6>	6		-	-
NATURAL SUBSTRATE	NATURAL REACTION PRODUCT	REACTION DIAGRAM	ORGANISM	COMMENTARY SUBSTRATE	LITERATURE (Substrate)	COMMENTARY PRODUCT	LITERATURE (Product)	ORGANISM (Product)
Neuroexocytosis multi-subunit complex + H <sub>2</sub> O	-		Clostridium botulinum	involved in limited hydrolysis of proteins of the neuroexocytosis apparatus, blocks release of neurotransmitter acetylcholine at neuromuscular junction <5>; causing flaccid paralysis, in contrast to spastic paralysis caused by EC 3.4.24.68, three functionally distinct domains: domain L blocks neuroexocytosis, domain HN governs cell penetration, domain HC responsible for neurospecific binding <5,6>; neurotoxin binds specifically to nerve cells, botulin neurotoxin-receptors are located on the motor neuron plasmalemma at neuromuscular junctions, neurotoxin binds via protein and lipid interaction, after binding it is internalized inside vesicles of unknown nature	5, 6	-	-	-

Neuroexocytosis  
multi-subunit  
complex + H<sub>2</sub>O



Clostridium  
barati

involved in limited  
hydrolysis of  
proteins of the  
neuroexocytosis  
apparatus, blocks  
release of  
neurotransmitter  
acetylcholine at  
neuromuscular  
junction <5>;  
causing flaccid  
paralysis, in contrast  
to spastic paralysis  
caused by EC  
3.4.24.68, three  
functionally distinct  
domains: domain L  
blocks  
neuroexocytosis,  
domain HN governs  
cell penetration,  
domain HC  
responsible for  
neurospecific  
binding <5>;  
neurotoxin binds  
specifically to nerve  
cells, botulin  
neurotoxin-receptors  
are located on the  
motor neuron  
plasmalemma at  
neuromuscular  
junctions, neurotoxin  
binds via protein and  
lipid interaction, after  
binding it is  
internalized inside  
vesicles of unknown  
nature

5










Neuroexocytosis  
multi-subunit  
complex + H<sub>2</sub>O



Clostridium  
butyricum

involved in limited  
hydrolysis of  
proteins of the  
neuroexocytosis  
apparatus, blocks  
release of  
neurotransmitter  
acetylcholine at  
neuromuscular  
junction <5>;  
causing flaccid  
paralysis, in contrast  
to spastic paralysis  
caused by EC  
3.4.24.68, three  
functionally distinct  
domains: domain L  
blocks  
neuroexocytosis,  
domain HN governs  
cell penetration,  
domain HC  
responsible for  
neurospecific  
binding <5>;  
neurotoxin binds  
specifically to nerve  
cells, botulin  
neurotoxin-receptors  
are located on the  
motor neuron  
plasmalemma at  
neuromuscular  
junctions, neurotoxin

5

			binds via protein and lipid interaction, after binding it is internalized inside vesicles of unknown nature			
			causing flaccid paralysis, in contrast to spastic paralysis caused by EC 3.4.24.68, three functionally distinct domains: domain L blocks neuroexocytosis, domain HN governs cell penetration, domain HC responsible for neurospecific binding <6>; neurotoxin binds specifically to nerve cells, botulin neurotoxin-receptors are located on the motor neuron plasmalemma at neuromuscular junctions, neurotoxin binds via protein and lipid interaction, after binding it is internalized inside vesicles of unknown nature			
Neuroexocytosis multi-subunit complex + H2O	-		Clostridium sp.	6	-	-
Synaptobrevin + H2O	-		Clostridium botulinum	4, 5, 6, 12	-	-
Synaptobrevin + H2O	-		Clostridium barati	5	-	-
Synaptobrevin + H2O	-		Clostridium butyricum	5	-	-
Synaptobrevin + H2O	-		Clostridium sp.	6	-	-
Synaptosome-associated protein + H2O	-		Clostridium botulinum	5	-	-
Synaptosome-associated protein + H2O	-		Clostridium barati	5	-	-
Synaptosome-associated protein + H2O	-		Clostridium butyricum	5	-	-
Synaptosome-associated protein + H2O	-		Clostridium sp.	13	-	-

# COFACTOR ORGANISM COMMENTARY LITERATURE IMAGE

No entries in this field

METAL IONS	ORGANISM	COMMENTARY	LITERATURE
More	Clostridium botulinum	no involvement of cobalt, copper, iron, manganese or nickel, atomic absorption spectroscopy	<a href="#">1</a>
More	Clostridium sp.	no involvement of cobalt, copper, iron, manganese or nickel, atomic absorption spectroscopy	<a href="#">14</a>
Zinc	Clostridium botulinum	zinc-dependent endopeptidase (serotype BoNT/B, #Clostridium botulinum,t#Clostridium sp.# <4, 6>) <4,6,12,15>; atom absorption spectroscopy <1,5,6>; : 1 atom of zinc per molecule botulinum neurotoxin (MW 150000, of serotypes A, B and E, each in 2-chain form, #Clostridium botulinum# <1>), bound to light chain (i.e. L-chain) <5>; the L-chain of BoNT/B is a form of zinc-endopeptidase <6>; 0.8-1 gatom zinc/mol neurotoxin <6>; contains zinc binding motif of metalloendopeptidases His-Glu-X-X-His <1,5,15>; or His223-Glu-Leu-Ile-His-X-X-His230 <10>; activation requires reduction of interchain disulfide bond <4,15>	<a href="#">1</a> , <a href="#">4</a> , <a href="#">5</a> , <a href="#">6</a> , <a href="#">10</a> , <a href="#">12</a> , <a href="#">15</a>
Zinc	Clostridium barati	atom absorption spectroscopy <5>; : 1 atom of zinc per molecule botulinum neurotoxin (MW 150000, of serotypes A, B and E, each in 2-chain form, #Clostridium botulinum# <1>), bound to light chain (i.e. L-chain) <5>; contains zinc binding motif of metalloendopeptidases His-Glu-X-X-His <5>	<a href="#">5</a>
Zinc	Clostridium butyricum	atom absorption spectroscopy <5>; : 1 atom of zinc per molecule botulinum neurotoxin (MW 150000, of serotypes A, B and E, each in 2-chain form, #Clostridium botulinum# <1>), bound to light chain (i.e. L-chain) <5>; contains zinc binding motif of metalloendopeptidases His-Glu-X-X-His <5>	<a href="#">5</a>
Zinc	Clostridium sp.	zinc-dependent endopeptidase (serotype BoNT/B, #Clostridium botulinum,n#Clostridium sp.# <4, 6>) <6,13,14>; atom absorption spectroscopy <6,14>; : 1 atom of zinc per molecule botulinum neurotoxin (MW 150000, of serotypes A, B and E, each in 2-chain form, #Clostridium botulinum# <1>), bound to light chain (i.e. L-chain) <14>; the L-chain of BoNT/B is a form of zinc-endopeptidase <6>; 0.8-1 gatom zinc/mol neurotoxin <6>	<a href="#">6</a> , <a href="#">13</a> , <a href="#">14</a>

INHIBITORS	ORGANISM	COMMENTARY	LITERATURE	IMAGE
1,10-Phenanthroline	Clostridium botulinum	-	<a href="#">1</a> , <a href="#">15</a>	● <a href="#">2D-image</a>
1,10-Phenanthroline	Clostridium sp.	r, Zn2+ restores <14>	<a href="#">14</a>	● <a href="#">2D-image</a>
Ala-Ser-Gln-Phe-Glu-Thr-Ser	Clostridium botulinum	synthetic peptide containing cleavage site of synaptobrevin, inhibits toxin action on buccal ganglion of Aplysia californica, serotype BoNT/B, not A or E	<a href="#">4</a>	● <a href="#">2D-image</a>
Captopril	Clostridium botulinum	serotype BoNT/B <4>	<a href="#">4</a> , <a href="#">5</a> , <a href="#">15</a>	● <a href="#">2D-image</a>
Captopril	Clostridium barati	-	<a href="#">5</a>	● <a href="#">2D-image</a>
Captopril	Clostridium butyricum	-	<a href="#">5</a>	● <a href="#">2D-image</a>
Captopril	Clostridium sp.	-	<a href="#">13</a> , <a href="#">14</a>	● <a href="#">2D-image</a>
Dipicolinic acid	Clostridium botulinum	-	<a href="#">1</a>	● <a href="#">2D-image</a>
EDTA	Clostridium botulinum	r, Zn2+ restores <1>; serotype BoNT/B <4>	<a href="#">1</a> , <a href="#">4</a> , <a href="#">15</a>	● <a href="#">2D-image</a>
EDTA	Clostridium sp.	r, Zn2+ restores <14>	<a href="#">13</a> , <a href="#">14</a>	● <a href="#">2D-image</a>
Gln-Phe-Glu-Thr	Clostridium botulinum	synthetic peptide containing cleavage site of synaptobrevin, inhibits toxin action on buccal ganglion of Aplysia californica, serotype BoNT/B, not A or E	<a href="#">4</a>	● <a href="#">2D-image</a>

ACTIVATING COMPOUND	ORGANISM	COMMENTARY	LITERATURE	IMAGE
Proteases	Clostridium botulinum	activation by rapid cleavage of MW 150000 polypeptide chain and generation of active di-chain neurotoxin <5,6>; bacterial or tissue proteases <5>	<a href="#">5,6</a>	-
Proteases	Clostridium barati	activation by rapid cleavage of MW 150000 polypeptide chain and generation of active di-chain neurotoxin <5>; bacterial or tissue proteases <5>	<a href="#">5</a>	-

<b>Proteases</b>	Clostridium butyricum	activation by rapid cleavage of MW 150000 polypeptide chain and generation of active di-chain neurotoxin <5>; bacterial or tissue proteases <5>	5	-
<b>Proteases</b>	Clostridium sp.	activation by rapid cleavage of MW 150000 polypeptide chain and generation of active di-chain neurotoxin <6>	6	-

**KM VALUE [mM] KM VALUE [mM] Maximum SUBSTRATE ORGANISM COMMENTARY LITERATURE IMAGE**

No entries in this field

**Ki VALUE [mM] Ki VALUE [mM] Maximum INHIBITOR ORGANISM COMMENTARY LITERATURE IMAGE**

No entries in this field

**TURNOVER NUMBER TURNOVER NUMBER MAXIMUM SUBSTRATE ORGANISM COMMENTARY LITERATURE IMAGE**

No entries in this field

**SPECIFIC ACTIVITY [μM/min/mg] SPECIFIC ACTIVITY MAXIMUM ORGANISM COMMENTARY LITERATURE**

No entries in this field

**pH OPTIMUM pH MAXIMUM ORGANISM COMMENTARY LITERATURE**

No entries in this field

**pH RANGE pH RANGE MAXIMUM ORGANISM COMMENTARY LITERATURE**

No entries in this field

<b>TEMPERATURE OPTIMUM</b>	<b>TEMPERATURE OPTIMUM MAXIMUM</b>	<b>ORGANISM</b>	<b>COMMENTARY</b>	<b>LITERATURE</b>
37	-	Clostridium botulinum	assay at	<a href="#">4</a> , <a href="#">6</a> , <a href="#">12</a> , <a href="#">15</a>
37	-	Clostridium sp.	assay at	<a href="#">6</a> , <a href="#">13</a> , <a href="#">14</a>

**TEMPERATURE RANGE TEMPERATURE MAXIMUM ORGANISM COMMENTARY LITERATURE**

No entries in this field

**SOURCE TISSUE ORGANISM COMMENTARY LITERATURE**

No entries in this field

<b>LOCALIZATION</b>	<b>ORGANISM</b>	<b>COMMENTARY</b>	<b>GeneOntology No.</b>	<b>LITERATURE</b>
cytosol	Clostridium botulinum	accumulates until bacterial lysis	<a href="#">GO:0005829</a>	<a href="#">5</a> , <a href="#">6</a>
cytosol	Clostridium barati	accumulates until bacterial lysis	<a href="#">GO:0005829</a>	<a href="#">5</a>
cytosol	Clostridium butyricum	accumulates until bacterial lysis	<a href="#">GO:0005829</a>	<a href="#">5</a>
cytosol	Clostridium sp.	accumulates until bacterial lysis	<a href="#">GO:0005829</a>	<a href="#">6</a>

**ACCESSION CODE ENTRY NAME ORGANISM NO. OF AA MOLECULAR WEIGHT[Da] SOURCE Sequence**

No entries in this field

<b>PDB</b>	<b>ORGANISM</b>
<a href="#">1E1H</a> , <a href="#">download</a>	Clostridium botulinum
<a href="#">1EPW</a> , <a href="#">download</a>	Clostridium botulinum
<a href="#">1F31</a> , <a href="#">download</a>	Clostridium botulinum
<a href="#">1F82</a> , <a href="#">download</a>	Clostridium botulinum
<a href="#">1F83</a> , <a href="#">download</a>	Clostridium botulinum
<a href="#">1FQH</a> , <a href="#">download</a>	Clostridium botulinum
<a href="#">1G9A</a> , <a href="#">download</a>	Clostridium botulinum

[1G9B, download](#) Clostridium botulinum  
[1G9C, download](#) Clostridium botulinum  
[1G9D, download](#) Clostridium botulinum  
[1I1E, download](#) Clostridium botulinum  
[3BTA, download](#) Clostridium botulinum

MOLECULAR WEIGHT	MOLECULAR WEIGHT MAXIMUM	ORGANISM	COMMENTARY	LITERATURE
155000	-	Clostridium botulinum	Clostridium botulinum, serotype BoNT/B, calculated from amino acid sequence	<u>8</u>
152000	-	Clostridium botulinum	Clostridium botulinum, serotype BoNT/E, calculated from amino acid sequence	<u>8</u>
150000	-	Clostridium botulinum	Clostridium botulinum, serotype BoNT/A, SDS-PAGE, calculated from amino acid sequence	<u>8</u>
149500	-	Clostridium botulinum	Clostridium botulinum, serotype BoNT/A, calculated from nucleotide sequence	<u>9</u>
149400	-	Clostridium botulinum	Clostridium botulinum, serotype BoNT/A, calculated from nucleotide sequence	<u>10</u>
148700	-	Clostridium botulinum	Clostridium botulinum, serotype BoNT/C1, calculated from nucleotide sequence	<u>3</u>
146900	-	Clostridium botulinum	Clostridium botulinum, serotype BoNT/D, calculated from nucleotide sequence	<u>2</u>
additional information	-	Clostridium botulinum	amino acid content <8>; comparison of amino acid sequences of H- and L-chains of serotypes A, B and E <8>; comparison of amino acid sequences of botulinum serotype BoNT/A and tetanus neurotoxin <9,10>; amino acid sequence similarity of clostridial neurotoxins	<u>8</u> , <u>9</u> , <u>10</u>
additional information	-	Clostridium sp.	amino acid content; comparison of amino acid sequences of H- and L-chains of serotypes A, B and E; comparison of amino acid sequences of botulinum serotype BoNT/A and tetanus neurotoxin; amino acid sequence similarity of clostridial neurotoxins <14>	<u>14</u>

SUBUNITS	ORGANISM	COMMENTARY	LITERATURE
Dimer	Clostridium botulinum	1 * 50000 + 1 * 102000, Clostridium botulinum, serotype BoNT/E, calculated from amino acid sequence, 1 * 51000 + 1 * 104000, Clostridium botulinum, serotype BoNT/B, calculated from amino acid sequence, 1 * 53000 + 1 * 97000, Clostridium botulinum, serotype BoNT/A, calculated from amino acid sequence	<u>8</u>
More	Clostridium botulinum	synthesized as single-chain polypeptide of about MW 150000, proteolytic activation yields 2-chain neurotoxin with N-terminal light (MW 50000) and C-terminal heavy chains (MW 100000) connected by single disulfide bonds <2,3,6>; serotype BoNT/E: single-chain polypeptide, serotype BoNT/B: mixture of single- and 2-chain molecules, serotype BoNT/A: 2-chain molecule <8>	<u>2</u> , <u>3</u> , <u>6</u> , <u>8</u>
More	Clostridium sp.	synthesized as single-chain polypeptide of about MW 150000, proteolytic activation yields 2-chain neurotoxin with N-terminal light (MW 50000) and C-terminal heavy chains (MW 100000) connected by single disulfide bonds <6>; serotype BoNT/E: single-chain polypeptide, serotype BoNT/B: mixture of single- and 2-chain molecules, serotype BoNT/A: 2-chain molecule	<u>6</u>

#### POSTTRANSLATIONAL MODIFICATION ORGANISM COMMENTARY LITERATURE

No entries in this field

#### Crystallization/COMMENTARY ORGANISM LITERATURE

No entries in this field

#### pH STABILITY pH STABILITY MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field

#### TEMPERATURE STABILITY TEMPERATURE STABILITY MAXIMUM ORGANISM COMMENTARY LITERATURE

No entries in this field



## GENERAL STABILITY ORGANISM LITERATURE

No entries in this field

## ORGANIC SOLVENT ORGANISM COMMENTARY LITERATURE

No entries in this field

## OXIDATION STABILITY ORGANISM LITERATURE

- Clostridium botulinum 6

## STORAGE STABILITY

-80°C, in 10 mM HEPES buffer, pH 7.2, 50 mM NaCl, after freezing in liquid N2, stable

## ORGANISM

Clostridium botulinum

## COMMENTARY LITERATURE

- 6

## Purification/COMMENTARY

serotypes BoNT/A to F

## ORGANISM

Clostridium sp.

## LITERATURE

11

serotypes BoNT/A, B, E (and their H-chain and L-chain <8>) <6,8>; C, D, F <6> Clostridium botulinum 6, 8

## Cloned/COMMENTARY

Clostridium botulinum <2,3>; serotypes BoNT/A (3 fragments encompassing the structural gene <9>) <9,10>; C1 <2,3>; or D <2>; expressed in Escherichia coli TG1 <9>

## ORGANISM

Clostridium botulinum

## LITERATURE

2, 3, 9, 10

## ENGINEERING ORGANISM COMMENTARY LITERATURE

No entries in this field

## Renatured/COMMENTARY ORGANISM LITERATURE

No entries in this field

## APPLICATION ORGANISM COMMENTARY LITERATURE

No entries in this field

## DISEASE

## TITLE OF PUBLICATION

## LINK TO PUBMED

Blepharoptosis

-

● [PubMed](#)

Blepharoptosis

-

● [PubMed](#)

Botulism

-

● [PubMed](#)

Botulism

-

● [PubMed](#)

Botulism, Infantile

-

● [PubMed](#)

Botulism, Infantile

-

● [PubMed](#)

Nerve paralysis

-

● [PubMed](#)

Nerve paralysis

-

● [PubMed](#)

Nystagmus, Pathologic Treatment of acquired nystagmus with botulinum neurotoxin A.

● [PubMed](#)

## REF. AUTHORS

## TITLE

## JOURNAL

## VOL.

## PAGES

## YEAR

## ORGANISM

## COMMENTARY

## LINK TO PUBMED

1

Schiavo, G.; Rossetto, O.; Santucci, A.; DasGupta, B.R.; Montecucco, C.

Botulinum neurotoxins are zinc proteins

J. Biol. Chem.

267

23479-23483

1992

Clostridium botulinum

-

● [PubMed](#)

2

Binz, T.; Kurazono, H.; Popoff, M.R.; Eklund, M.W.; Sakaguchi, G.; Kozaki, S.; Krieglstein, K.; Henschen, A.; Gill, D.M.; Niemann, H.

Nucleotide sequence of the gene encoding Clostridium botulinum neurotoxin type D

Nucleic Acids Res.

18

5556

1990

Clostridium botulinum

-

● [PubMed](#)

<u>3</u>	Hauser, D.; Eklund, M.W.; Kurazono, H.; Binz, T.; Niemann, H.; Gill, D.M.; Boquet, P.; Popoff, M.R.	<b>Nucleotide sequence of Clostridium botulinum C1 neurotoxin</b>	Nucleic Acids Res.	18	4924	1990	Clostridium botulinum	-	● <a href="#">PubMed</a>
<u>4</u>	Schiavo, G.; Benfenati, F.; Poulain, B.; Rossetto, O.; Polverino de Laureto, P.; DasGupta, B.R.; Montecucco, C.	<b>Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin [see comments]</b>	Nature	359	832-835	1992	Clostridium botulinum	-	● <a href="#">PubMed</a>
<u>5</u>	Montecucco, C.; Schiavo, G.	<b>Mechanism of action of tetanus and botulinum neurotoxins</b>	Mol. Microbiol.	13	1-8	1994	Clostridium botulinum, Clostridium barati, Clostridium butyricum	review	● <a href="#">PubMed</a>
<u>6</u>	Schiavo, G.; Montecucco, C.	<b>Tetanus and botulism neurotoxins: isolation and assay</b>	Methods Enzymol.	248	643-652	1995	Clostridium botulinum, Clostridium sp.	review	● <a href="#">PubMed</a>
<u>7</u>	Eisel, U.; Jarusch, W.; Goretzki, K.; Henschen, A.; Engels, J.; Weller, U.; Hudel, M.; Habermann, E.; Niemann, H.	<b>Tetanus toxin: primary structure, expression in E. coli, and homology with botulinum toxins</b>	EMBO J.	5	2495-2502	1986	Clostridium botulinum	-	● <a href="#">PubMed</a>
<u>8</u>	Saathyamoorthy, V.; DasGupta, B.R.	<b>Separation, purification, partial characterization and comparison of the heavy and light chains of botulinum neurotoxin types A, B, and E</b>	J. Biol. Chem.	260	10461-10466	1985	Clostridium botulinum	-	● <a href="#">PubMed</a>
<u>9</u>	Thompson, D.E.; Brehm, J.K.; Oultram, J.D.; Swinfield, T.-J.; Shone, C.C.; Atkinson, T.; Melling, J.; Minton, N.P.	<b>The complete amino acid sequence of the Clostridium botulinum type A neurotoxin, deduced by nucleotide sequence analysis of the encoding gene</b>	Eur. J. Biochem.	189	73-81	1990	Clostridium botulinum	-	● <a href="#">PubMed</a>
<u>10</u>	Binz, T.; Kurazono, H.; Wille, M.; Frevert, J.; Wernars, K.; Niemann, H.	<b>The complete sequence of botulinum neurotoxin type A and comparison with other clostridial neurotoxins</b>	J. Biol. Chem.	265	9153-9158	1990	Clostridium botulinum	-	● <a href="#">PubMed</a>
<u>11</u>	Simpson, L.L.; Schmidt, J.J.; Middlebrook, J.L.	<b>Isolation and characterization of the botulinum neurotoxins</b>	Methods Enzymol.	165	76pp	1988	Clostridium sp.	-	-
<u>12</u>	Schiavo, G.; Santucci, A.; DasGupta, B.R.; Mehta, P.P.; Jontes, J.; Benfenati, F.; Wilson, M.C.; Montecucco, C.	<b>Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds</b>	FEBS Lett.	335	99-103	1993	Clostridium botulinum	-	● <a href="#">PubMed</a>
<u>13</u>	Schiavo, G.; Rossetto, O.; Catsicas, S.; Polverino de Laureto, P.; DasGupta, B.R.; Benfenati, F.; Montecucco, C.	<b>Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E</b>	J. Biol. Chem.	268	23784-23787	1993	Clostridium sp.	-	● <a href="#">PubMed</a>
<u>14</u>	Schiavo, G.; Shone, C.C.; Rossetto, O.; Alexander, F.C.G.; Montecucco, C.	<b>Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin</b>	J. Biol. Chem.	268	11516-11519	1993	Clostridium sp.	-	● <a href="#">PubMed</a>
<u>15</u>	Schiavo, G.; Malizio, C.; Trimble, W.S.; Polverino de Laureto, P.; Milan, G.	<b>Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a</b>	J. Biol.	269	20213-	1994	Clostridium	-	● <a href="#">PubMed</a>

Sugiyama, H.;  
Johnson, E.A.;  
Montecucco, C.

single Ala-Ala peptide  
bond

Chem.

20216

botulinum

LINKS TO OTHER DATABASES (specific for EC-Number 3.4.24.69)

[ExPASy](#)

[Online Mendelian Inheritance in Man](#)

[KEGG](#)

NCBI: [PubMed](#), [Protein](#), [Nucleotide](#), [Structure](#), [Genome](#), [OMIM](#), [Domains](#)

[IUBMB Enzyme Nomenclature](#)

[WIT database](#)

[EMP Project](#)

[PDB database\(3D structure\)](#)

[PROSITE Database of protein families and domains](#)

**[SYSTEMS](#)**

[Protein Mutant Database](#)